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Summary 
 
 
Transcription of the eukaryotic genome is a highly regulated process which is accomplished 
in a number of steps, known as the transcription cycle. One of these steps is promoter-proximal 
pausing, a regulatory halt of the RNA polymerase II (Pol II) shortly after transcription 
initiation that is released by the P-TEFb kinase CDK9. A kinetic model of transcription 
predicted that pause duration delimits the initiation frequency and suggested that paused 
Pol II sterically interferes with initiation. The relationship between promoter-proximal 
pausing and initiation could thus far not be tested, as no method was available to measure 
initiation frequencies in vivo. Other kinetic parameters such as pause duration and elongation 
velocity could likewise not be described genome-wide. 
 
Here we show that in human hematopoietic cells the ‘pause-initiation limit’ restricts 
transcription in steady state, upon perturbation of the CDK9 kinase, and upon heat shock.  
 
To elucidate this relationship, we developed a novel multi-omics approach that quantifies 
transcription kinetic parameters by combining two state-of-the-art sequencing methods with 
novel kinetic modeling. Specifically, mammalian native elongating transcript sequencing 
(mNET-seq) and transient transcriptome sequencing (TT-seq). mNET-seq maps the position 
and amount of Pol II in high-resolution across each strand of the entire human genome. TT-
seq allows to distinguish newly synthesized from pre-existing RNA, and thus, measures 
immediate transcription activity as transcribed nucleotides per time. Combining 
measurements of TT-seq and mNET-seq enables us to derive productive initiation frequency, 
pause duration and elongation velocity genome-wide. 
 
For highly specific and fast inhibition of the pause release kinase CDK9, we engineered an 
analog-sensitive human cell line using CRISPR/Cas9. Upon CDK9 kinase inhibition, pause 
duration increased and productive initiation frequency decreased genome-wide. This shows 
that CDK9 activity stimulates the release of paused polymerase and activates transcription 
by increasing the number of transcribing polymerases and thus increases the amount of RNA 
synthesized per time. We found that highly CDK9 responsive genes are associated with long-
range chromatin interactions. We showed that human pause sites are located ~50 bp 
downstream of the transcription start site and show an enrichment for G/C-C/G 
dinucleotides. Furthermore, transcribed RNA of genes with longer pause durations shows 
higher secondary structure propensity upstream of the pause site. 
 
We next explored whether the pause-initiation limit applies to transcription activation upon 
heat shock. To this end, we annotated protein-coding RNAs, and six major long noncoding 
transcript classes in human hematopoietic cells. Using our multi-omics approach, we observed 
a reciprocal behavior of productive initiation frequency and pause duration in steady state for 
all gene classes except enhancers. We showed that upon heat shock the pause-initiation limit 
indeed restricts transcription activation at most genes. Surprisingly, enhancer elements are 
not limited by pausing and depend less on CDK9 activity than protein-coding genes. 
 
   VI 
Together these results suggest a model in which transcription might be activated by an 
increase of the productive initiation frequency at enhancer elements, accompanied by a 
decrease in pause duration at the target gene. This allows for an increase of productive 
initiation events at the target gene. Our multi-omics approach can now be used to further 
dissect the effect of other known Pol II pause and release factors in a quantitative and genome-
wide manner, ultimately revealing the nature of gene regulation in human cells. This will pave 
the way for novel treatments of diseases with transcriptional malignancies such as cancers, 
HIV infection or cardiac hypertrophy. 
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I. Introduction 
 
 
 
 
 
 
Three billion base pairs (bp) of deoxyribonucleic acid (DNA) 1 contain the molecular 
information that is fundamental to growth, development and survival of the human 
organism 2,3. This information is encoded in its genome, spanning 23 pairs of chromosomes, 
each one a linear and complementary DNA molecule organized in a superior layer of three-
dimensional (3D) nuclear architecture contained in each of its cells 4,5. Its linear nucleic acid 
complementarity 6 and structure is essential for the process of transcription which can manage 
the genome’s wealth of information and deliver it to the organism. At the heart of this process 
is an enzyme called DNA-dependent RNA polymerase 7-9 which catalyzes the transcription of 
double-stranded DNA to single-stranded ribonucleic acid (RNA) molecules by employing 
ribonucleoside triphosphates as substrates 10,11. The copying process from so-called coding 
regions of the DNA, in which RNA serves as the messenger of genetic information for the 
production of a polypeptide sequence which then folds into a functional protein is also referred 
to as ‘central dogma of molecular biology’ 12-14. In the last couple of years, it has come to light 
that noncoding RNAs contribute equally to human growth, development and survival 15,16. 
Transcription of coding and noncoding RNAs is accomplished in a number of steps, known as 
the transcription cycle, during which the cell can regulate and control RNA outcome 17. One 
of these steps is promoter-proximal pausing, a regulatory halt of the RNA polymerase during 
the active transcription process 18,19. In this thesis, I will discuss new insights we have gained 
into how promoter-proximal pausing is used by the cell for regulatory purposes and why this 
is a major leap forward in our understanding of transcription regulation. 
 
In order to introduce the reader to the relevant information needed to understand this work, 
I first review selected milestones in the transcription field. For this purpose, I focus on the 
transcription cycle, its regulation, and the concept of a gene (chapter 1). Then, I focus on the 
details of promoter-proximal pausing which links transcription initiation to productive 
elongation (chapter 2). Finally, I will summarize the consensus methods (chapter 3) and 
present results and contributions that expand the current understanding of global 
transcription regulation in human cells (chapter 4). 
 
 
1. Chromatin transcription and regulation in human cells 
 
The nucleus of eukaryotic cells provides a nanoenvironment for the tightly compacted but 
highly organized 3D architecture of the genome 20-23 (Figure 1 a, left). The building blocks of 
this complex structure are canonical histones or histone variants that assemble into 
octamers 24-26, which then form nucleosome core particles with DNA 27-29. These particles are 
then organized into higher ordered 3D structures with additional architectural factors 30. 
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Different ‘phases’, such as hetero- and euchromatin 31, or the A- and B-compartment 5, as well 
as subordinate entities (0.2-1.0 Mbp range) of the chromatin architecture have been identified, 
including chromosome territories 32, topologically associating domains (TADs) 33,34, lamina-
associated domains (LADs) 35-37 or nucleolar-associated domains (NADs) 38,39. Numerous 
chromatin remodeling mechanisms operate on these structures to ensure accessible surface 
area for transcription initiation 40,41. Once transcription is initiated, polymerases are capable 
of reading through nucleosomes to unravel the stored genetic information 42-46. 
 
Transcription starts at a defined position: the 5’end of the transcribed unit which is also 
referred to as transcription start site (TSS) 47,48. The TSS is flanked by 50 bp sequences (core 
promoter) which serve as binding platform for the pre-initiation complex (PIC) 49,50. The PIC 
consists of RNA polymerase II (Pol II) and general transcription factors (TFs) TFIID, TFIIA, 
TFIIB, TFIIF, TFIIE and TFIIH 51-53. The molecular details of transcription initiation have 
been extensively studied and are reviewed elsewhere 48,54. Together with upstream regulatory 
sequences 55 (the so-called extended promoter) and more distant located regulatory elements 
(enhancers) 56-58, PIC recruitment allows for a highly regulated initiation of transcription. For 
most transcribed units, transcription initiation occurs bidirectional on two promoters sharing 
a nucleosome depleted region (NDR) 59-62. After transcribing 20-100 nucleotides (nt), Pol II 
pauses 18,19 (see chapter 2). By the action of several pause release factors, transcription 
proceeds into productive elongation where other elongation factors join Pol II to complete 
copying the transcribed unit 19. The entire process of transcribing a human gene can take 
between a few seconds up to several hours (average time of ~30 min) 63. Once Pol II passes 
the polyadenylation (pA) signal, the nascent RNA is cleaved. Pol II is terminated at a 
transcription termination site (TTS) 64,65, and eventually recycled 17,66 (Figure 1 a, right). Co-
transcriptionally, several RNA processing events 67 are initiated or completed, including 5’ 
end capping (the addition of a methylated guanoside to the 5’ end of the nascent RNA) 68,69, 
splicing (the removal of noncoding introns) 70,71, editing (modification of ribonucleosides) 72-74 
and polyadenylation (the addition of a poly(A) stretch to the 3’ end of the RNA) or 3’ end 
cleavage at a stem-loop structure 64,65. 
 
1.1 Key concepts of Pol II transcription regulation 
 
As outlined above, Pol II undergoes an elaborate and repetitive cycle from initiation to 
recycling which is enabled and regulated by factors acting in trans with Pol II and the nascent 
RNA backbone 75,76. Multiple interconnected steps allow for control of when and to which 
extend transcriptional output is generated. These regulatory steps entail changes in chromatin 
accessibility 77,78, (co-) regulator recruitment 79, as well as allosteric changes 80 and post-
translational modifications of factors involved in initiation, promoter-proximal pausing, 
elongation, termination and recycling 81. Post-translational modifications are reversible and 
allow for a dynamic code using regulation by writers, readers and erasers 82. Since the 
characterization of Pol II was initiated 50 years ago by Pierre Chambon and Robert Roeder 83-
86, substantial advances have been made towards a mechanistic understanding of transcription 
and its regulation.  
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Figure 1. Key regulatory concepts of chromatin transcription in human cells. 
(a) Genome organization. Left: 3D organization of chromatin in the cell nucleus. Middle: zoom to chromosome 
territories. Right: representation of the transcription cycle. Pol II is depicted in silver (the CTD of Pol II is not 
shown) and additional factors in dark grey. RNA and RNA-binding proteins (RBPs) are depicted in blue. Solid 
line represents DNA and nucleosomes (chromatin). Right schematic is adapted from Hantsche and Cramer 87. 
(b) Transcriptional states ordered by activity. The basal state varies between segments of the genome. The ground 
state of the majority of the genome is repressed (basal state ‘B’), while certain regions have a higher intrinsic 
activity (basal state ‘A’) such as promoters. Parts of the genome are strongly repressed (basal state ‘C’) such as 
pericentric heterochromatin. Right: negative co-factors repress transcription, while activators and positive co-
factors increase transcriptional activity. Schematic is adapted from Burley and Roeder 88. (c) Pol II has an 
unstructured CTD. Disorder analysis (top) and schematic view (bottom) was kindly provided by Marc Böhning 
(MPI-bpc, Dept. of Molecular Biology) 89. (d) Simplified representation shows the layers of transcription regulation. 
For details refer to main text. (e) Diagram illustrating the classes of genes (as boxes on the plus or minus DNA 
strand) encoding protein-coding and long noncoding RNAs: messenger (m) RNA in green; long intergenic 
noncoding (linc) RNA in purple; enhancer (e) RNA in red; antisense (as) RNA, upstream antisense (ua) RNA, 
convergent (con) RNA, and short intergenic noncoding (sinc) RNA in black. Sense TSS is marked by asterisk. 
Promoter states (grey ovals) are associated with multiple gene classes, whereas enhancer states (red ovals) are only 
associated with genes encoding eRNAs. Top and bottom panels: boxes represent transcribed exons, solid lines 
represent introns. 
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For a detailed state-of-the-art picture of the individual steps of transcription the reader is 
referred to several excellent reviews with recent structure-function 87,90,91, biochemical, single-
molecule imaging 92,93, or functional genomics insights 25,48,64,71,94,95. The following paragraphs 
highlight multiple layers and the dynamics of transcription regulation relevant to this work 
(Figure 1). 
 
3D organization and chromatin accessibility. Transcriptional activity of a genomic region 
depends on its accessibility to pioneering factors, remodelers, and transcription factors 96. This 
is determined by chromatin compaction 41,97, DNA sequence 98, topology 99 and its 
modifications (of CpG islands) 100 either of which might restrict access to underlying DNA 
elements. It is further influenced by the composition and post-translational modifications of 
the histone octamers 78. Histones, particularly their accessible N-terminal tail region, can be 
methylated (me), acetylated (ac), phosphorylated, ubiquitinated, sumoylated, ADP 
ribosylated, propionylated, buryrylated, deaminated 78,101,102 and serotonylated 103 (histone 
code). The addition or removal of modifications, or deposition of specialized histone variants 
can reduce chromatin compaction, act as scaffolds to recruit transcription activators or 
repressors and thus, associate dynamically with certain transcription states (active, poised, 
repressed, silenced) 101 (Figure 1 b). On top of this, nucleosome positioning 41 and spacing is 
actively regulated by ATP-dependent chromatin-remodeling complexes which slide, exchange, 
and evict nucleosomes 40. 
 
Repetitive carboxy-terminal domain (CTD) of POLR2A. Pol II is a 514 kDa enzyme 
consisting of 12 subunits 104,105.The largest subunit of Pol II, POLR2A (alias human Rpb1) 
has a large unstructured CTD which consists of a linker and 52 repeats with the consensus 
sequence YSPTSPS (Y: tyrosine, S: serine, P: proline, and T: threonine) 82,106,107 (Figure 1 c). 
It serves as landing platform for transcription factors. The CTD of Pol II is 
hypophosphorylated when it is not bound to its template DNA 108,109. Beginning from 
initiation, cyclin-dependent kinases (CDKs) decorate the CTD linker 110,111 and repeats with 
phosphorylations 82 (Figure 1 d). These dynamic modifications recruit factors specific to each 
step of the transcription cycle 81,82 (CTD code). Upon recycling, the RNA is released, the CTD 
modifications are reset and Pol II is available for another round of transcription 112. 
 
Concentration of factors. Binding of any factor to Pol II or nascent RNA backbone is dictated 
by both the concentration of the factor itself and the number of competing binding sites on 
the target 113. Each step of the transcription cycle requires a distinct set of factors which have 
to be provided and organized in space and time 17,114. An attractive model for local ‘caging’ 
and organization of multiple factors is liquid-liquid phase separation (LLPS) 115-117. 
Furthermore, LLPS might be a crucial for 3D nuclear organization 95. As it stands today, it 
is not entirely clear what the components (DNA 118, RNA 119, proteins) of transcription 
condensates are. However, recent reports show that proteins with low complexity intrinsically 
disordered regions like the  CTD of POLR2A 89,120 or the histidine-rich domain in the cyclin 
subunit of P-TEFb 121 (chapter 2.1) have the potential to phase separate. Switches of the 
phosphorylation status of the Pol II CTD allow to drive or prevent LLPS dynamically 89,120. 
 
(Co-) regulators such as the Mediator complex. Regulators might act as activators or 
repressors to modulate transcription 122. Transcription initiation is stimulated by co-
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activators 123 and the Mediator complex to direct Pol II to the correct genomic loci 124. 
Activators are characterized by a bipartite organization consisting of a sequence-specific DNA-
binding domain and an activation domain 125. The activation domain contacts and recruits 
additional multi-protein complexes which are referred to as co-activators 126,127. A crucial co-
activator is the Mediator complex which bridges dynamically between both activators and 
Pol II as part of the PIC 124. 
 
Transition to productive elongation. After Pol II escapes the promoter, the RNA 5’ end is 
capped and Pol II enters a promoter-proximal window 68,69. Pol II traverses this window at a 
rate controlled by accessibility, concentration of factors, and regulators before its release into 
productive elongation 19,92 (chapter 2). Elongating Pol II is highly processive 128. Elongation 
occurs at different velocities along a gene 129,130 (chapter 3.1.1) and thus, coordinates co-
transcriptional mechanisms such as RNA processing 71,131,132, or chromatin modifications by 
recruitment of modifiers 133. The process of co-transcriptional mechanisms might also affect 
the elongation velocity 63. In addition, dynamically formed RNA secondary structures might 
modulate elongation velocity due to co-transcriptional folding 134. 
 
Termination and recycling. Efficient termination is important for maintaining the pool of free 
polymerases for re-initiation 112. Termination is coupled to RNA 3’ end processing and depends 
on the dissociation of elongation factors in concert with recruitment of termination factors 135. 
For recycling and re-initiation of Pol II and the transcription machinery, two nonexclusive 
models have been proposed: chromatin loop formation to bring the 3’ end to the vicinity of 
the TSS 136-138, or chromatin compartmentalization 139 for local caging of transcription 
factors 112. 
 
If factors involved in the transcription cycle act independently, the informational output 
would be a simple summation of the effects of each individual factor listed above. However, 
fine-tuning of transcriptional output suggests an intensive crosstalk between molecular 
processes which remains to be characterized (Figure 1 d). Factors may synergize or antagonize 
the functions of each other, leading to a complex output dependent on the specific 
composition. 
 
1.2 The definition of a gene 
 
By the late 1970s, a gene was defined as a continuous segment (transcribed unit) within the 
DNA molecule coding for a protein 140. This definition was challenged when Richard Roberts 
and Phillip Sharp discovered that a gene might be discontinuous, containing noncoding 
(introns) and coding segments (exons) 141-143. After characterization of the human genome by 
various high-throughput experimental and computational techniques 144, a gene was redefined 
as ‘a union of genomic sequences encoding a coherent set of potentially overlapping functional 
products’ 145. To date, deep sequencing has uncovered the existence of many novel noncoding 
RNAs with or without an evident functional role of the RNA itself. The latter may still be 
considered functional due to local effects of the transcription process (incl. proteins related to 
transcription) on the 3D nuclear architecture e.g. impacting the gene expression of nearby 
gene loci 146-148, or as an evolutionary driver in the generation of new functional RNAs 149. 
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However, the current challenge is to distinguish transcripts with yet unknown functionality 
against transcriptional noise. Given that uncertainty, we refer to a gene as the continuous 
segment (transcribed unit) within the DNA molecule beginning at the TSS of its 5’ end, 
including intronic and exonic sequences 150 and excluding the requirement of validated 
functionality. 
The exon-intron architecture of a gene is highly species-dependent 151. Most human 
genes are multi-exonic with an average number of eight exons per gene 3,152. The maximum 
number of exons in a human gene is 312 coding for titin – whose name originates from the 
giants (Titans) of Greek mythology 153,154. Most exons are short (< 0.2 kbp) 155 while introns 
are 10- to 100-fold longer (< 3 kbp, only 10 % of introns are > 10 kbp) 154. An accurate 
annotation of genes is crucial for the study of molecular biology, and annotation errors 
propagate into downstream analyses 156. 
 
1.2.1 Long noncoding RNA 
 
Long noncoding (lnc) RNA refers to autonomously transcribed RNA of >200 nt in length (to 
exclude small RNAs such as miRNAs and snRNAs) that does not encode a protein 157. By 
current estimates from the GENCODE reference annotation for the human genome 
(version 29, GRCH38.p12) 158,159, 27 % of the total number of genes encode lncRNAs (34 % 
encode protein-coding RNAs). Similar to protein-coding (m) RNAs, they are often capped 160, 
spliced 161 and polyadenylated 162 or form a triple-helix at the 3’ end 163. LncRNAs can be 
nuclear, cytoplasmic or both 164. Despite recent insights, many questions concerning the roles 
of lncRNAs remain 146,165. In the following paragraphs, I discuss the classification of lncRNA 
according to genomic location and states (promoter versus enhancer) (Figure 1 e), and if 
applicable, some recent examples of each class. 
Genes encoding long intergenic noncoding RNA (lincRNA) do not overlap with 
protein-coding genes 166,167. Due to their stability, the annotation of genes encoding lincRNAs 
is equally well established as for protein-coding genes, and can serve as reference (sense TSS) 
for the annotation of antisense lncRNAs 168. Prominent examples of functional lincRNAs in 
humans are the Xist lincRNA in X-chromosome inactivation 169,170, or the MALAT1 lincRNA 
in modulation of splicing efficiency 171,172. Less stable transcripts of genes that do not overlap 
with protein-coding genes, are referred to as short intergenic noncoding RNA (sincRNA) 168. 
In humans, sincRNAs are on average five-times shorter than lincRNAs 168. 
Genes encoding antisense RNA (asRNA) overlap with annotated genes on the opposite DNA 
strand 173. They often have the potential to regulate their overlapping genes 174. For example, 
the Sirt1 asRNA increases the stability of Sirt1 mRNA by masking miRNA binding sites 175, 
or erbA asRNA inhibits splicing of the erbA pre-mRNA 176. If the TSS of a gene encoding an 
asRNA is in close proximity to the sense TSS (<1 kbp downstream) it is referred to as 
convergent RNA (conRNA) 177. Elongating Pol II molecules stop upon head-to-head 
collision 178. However, in living cells, transcription of sense and antisense transcripts might be 
lagged and therefore rarely occurring simultaneously. Upstream antisense RNA (uaRNA) is 
encoded by genes upstream to annotated genes on the opposite DNA strand 174. It is unclear 
whether these transcripts have a functional role or are byproducts of the intrinsic bidirectional 
nature of mammalian promoters and enhancers 59-61,179. 
All of the above listed lncRNA classes might fall in either promoter or enhancer 
states 48. Enhancers are regulatory sequences which when in contact with a promoter can 
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activate gene expression, independently of position, orientation and distance relative to their 
target gene 56-58. How to accurately annotate sequences as promoter or enhancer is a significant 
challenge, especially since enhancer definitions strongly vary 180. Generally, promoter states 
are marked by higher levels of trimethylation of lysine 4 of histone 3 (H3K4me3) compared 
to monomethylation of the same residue (H3K4me) at their promoter 166. The opposite marks 
(low H3K4me3, high H3K4me) in combination with H3K27ac were found for enhancers 181. 
However, due to the emerging evidence of highly active enhancers displaying a H3K4me3 
promoter mark 182, and promoters serving as enhancers 183,184, it has to be acknowledged that 
classification purely based on epigenetic marks is incomplete. Thus, to better distinguish 
enhancers from promoters, additional characteristics of enhancer functionality have to be 
included such as chromatin accessibility, the scaffold function of enhancer sequences for 
transcription factors and chromatin-modifying enzymes 185, and a functional dissection by 
reporter gene analysis and CRISPR/Cas9 deletion experiments 186. If genes fall in enhancer 
states, their instable product is referred to as enhancer RNA (eRNA) 56. To date, it remains 
unclear how eRNAs participate in enhancer function 187,188. 
 
1.3 Case study for transcription regulation: heat shock 
 
At any given time, only a fraction of genes is active while the majority of the genome is 
repressed (basal state) 88,189. Transcription regulation allows cells to react in a rapid and 
coordinated manner to temporary signaling cues (activated or repressed states), or to adapt 
to permanent changes in their environments 190 (Figure 1 b). The regulated changes in 
transcription can be grouped in three categories: (i) 3D architecture level, (ii) transcription 
activator level, (iii) transcription machinery and RNA level (Figure 1 d). Here, the heat shock 
response (HSR) was chosen as a case study of transcription regulation because it provides a 
well-established model system, and it involves global transcriptional mechanisms that are 
conserved across species 191-195. The adaptive HSR is an emergency response hallmarked by a 
disruption in protein homeostasis, and subsequent high induction of heat shock (HS) genes 196. 
HS refers to a temperature above the optimum growth temperature (T) of an organism 
representing a challenge for its survival 197. Humans have a core body temperature (Tcore)	of	
~37 °C upon homeostasis. Tcore increases upon fever to 39-41 °C 198, and Tcore above 43 °C is 
defined as upper limit for survival 199. To date, a substantial amount of our understanding 
regarding the HSR has come from studies in yeast 200,201 and Drosophila 139,193,202. The human 
HSR is less well understood and molecular details are just beginning to emerge. In humans, 
physiological HS inducing conditions are environmental stress (e.g. heat, energy depletion, 
ultraviolet radiation), cell development and differentiation, or physical exercise 196,203-205. 
Pathological inducers are inflammation and fever, aging, neurodegeneration, or tissue injuries 
and repair 196,204,206. Furthermore, a diverse spectrum of human cancers shows a strong 
correlation of increased gene expression of heat shock factors with reduced survival rates 207,208 
(Figure 36). After sensing of HS, the cell’s survival is not only accomplished on the 
transcriptional level but further supported by complex post-transcriptional 209-211, and 
translational processes 212,213 which are reviewed elsewhere. The aim of this subsection is to 
briefly summarize what is known for human cells about the various factors that modulate 
gene expression in response to HS, with focus on the above defined layers (i to iii) of global 
transcriptional regulation 214. 
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3D architectural changes upon HS. The 3D architecture of the genome can be measured by 
high-throughput chromosome conformation capture assays such as Hi-C at ~50 kbp 
resolution 215. In human cells, no changes in global compartments (TADs) or looping 
interactions were observed upon short exposure to heat (30 min) 216. These data suggest that 
the 3D architecture (>50 kbp) is already established prior to HS to enable a rapid response. 
On the chromatin accessibility level, however, dramatic changes were observed upon HS 217. 
These changes occur due to nucleosome loss at activated loci 218 and histone modifications, i.e. 
an increased acetylation of H4 219. 
 
Activation. Unlike Drosophila or yeast, plants 220 and animals 204 have multiple heat shock 
factor (HSF) isoforms. HSFs are the primary stress sensors for HS gene upregulation 206. In 
humans, studies have analyzed the genome-wide distribution of HSFs 207,221 and Pol II 219,222 in 
steady state and upon HS. These studies have identified HSF target genes which are marked 
by promoter-proximal paused Pol II in steady state 219. HSF1 is considered the master 
regulator of the HSR. Upon HS, the monomeric HSF1 is modified by acetylation, 
phosphorylation and sumoylation, it trimerizes, and translocates to the nucleus 223. There it 
binds to certain sequence elements (inverted repeats of nGAAn pentamers) at promoters and 
enhancers of HS-inducible genes 224. For selected model genes, it has been shown that 
transcription is upregulated by recruiting various chromatin remodelers and co-
activators 217,225. Furthermore, HS induces polyADP-ribosylation (PARylation) of chromatin 
which results in nucleosome destabilization and mimics the effects of linker histone 1 
depletion 226. PARylation also supports local ‘caging’ of transcription factors and Pol II at the 
activated HSP70 gene locus 139,227. 
 
Downregulation. Upon HS, cells shift all resources from growth to combat stress and ensure 
survival 197. This involves the global shut-down of transcription and re-distribution of the 
transcription machinery to loci with stress-related functions as was shown in yeast during 
HS 228. This immediate downregulation of transcription could so far not be investigated 
quantitatively owing to limitations in extracting transcriptional changes of mRNA in 
microarray analyses 224,229,230 which measure stable mRNAs and lack the temporal resolution 
for rapid changes. In the context of global transcriptional shut-down, it is still unknown how 
HS is sensed and what causes the downregulation at the molecular level. In mice, it was 
previously reported that HSFs are not required for downregulation 231. Recent data in human 
cells suggest that Pol II 219 and negative elongation factors such as NELF increase their 
residence time on promoters of downregulated genes 232. This supports a model in which 
increased promoter-proximal Pol II pausing sustains downregulation upon HS 194,219,231. 
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2. Pol II promoter-proximal pausing 
 
Widespread peaks of elongating Pol II at 20 to 100 nt near promoters in eukaryotes were 
initially described for several model genes, including the mammalian β-globin locus233, 
Drosophila heat shock genes 234, human c-myc and c-fos genes 235-238. Over the last 
decades 239,240, promoter-proximal pausing of Pol II has emerged as a general phenomenon 
across protein-coding genes (including up to 90 % of active promoters 241), and has blossomed 
into a rich research field. More recently, Pol II pausing was reported at noncoding genes that 
produce long noncoding RNAs 242,243, including enhancer RNAs 182, and upstream antisense 
RNAs 244. In this chapter, I briefly summarize the biological impact of Pol II pausing in human 
cells, its regulation – focusing on the prominent release factor P-TEFb –, and an emerging 
model of the molecular mechanism of Pol II pausing. 
 
What biological functions might Pol II pausing serve in human cells? Interestingly, Pol II 
pausing occurs at both, genes actively producing RNA and genes without efficient transcript 
completion 19. At genes that are fully transcribed, pausing facilitates the assembly of RNA 
processing factors 245. This pausing checkpoint ensures that 5’ ends of nascent RNA molecules 
are capped and protected from degradation prior to elongation 246,247. Genes that experience 
initiation but not elongation are often in an uninduced state 248. As a result, the Pol II pausing 
associated transcription machinery alters chromatin and maintains an open promoter 
structure enabling regulatory factors to access underlying DNA elements 18. Upon 
developmental regulation 249,250, or in response to other stimuli 251,252 pausing is reduced and 
responsive genes are fully transcribed. Furthermore, pausing was shown to synchronize gene 
activation events in Drosophila 253. Negative consequences of pausing may be transcription-
replication conflicts during S phase, especially when paused Pol II encounters the replication 
machinery head-to-head, leading to DNA damage and genomic instability 254. Paused Pol II 
could also interfere with transcription of other genes in its vicinity by steric hindrance 255. 
 
What factors affect Pol II pausing in human cells? At the outset of my graduate work, it has 
been reported in Drosophila 256 and Escherichia coli 257 that the DNA sequence composition is 
affecting Pol II pausing. However, the underlying sequence determinants at human genes were 
unknown. Similar to other transcription steps (section 1.1), pausing is stabilized by several 
factors, including DSIF composed of Spt4 and Spt5 258 and the NELF complex with A, B, 
C/D and E subunits 259. Paused Pol II has been shown to relocate nucleosomes 260, and vice 
versa, nucleosomes seem to enhance pausing 261. Additional factors influence the stability of 
paused Pol II, such as GDOWN1 and TFIIF 262. Most prominent among the pause release 
factors is the CDK9-containing kinase complex P-TEFb 263-265. Other factors involved in the 
transition to productive elongation are the PAF1 complex 110,266-268, the elongation factors SPT6 
269-272, and TFIIS 273, as well as several other factors recruiting P-TEFb. 
Part I – Introduction 
 
   10 
2.1 Positive transcription elongation factor b (P-TEFb) 
 
The positive transcription elongation factor b (P-TEFb) 263 is a heterodimer which is 
constitutively expressed throughout the cell cycle 274 (recently reviewed in 275,276). It consists 
of the cyclin-dependent kinase CDK9 originally termed PITALRE 264,277 and a T-type cyclin 
(CCNT1 or CCNT2) 278-280. In human cells, P-TEFb is either active or inactive 281,282. In its 
inactive form, 7SK RNA serves as a scaffold for interacting proteins (LARP7, MePCE, 
HEXIM1, HEXIM2 283), ultimately sequestering P-TEFb in a 7SK small nuclear 
ribonucleoprotein complex (snRNP) 284. The ratio of both forms varies between different cell 
lines but the majority is inactive in steady state 281,282,285. 
 
Recruitment and activation of P-TEFb. Both forms of P-TEFb can be recruited to its target 
genes via several different recruitment complexes including (co-)activators or chromatin-
associated factors (reviewed in 276). Activators as C-MYC 240,286, NF-kappaB 287 or the viral 
HIV Tat 288 transcription factors can directly recruit active P-TEFb to target genes by 
physically interacting with its CCNT subunit. The subunit MED26 of the Mediator complex 
binds the super elongation complex (SEC) which contains active P-TEFb, ELL/EAF family 
members and other factors 289. Another recruitment mechanism of active P-TEFb utilizes 
histone tail binders such as BRD4 or MePCE. BRD4 interacts with promoter-proximal histone 
4 acetylated lysine (H4K16ac) via its bromodomain 290,291. MePCE acts independently during 
P-TEFb recruitment by interacting with histone H4 of the +1 nucleosome 292. The inactive, 
7SK snRNP-bound P-TEFb can be nuclear or chromatin-bound by TRIM28/KAP1 293. 
Nuclear 7SK snRNP-bound P-TEFb is activated by T-loop phosphorylation of CDK9 by 
CDK7 which frees P-TEFb from the 7SK snRNP complex 294,295. However, it is not known 
which factor releases P-TEFb from the chromatin-associated 7SK snRNP complexes. To date, 
our understanding of P-TEFb recruitment remains incomplete and needs to be established at 
a genome-wide scale. The timing of P-TEFb activation and the localization of its recruitment 
complexes at a certain gene might define the length of the pause duration. 
 
P-TEFb controlled checkpoints: promoter-proximal pausing and pA site. After recruitment to 
its target and activation, the CDK9 kinase phosphorylates the Spt5 subunit of DSIF 296, NELF 
297 and the CTD of POLR2A 298. For the latter, CDK9 has been shown to phosphorylate the 
POLR2A linker region of the CTD 110,111, as well as serine 2 299,300 and serine 5 301 of the CTD 
heptad repeats (Figure 1 c). CDK9 was recently shown to be implicated in a second 
checkpoint around the polyadenylation site 302. The second checkpoint is still poorly 
understood and might implicate CDK9 in 3’-end RNA processing and transcription 
termination 302,303. This implication is supported by the observation that P-TEFb enhances 
the activity of the transcription termination factor XRN2 by phosphorylation 303. 
 
2.2 Integration of pausing models 
 
Today we have a better knowledge of the biochemical composition of paused and elongating 
Pol II complexes, and many pause and release factors have been identified 304. But our 
knowledge about the timing and molecular mechanisms of assembly and composition of Pol II 
pause and release complexes remains limited (Supplementary Note 1). Three models for 
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establishing promoter-proximal pausing were described in the literature: the kinetic model, 
the barrier model and the interaction model (reviewed in 304). The kinetic model describes 
pausing as a combination of the slow elongation rate of Pol II (see section 3.1.1), reversible 
sliding of Pol II with low processivity along DNA and RNA (backtracking) 305 and the delayed 
recruitment rate of Pol II release (P-TEFb complex) and elongation factors prior to productive 
elongation. The barrier model (also referred to as ‘ubiquitous pausing’ 46) builds on 
observations that nucleosomes, especially the first downstream of the TSS, hinder Pol II’s 
transition to productive elongation 261. The interaction model suggests that factors stabilizing 
the paused Pol II complex such as NELF, DSIF, or other factors (of which the activity still 
needs to be established) determine pausing. Depending on the gene’s architecture and 
nanoenvironment, the energy landscape and thus, the transition rate to productive elongation 
will be variable and each of the three models might contribute differently to establishing a 
paused Pol II 306 (see also Supplementary Note 1). 
Recent studies revealed structures of the Pol II elongation complex in the paused and 
activated state, and provided the first mechanistic insights into the P-TEFb dependent switch 
to active elongation 110,307 (Figure 2 a). The RNA-DNA hybrid within the paused polymerase 
is in the tilted state that hinders nucleotide addition at the active site 307. Thus, the subsequent 
nucleotide is not added yet. We defined the pause site (position 0) to be the position in line 
with the 'post-translocated' RNA rather than with the 'pre-translocated' DNA (see Methods 
II.2.2.4). A tilted hybrid might be the hallmark of a paused state and was also observed in 
bacterial elongation complexes 308. 
 
 
 
 
Figure 2. Structural modeling of promoter-proximal pausing and initiation. 
 (a) Top: close-up view of the DNA-RNA hybrid in the paused transcription elongation complex (paused EC) (in 
dark blue and red) (PDB-code 6GML 307) compared to the elongation complex (EC) (in silver) (PDB-code 
5OIK 105). In the paused EC, the DNA-RNA hybrid is in an offline transcription state. The template DNA strand 
(in dark blue) passes over the Pol II bridge helix (in green). Structural view (top) was kindly provided by 
Dr. Seychelle Vos (MPI-bpc, Dept. of Molecular Biology) 307. Bottom: schematic of nucleic acid residues (DNA in 
blue, RNA in red). Shaded area highlights the DNA-RNA hybrid. The pause site (n*) (throughout this work 
referred to as ‘position 0’) is denoted at +1 of the template DNA. Bottom schematic is adapted from Armache et 
al. 309. (b) Modeling shows that paused Pol II (silver, right) positioned 50 bp downstream of the TSS allows for 
formation of the Pol II initiation complex (different colors, left). Modeling is based on the latest structural 
information (Mediator EMD-8307 310, TFIID EMD-3305 311, TFIIH EMD-3307 312, closed complex PDB-code 
5FZ5 313, EC PDB-code 1WCM 314). Structural modeling was performed by Dr. Merle Hantsche (MPI-bpc, 
Department of Molecular Biology). 
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Jesper Svejstrup and co-workers explored footprints of initiating and paused Pol II molecules 
and proposed a theoretic model (referred to as ‘Ehrensberger theory’) in which a paused 
polymerase interferes with the binding of the Pol II initiation complex, or a newly initiating 
polymerase triggers the release of a paused polymerase to productive elongation 315. As a 
consequence, the authors suggest that initiation might still be the rate limiting step of 
transcription and pausing might serve as a window of opportunity to collect necessary 
transcription elongation factors for full processivity during elongation 315. Structural modeling 
shows that Pol II positioned 50 bp downstream of the TSS allows for formation of the Pol II 
initiation complex while shorter distances between the active sites of paused and initiating 
Pol II are predicted to lead to steric clashes (Figure 2 b). Even if a paused Pol II is located 
further downstream, it may still restrict initiation events if additional polymerases line up 
behind it. 
 
 
3. Studying transcription kinetics genome-wide 
 
To arrive at a mechanistic understanding of transcription it must be studied at multiple levels: 
by structural analysis of the components, their functionality in vitro (biochemical and single-
molecule assays) and in vivo (systems biology, imaging). This work contributes to the field of 
systems biology which combines experimental data and theory, with many researchers 
contributing to both. In particular, this work focusses on Pol II transcription kinetics in 
human cells during steady state and changes of transcription kinetics upon perturbation in a 
genome-wide manner. 
 
3.1 Background reading on transcription kinetics 
 
Transcription kinetics refer to all relevant parameters involved in transcribing RNA in units 
of molecules or nucleotides and time. In human cells, RNA synthesis depends on multiple 
(potentially) rate-limiting steps (see chapter 1.1). 
Here, I briefly discuss the progress that has been made in recent years in a quantitative 
description of transcription kinetics, specifically initiation frequency, pause duration, and 
elongation rate. At the onset of this work, elongation rates were the only rate which had been 
studied quantitatively genome-wide. 
 
3.1.1 Elongation rates 
The elongation velocity of Pol II is influenced by the translocation rate of Pol II as well as 
the frequency and duration of pauses along a gene 316. The translocation rate is governed by 
the dynamics of the trigger loop structure of Pol II 317. The translocation rate of Pol II’s 
movement per base depends on the DNA sequence and other processivity factors joining Pol II 
during elongation 92. At certain positions, Pol II moves slowly (e.g. promoter-proximal pause 
window) while it accelerates within other regions (e.g. intronic sequences) 129,130. The promoter-
proximal pause duration can also be influenced by several factors (see chapter 2). 
By the late 1950s, Igor Tamm and colleagues suggested that 5,6-Dichloro-1-β-D-ribo-
furanosylbenzimidazole (DRB) reversibly reduces the rate of transcription 318. Two decades 
later, they were the first measuring elongation rates (3-6 kbp/min) by following the declining 
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wave of elongating polymerases after DRB induced transcriptional shut-down by radioisotope 
pulse labeling 319. Several groups joined to delineate the mode of action of DRB 320,321, and 
identified the DRB-sensitive component as the kinase component CDK9 of P-TEFb 264. Thus, 
DRB inhibits promoter-proximal pause release resulting in a failure of promoter-proximal 
Pol II to progress further, while elongating Pol II complexes are able to complete 
transcription 264. Following DRB drug removal (wash-out), promoter-proximal Pol II enters 
productive elongation and nascent transcription can be followed. By measuring the width of 
the emerging (wash-out) or retreating (shut-down) transcription wave, elongation rates could 
be assessed (distance/time) (Figure 3 a). DRB shut-down or wash-out experiments in 
combination with a variety of techniques, incl. RT-qPCR 322-324, tiling microarrays 325, 
fluorescent labeling of Pol II 272,326-328 or RNA 329-333, became a consensus approach for 
estimating elongation rates of individual model genes (Figure 3 b). 
Until 2013, studies were limited to a single or small number of genes and reported a 
wide range of elongation rates (1 to 6 kbp/min) (Table 28). This was initially explained by 
variations between cell types, treatment systems, and technical differences, however, 
systematic studies of elongation rates were missing. The application of GRO-seq (see 
subsection 3.1.2) in combination with DRB 129, or with physiological inducers (17β-estradiol 334 
or the cytokine TNF𝛼 334), was a breakthrough, soon to be followed by a number of genome-
wide studies 130,335,336. These studies addressed elongation rate changes along the gene and 
between different gene classes. They found that Pol II elongation rates are the slowest close 
to the beginning of the gene (5’ end) and increase within the first 15 kbp for human 
genes 129,334. However, the local resolution of these studies was limited to windows of >5 kbp, 
and thus, offers insufficient resolution on short genes 19. In addition, DRB does not have high 
specificity and targets other kinases involved in transcription. Thus, in order to minimize 
possible physiological perturbations caused by drug treatment, future experiments would 
benefit from substitution of DRB with a more specific and potent CDK9 kinase inhibitor. To 
date, commercially available compounds targeting CDK9 suffer from multiple off-target effects 
(Figure 35) and the field lacks tools to do precise molecular perturbations of CDK9 (for review 
see 337). 
An elegant chemical-genetic approach to inhibit kinases in vivo highly specific and 
within minutes was developed by Kevan Shokat 338-340. By mutating the so-called gatekeeper 
residue in the active site of the kinase from the natural amino acid to an amino acid with a 
smaller side chain (glycine or alanine), a unique interface of the kinase’s ATP binding pocket 
to a small molecule is engineered 339. The mutant (analog-sensitive) kinase retains its function 
and cellular distribution in vivo 338,341,342. At the same time, the enlarged binding pocket allows 
for an unnatural bulky ATP analog (e.g. 1-NA-PP1) to bind which is non-hydrolysable 339 
(Figure 3 c). It has to be acknowledged that any type of reversible inhibitory ligand spends 
part of its time ‘off’ its binding site. However, once bound, the dissociation constant and thus, 
a background kinase activity, are minimal for bulky ATP analogs 338. With the development 
of the CRISPR/Cas9 system343-345, a tool was in place to engineer endogenous analog-sensitive 
CDK9 in human cells. 
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Figure 3.  Studying transcription kinetics genome-wide. 
(a)  Pol II density (arbitrary unit) across a gene. DRB was used to shut-down transcription. Waves of emerging 
Pol II (blue) after DRB (red) wash-out, or after induction by natural stimuli were studied by time-course. 
Elongation velocity [bp/min] was assessed by the ratio of distance [bp] and time [min]. (b) Historic overview of 
studies measuring elongation rates. Single gene studies dominated the transcription field until 2013. A detailed 
overview of the conducted studies including applied methods and references can be found in Table 28. 
Abbreviations: endotoxin/lipopolysaccharides (LPS) (orange), 17β-estradiol (E2) (yellow), heat shock (HS) (red), 
tumor necrosis factor alpha (TNF𝛼) (braun), doxycycline (dox) (white), actinomycin D (AD) (red), flavopiridol 
(FP) (grey), triptolide (TRP) (black), 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) (red). Bottom: 
elongation rates [kbp/min] for single gene(s) (box with solid line) or average of >160 genes (dotted line) are 
displayed. (c) Schematic of chemical-genetic approach (Shokat mutation): mutant analog-sensitive kinase (bottom, 
grey) binds the bulky non-hydrolysable ATP analog (1-NA-PP1, red) which blocks binding of ATP (black). 
Wildtype kinase (grey, top) can only bind ATP (black) due to gatekeeper amino acid. (d) Comparison of methods 
used to detect human Pol II complexes. Detected Pol II states and resolution are depicted for each method. Except 
ChIP-seq assays, all methods (GRO-seq 346, PRO-seq 347, CoPRO 247, 3’NT-seq 348, NET-seq 349, mNET-seq 350) are 
strand-specific. For comparison see 168,351. 3’NT-seq 348 and NET-seq without IP 349 are not covered in the main 
text. Both methods purify chromatin-associated RNAs and are not specific to Pol II 351. CoPRO is a combination 
of PRO-seq with a subsequent selection of (un-)capped transcripts which allows accurate mapping of the TSS 247. 
 
 
3.1.2 Occupancy profiles as a consensus measure of Pol II half-lives 
Genes can be distinguished on the basis of their Pol II distribution: no Pol II across the entire 
gene, evenly distributed Pol II across the gene, or Pol II enriched on the 5’-end of genes 352,353. 
Polymerase occupancy can be mapped along DNA or RNA 351. The respective techniques to 
measure polymerase occupancy are described in chapter 3.2.2. 
Most available studies estimated the degree of Pol II pausing as the relative ratio of 
Pol II occupancy in the promoter-proximal region and the gene body, which has been termed 
the traveling ratio 354, or the pausing index 352,353. Rapid transition of promoter-proximal Pol II 
to elongation would yield a low ratio. Promoter-proximal enrichment of Pol II and thus, a 
slow transition to productive elongation would yield a high ratio. Measuring changes in Pol II 
occupancy upon chemically inhibiting initiation was the only measure to determine the half-
life of Pol II at paused genes. The decay of Pol II occupancy was mostly studied at selected 
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model genes by ChIP-qPCR 355, run-on assay 356, or imaging 357 upon initiation inhibition by 
triptolide (TRP). TRP blocks the ATPase activity of the TFIIH helicase XPB, thus, opening 
of the DNA template is not possible 358,359. However, reported half-lives of paused Pol II studied 
at individual model genes varied strongly among studies. For example, Pol II half-lives at 
hsp70 in steady state were reported to be of 2.5 min 360, 5 min 357, 10 min 355, 25 min 356 in 
Drosophila, or even up to 60 min in human cells 361. Furthermore, half-lives of paused Pol II 
varied strongly between genes (at 13 genes in Drosophila: 1 to 25 min 355). A single study 
addressed half-lives genome-wide: in mouse embryonic stem cells, an average Pol II half-life 
of 6.9 min was measured at 3,181 genes by GRO-seq with TRP 130. Systematic studies of half-
lives in human cells were missing at the outset of this work. 
It is critical to point out that although Pol II occupancy depends on pausing, it does 
not directly relate to the kinetics of pausing 315. This is because the Pol II occupancy signal 
at a given time depends on the number of polymerases and their speed, and cannot be used 
in isolation to distinguish between these two. Indeed, when a Pol II occupancy peak increases, 
this can be due to an increase in the number of pausing polymerases or due to an increase in 
the duration of pausing, or both. Taken together, conclusions about the pause duration 
starting from occupancy profiles can only be drawn by factoring in the number of polymerases 
released into elongation (productive initiation frequency). 
 
3.2 A novel multi-omics approach to quantify transcription kinetics 
 
Kinetic modeling minimally requires: (i) a measure of transcriptional output per time and 
(ii) a measure of Pol II occupancy. At the outset of my graduate work, existing evidence was 
primarily limited to measures of Pol II occupancy providing only snapshots but no kinetic 
insights to promoter-proximal pausing (see section 3.1). 
We used TT-seq (transient transcriptome sequencing) in combination with mNET-seq 
(mammalian native elongating transcript sequencing) analysis, hereafter called multi-omics, 
as a new method to analyze elongation velocity, pause duration and productive initiation 
frequency genome-wide in living human cells. 
 
3.2.1 Transient transcriptome sequencing (TT-seq) 
Natural derivatives of nucleosides such as 4-thiouridine (4sU) are rapidly taken up by a broad 
range of cells, undergo phosphorylation by cellular uridine kinases, and get incorporated into 
endogenous RNA 362. Metabolic labeling with 4sU was first introduced 40 years ago 362. It was 
later used in combination with affinity purification and microarray analysis 363-367. More 
recently, it was combined with next-generation sequencing (4sU-seq) 368-370 (for review see 371). 
Gene expression profiling using 4sU-seq has higher sensitivity than standard transcriptomics, 
as 4sU-seq separates newly transcribed RNA from the pre-existing RNA pool 366,368,372. 
However, if the labeling pulse is shorter than 30 min, these protocols are less sensitive for 
organisms with larger transcriptomes 373. This is due to the long unlabeled 5’ region of 
transcripts, which were produced in cells before labeling, compared to the short, labeled newly 
transcribed 3’ region 373. 
The development of transient transcriptome sequencing (TT-seq) solved this problem 
by introducing an additional fragmentation step after total RNA isolation, followed by 
sequencing only newly synthesized RNA fragments that are formed during the 5 min labeling 
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time 168 (see Figure 6 a for a detailed experimental workflow). TT-seq can quantify 
transcriptional activity and RNA metabolism in steady state 168 and during transcription 
responses such as T cell activation 374. TT-seq quantifies even short-lived noncoding RNAs, 
including enhancer RNAs (eRNA) 375 and their changes 374. TT-seq also detects transient 
RNAs between the polyadenylation site (pA) and the site for transcription termination 
(TTS) 168. Compared to RNA-seq, TT-seq is particularly powerful in monitoring 
downregulation of transcription because it is not biased by stable transcripts which mask 
rapid changes. Downregulation of transcription was studied by TT-seq for example during X 
chromosome inactivation in mouse embryonic stem cells 376. 
Other recently developed methods involve chemical conversion of 4sU into cytosine 
analogs which is detected as T-to-C point mutation in sequencing 377-379. The benefit is that 
biochemical separation of 4sU labeled RNAs is not necessary. However, since these assays 
preserve labeled and unlabeled molecules, a much higher sequencing depth is required. This 
is especially problematic if the focus is on fast transcription kinetics using short labeling times. 
Since the relevant labeled RNA fragments are strongly diluted in unlabeled molecules, these 
methods are outperformed by TT-seq (for a comparison see 380). 
TT-seq provides a measure of transcriptional output per time (criterium i) as it 
measures local synthesis rates at nucleotide resolution. Thus, it allows to monitor and quantify 
productive transcription initiation frequency globally 381 which could not be done before since 
no alternative method was available. 
 
3.2.2 Mammalian native elongating transcript sequencing (mNET-seq) 
Polymerase distribution can be mapped with DNA or RNA. Chromatin immunoprecipitation 
(ChIP) assays such as ChIP-seq 382-384, ChIP-exo 385 or ChIP-nexus 386 detect the distribution 
of Pol II by crosslinking to DNA, fragmentation and immunoprecipitation using a Pol II 
specific antibody. ChIP assays lack strand specificity and are limited in their resolution to 
>100 bp. To date, ChIP assays are the only method covering all stages of transcription 
including initiating Pol II 351 (Figure 3 d). 
RNA-based methods are powerful tools to locate polymerases in a strand-specific 
manner and at high resolution. To uniquely align an RNA sequence back to the human 
genome, RNA fragments of >20 nt length are required 346. Thus, RNA-based methods cannot 
map initiating Pol II. Widely used RNA-based techniques are nuclear run-on (NRO) 
assays 346,347, and native elongating transcript sequencing (NET-seq) 350,387. NRO assays such 
as global run-on sequencing (GRO-seq) 346 or precision nuclear run-on sequencing (PRO-
seq) 347 can detect actively elongating and paused polymerases in isolated nuclei, but not 
backtracked and arrested polymerases. To this end, isolated nuclei are treated with sarkosyl 
which blocks new initiation but releases elongation-competent polymerases for in vitro 
polymerization (NRO) of approximately 1 to 50 nt 346,347. During NRO, 5-bromouridine 5’-
triphosphate (BrUTP) (GRO-seq) 346, or biotin-labeled ribonucleotide triphosphate analogs 
(biotin-rNTP) (PRO-seq) 347 are incorporated, allowing the affinity purification of nascent 
RNAs. Thus, these protocols are specific to NRO-RNAs but not to Pol II-associated RNAs. 
Mammalian NET-seq (mNET-seq) maps Pol II by tracking the RNA in the active site 
of Pol II without crosslinking or in vitro run-on 350,387. mNET-seq in adherent human cells 
(HeLa S3) 350,388 was published as an updated version of the original NET-seq in Saccharomyces 
cerevisiae 387. The mNET-seq protocol makes use of cellular fractionation 350. The solubilized 
chromatin fraction is subjected to a Pol II-specific immunoprecipitation (IP) 350,387. 
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Crosslinking is not required because the chromatin-associated Pol II-RNA complex is very 
stable and remains bound even in the presence of high salt, urea, polyanions and 
detergents 389,390. Next, RNA fragments are selected by size (25 to 110 nt), purified and 
subjected to cDNA library preparation 350. The strand-specific distribution of Pol II is 
characterized by sequencing the 5’ and 3’ ends of each RNA molecule. The 3’ end sites of 
individual RNA molecules are then used to identify Pol II occupancy at single-nucleotide 
resolution 350,387 (see Figure 6 b for a detailed experimental workflow). With the transfer of 
the protocol from yeast to human cells, a bias of (m)NET-seq became visible: non nascent 
RNA intermediates with 3’-OH groups remain bound to Pol II after IP and lead to an 
overestimation of Pol II molecules in certain areas along the gene 391. These non nascent RNAs 
arise due to stable protein-protein interactions of RNA processing complexes with Pol II e.g. 
spliceosome or microprocessor complex associated RNAs 391,392. The addition of the strong 
detergent Empigen BB during the IP (0.1-2 % v/v) overcomes these limitations by weakening 
protein-protein interactions 393,394. Thus, non nascent RNAs are lost and only nascent RNAs 
associated with the active center of Pol II remain 391,392. 
To date, mNET-seq (with Empigen BB treatment) is the superior method catching all 
post-initiation states of Pol II including backtracked and arrested polymerases (which is 
critical to estimate the total number of Pol II molecules on a gene, criterium ii) at single-
nucleotide resolution and without crosslinking or in vitro NRO (for a comparison see 351, Table 
27, and Figure 3 d). 
 
 
4. Motivation and aims of this thesis 
 
At the outset of my graduate work the Ehrensberger theory 315 (chapter 2.2) served as an 
attractive explanation for how promoter-proximal pausing might regulate the amount of RNA 
synthesized per time. However, a fundamental component of this hypothesis remained 
untested in vivo: how does the productive initiation frequency change upon pause duration 
changes? We reasoned that addressing this central question could enable a mechanistic 
understanding of how genes are regulated in steady state cellular conditions as well as in 
response to natural stress, and might reveal which of the steps is rate limiting (Figure 4 a). 
 
As pointed out above (chapter 3) current consensus methods to determine transcription rates 
have several shortcomings. Limitations are low resolution (>5 kbp) and unspecific inhibitors 
for elongation rate estimation, ambiguous occupancy read-out of Pol II for pause duration 
estimation, or the lack of a method to quantify rates in vivo to estimate the initiation 
frequency. The major obstacle to addressing transcription kinetics was the lack of biochemical 
techniques to measure newly synthesized nucleotides per time. The development of TT-seq 168 
enabled us to solve this issue and to measure productive initiation frequencies in vivo. The 
second obstacle was the lack of a strand-specific Pol II occupancy profiling protocol in human 
suspension cells (Figure 4 b). Therefore, I set out to establish the recently reported method 
mNET-seq (with Empigen BB treatment) in our lab. A third development (CRISPR/Cas9 
system) allowed us to engineer a human cell line for highly specific chemical inhibition of the 
P-TEFb kinase CDK9, the key factor that triggers promoter-proximal pause release of Pol II. 
By combining the specific pause-release kinase inhibition with our novel multi-omics approach, 
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we measured global transcription kinetics and their changes at human genes. In specific, the 
following questions were investigated: 
Question 1. Can we measure the kinetic parameters initiation frequency, pause duration, and 
elongation velocity globally? 
Question 2. How can Pol II promoter-proximal pausing control the frequency of productive 
initiation and by that the amount of RNA synthesized per time?  
Question 3. What are the determinants of long pause duration in human cells? 
 
Furthermore, our multi-omics approach allows to refine our understanding of (non)coding 
transcription regulation. Thus, in a second study, we annotated (non)coding transcript classes 
in human hematopoietic cell lines. To this end, we combined the segmentation algorithm 
GenoSTAN 177 with GRO-cap 50 which recovers nascent RNAs with capped 5’ ends of 
transcriptionally engaged polymerases. In addition, we used published cell line specific 
epigenomic datasets 177 to define coding and noncoding transcript classes including putative 
enhancer RNAs. We used perturbation experiments (CDK9 inhibition or heat shock) to 
stimulate cells in a controlled manner and measured their response with the aim to more fully 
expose the underlying transcriptional program of different transcript classes. We focused on 
the following questions: 
Question 4. Are there differences with respect to average Pol II pausing and/or productive 
initiation behavior of coding compared to noncoding transcript classes? 
Question 5. How are rapid and reversible changes in transcription upon stress achieved at a 
molecular level? Specifically, are changes refined by the pause-initiation limit? 
 
 
 
 
Figure 4. Multi-omics analysis of transcription kinetics in human cells. 
(a) Schematic of questions to be addressed in this work using a novel multi-omics approach to derive productive 
initiation frequency I, pause duration d and elongation velocity v genome-wide. Parameters and their relationship 
unknown at the outset of this work are highlighted with red question marks. (b) Structure of our multi-omics 
experiments. mNET-seq is depicted in green, TT-seq in blue. Individual steps of the protocol are highlighted by 
black circles. For a detailed experimental overview see also Figure 6. The subway map is inspired by Shendure 
and Liebermann Aiden 395. 
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II. Materials and Methods 
 
 
 
 
 
 
1. Materials 
 
This section lists chemicals, enzymes, kits and consumables used as part of this thesis. All 
materials, consumables and chemicals used for (RT-qPCR, TT-seq, RNA-seq, mNET-seq) 
were RNase-free, and molecular biology grade. If not stated otherwise, materials were obtained 
from Sigma-Aldrich [A], Thermo Fisher Scientific [B], Merck Millipore [C], PanReac 
AppliChem [D], Jena Bioscience [E], Carl Roth [F], bioworld [G], Bio-Rad [H], QIAgen [I], New 
England Biolabs (NEB) [J], Epicentre [K], Eppendorf [L], Miltenyi Biotec [M], Agilent [N], Illumina 
[O], NuGEN [P]. Instruments and laboratory equipment are listed in part V (Table 29). 
 
 
1.1 Chemicals, enzymes, kits and other consumables 
 
Table 1. Chemicals and reagents used in this study in alphabetical order. 
 
Chemicals Supplier Identifier Application(s) 
1-NA-PP1 [C] 529605 CDK9as inhibition 
4-thio-uridine, 4-thio-UTP [E] NU-1156S spike-ins 
4-thiouracil, 4sU [A] T4509 TT-seq 
Ammonium persulfate, APS [D] A00304 mNET-seq, spike-ins 
Bis-acrylamide 19:1 (40 %) [A] A9926-100 mNET-seq, spike-ins 
β-mercaptoethanol [F] 4227.1 Western blot 
Bovine serum albumin, BSA (1 %) in PBS [G] 40120706-1 mNET-seq 
Bromophenol blue (tracking dye) [A] B0126 mNET-seq 
Chloroform [A] 372978 mNET-seq, TT-seq 
DL-Dithiothreitol, DTT [A] 43815 TT-seq 
Dimethylsulfoxid, DMSO [A] D8418 mNET-seq, TT-seq 
dNTPs mix (10 mM each) [B] R0191 RT-qPCR 
Empigen BB (~30 %) [A] 30326 mNET-seq 
Ethanol [C] 159010 mNET-seq, TT-seq 
EDTA (0.5 M, pH 8.0) [B] 15575020 mNET-seq, TT-seq 
EGTA (0.5 M, pH 8.0) [G] 40520008-1 mNET-seq 
EZ-link HPDH Biotin [B] 21341 TT-seq 
Glycerol [A] G5516 mNET-seq 
GlycoBlue co-precipitant [B] AM9516 mNET-seq 
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InstantBlue gel staining solution Expedeon ISB1L Western blot 
Isopropanol [C] 109634 TT-seq 
Laemmli Sample Buffer (4 x) [H] #1610747 Western blot 
Magnesium chloride solution, MgCl2 (1 M) [A] M1028 mNET-seq 
Milk powder [F] T145.2 Western blot 
MOPS buffer (20 x) [B] NP0001-02 Western blot 
N,N-Dimethylformamide, DMF [A] D4551 TT-seq 
Sodium chloride, NaCl (5 M) [A] S5150 TT-seq 
Nonident™ P40 Solution (NP-40) [A] 74385 mNET-seq 
NuPAGE Transfer Buffer (20 x) [B] NP0006-1 Western blot 
Phosphatase Inhibitor Cocktail Tablets [A] 4906837001 mNET-seq 
Ponceau S [A] P3504 Western blot 
Protease inhibitor cocktail (100 x) [A] P8340 mNET-seq 
QIAzol lysis reagent [I] 79306 TT-seq 
QuickExtract™ DNA Extraction Solution [K] QE09050 CDK9as validation 
Random Hexamer primers [B] 48190-011 RT-qPCR 
RNase-free AMPure XP beads Beckman A63987 TT-seq, spike-ins 
Sodium acetate, NAOAc (3 M, pH 5.2) [B] R1181 mNET-seq, TT-seq 
Sucrose [A] S0389 mNET-seq 
SYBR Safe DNA Gel Stain [B] S33102 CDK9as 
SYBR™ Gold Nucleic Acid Gel Stain [B] S-11494 mNET-seq, spike-ins 
Tetramethylethylenediamine, TEMED [A] A00115 mNET-seq, spike-ins 
TRIS borate EDTA, TBE (10 x) [A] 93290-1L mNET-seq, spike-ins 
Tris-HCl (1 M, pH 7.0) [B] AM9851 mNET-seq 
Tris-HCl (1 M, pH 7.5) [B] 15567-027 mNET-seq 
Tris-HCl (1 M, pH 8.0) [B] 15568-025 mNET-seq 
Trypan blue solution (0.4 %) [A] T8154 Cell viability 
Tween-20 [A] P9416 TT-seq, Western blot 
UltraPure Agarose [B] 16500500 CDK9as 
Urea [D] A1049 mNET-seq, spike-ins 
Water, H2O [B] 10977049 all 
Xylene cyanol (tracking dye) [A] X4126 mNET-seq 
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Table 2. Enzymes used in this study in alphabetical order. 
 
Enzymes Supplier(s) Identifier Application 
AccuPrime GC-Rich DNA Polymerase [B] 12337-016 CDK9as  
BstUI enzyme (1,000 units) [J] R0518S CDK9as  
HL-dsDNase ArcticZymes 70800-201 TT-seq 
Maxima H Minus Reverse Transcriptase Mix [B] EP0742 RT-qPCR 
RNase-free DNase Set [I] 79254 TT-seq 
SuperScript II Reverse Transcriptase  [B] 18080-044 mNET-seq 
T4 Polynucleotide Kinase (3’ phosphatase minus) [J] M0236S mNET-seq 
T4 RNA ligase, deletion mutant 2 [K] LR2D1132K mNET-seq 
 
 
Table 3. Kits used in this study in alphabetical order. 
 
Kits Supplier Identifier Application 
ERCC RNA Spike-in Mix [B] 4456740 spike-ins 
KAPA HIFI Library Amp Real Time peqlab 07-KK2701-01 TT-seq 
MEGAscript T7 kit [B] AM1334 spike-ins 
miRNeasy Micro Kit [I] 217084 TT-seq 
Ovation Universal RNA-Seq System [P] 0343-32 TT-seq 
QIAquick MinElute Gel Extraction Kit  [I] 28704 mNET-seq 
Qubit dsDNA HS Assay Kit [B] Q32854 mNET-seq 
Qubit RNA HS Assay Kit [B] Q32855 TT-seq 
RNA PCR Primer Indices A, D [O] RS-200-0012; RS-200-0048 mNET-seq 
Strand Selection Reagent, SS5 ver 3 
(human rRNA depletion) 
[P] S01859 TT-seq 
Super Signal West Pico Plus 
Chemiluminescent Substrate 
[B] 34580 Western blot 
SYBR Select Master Mix  [B] 4472919 RT-qPCR 
TapeStation D1000 Reagents [N] 5067-5583 mNET-seq 
TapeStation D1000 ScreenTape [N] 5067-5582 mNET-seq 
TapeStation HS RNA ScreenTape [N] 5067-5579 TT-seq 
TapeStation HS RNA ScreenTape 
Sample Buffer 
[N] 5067-5580 TT-seq 
TruSeq Small RNA Library Kit [O] RS-200-0012 mNET-seq 
TURBO DNA-free Kit [B] AM1907 RT-qPCR 
µMACS Streptavidin Kit [M] 130-074-101 TT-seq 
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Table 4. Consumables used in this study. 
 
Consumables Supplier Identifier Application 
96 well plate, round bottom VWR 734-0955 RNA, cDNA 
96 well plates, FrameStar® 96 non-skirted 4titude 4ti-0711 RT-qPCR 
Cassette (1 mm) [B] NC2010 mNET-seq 
E-Gel High-ReSolution (4 %) agarose gels  [B] G501804 mNET-seq 
SurPhob SafeSeal LOW BINDING tips, polyethylen 
(PE), Biozym 
Sarstedt 70.1186.210 RNA 
MaXtract High Density tubes (1.5 mL) [I] 129046 TT-seq 
MaXtract High Density tubes (2 mL) [I] 129056 TT-seq 
microTUBE AFA Fiber Snap-Cap (130 µL) Covaris Ltd 520045 TT-seq 
Optical adhesive cover, Microseal ‘B’ seal [H] MSB1001 RT-qPCR 
Polypropylene (PP) low bind filter tips 10 µL Biozym VT0200 TT-seq 
Polypropylene (PP) low bind filter tips 20 µL Biozym VT0220 TT-seq 
Polypropylene (PP) low bind filter tips 30 µL Biozym VT0250 TT-seq 
Polypropylene (PP) low bind filter tips 1250 µL Biozym VT0270 TT-seq 
Polypropylene (PP) lowbind tubes (1.5 mL) [L] 022431021 TT-seq 
Polypropylene (PP) lowbind tubes (2 mL) [L] 022431048 TT-seq 
Precast polyacrylamide gel, NuPAGE (4-12 %, 15-
well)  
[B] NP0323BOX Western blot 
PVDF Transfer Membrane (0.45 µm) [B] 88518 Western blot 
Qubit Assay Tubes [B] Q32856 TT-seq, mNET-seq 
Scalpels no. 23, sterile disposable Swann-Morton 0510 mNET-seq 
Spin-X column with cellulose acetate membrane  Costar 8160 mNET-seq 
µ columns [M] 130-042-701 TT-seq 
µMACS Streptavidin kit [M] 130-074-101 TT-seq 
 
 
Table 5. Protein, DNA and RNA ladder used in this study. 
 
Ladder Range Supplier Identifier Application 
TrackIt 25 bp DNA 10-1,200 bp [B] 10488022 mNET-seq 
HRL 100-500 bp [O] - mNET-seq 
CRL 145, 160, 500 bp [O] - mNET-seq 
Precision Plus ProteinTM All Blue Prestained 
Protein standard 
10-250 kDa [H] 1610373 
 
Western blot 
Small RNA marker 20-100 nt Abnova R0007 mNET-seq 
High Sensitivity RNA ScreenTape ladder 25-6,000 nt [N] 5067-5581 TapeStation 
D1000 Ladder 35-1,000 bp [N] 5067-5586 TapeStation 
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1.2 Plasmids and oligonucleotides 
 
Table 6. Plasmids used as IVT template of RNA spike-ins in this study. 
The cloning vector for all spike-in inserts was pUC19 396. See Appendix for plasmid maps and subsection 2.2.1 and 
Table 20 for experimental details. Cloning of the selected spike-in sequence into a pUC19 cloning vector and 
verification was done by Dr. Anna Sawicka and Dr. Kristina Žumer (MPI-bpc, Dept. of Molecular Biology). 
 
Name Insert IVT template Backbone Source 
2-4sU-pUC19 Spike-in 2 (derived from ERCC-00043) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
12-pUC19 Spike-in 12 (derived from ERCC-00170) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
4-4sU-pUC19 Spike-in 4 (derived from ERCC-00136) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
5--pUC19 Spike-in 5 (derived from ERCC-00145) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
8-4sU-pUC19 Spike-in 8 (derived from ERCC-00092) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
9-pUC19 Spike-in 9 (derived from ERCC-00002) pUC 19 (e.g. [J], N3041) Cramer lab, this study 
 
 
Table 7. Plasmid used for CRISPR/Cas9 engineering in this study. 
This plasmid was a gift from Feng Zhang (Addgene plasmid #48138, RRID:Addgene_48138) 397. See Appendix 
for plasmid map, Table 10 for sgRNA primers and subsection 2.3.1 for experimental details. Cloning of the 20 nt 
guide RNA sequence for the canonical CDK9 into the Addgene plasmid and verification was done by Dr. Weihua 
Qin (LMU Munich, Dept. of Biology II, group of Prof. Dr. Heinrich Leonhardt). 
 
Name Insert Source 
pSpCas9(BB)-2A-GFP (PX458) 20nt guide RNA sequence targeting 
CDK9 
Dr. Weihua Qin, this study 381 
 
 
1.3 Primers 
 
Primers were synthesized by Integrated DNA Technologies (IDT) or Biomers. 
 
Table 8. RT-qPCR primers used in this study. 
See Appendix for synthetic spike-in sequences. Primer sequences for Spike-in 4-sU and Spike-in 12 were designed 
by Dr. Margaux Michel (MPI-bpc, Dept. of Molecular Biology). 
 
Target 
name 
Direction Primer sequences 
5’>3’ 
Length 
(nt) 
Tm 
(°C) 
Amplicon 
size (bp) 
Genomic 
Sequence 
Amplifie
d Region 
Spike-in 4-
4sU 
forward CCGAGTTCGCCT
TACTGCTC 
20 60 95 Synthetic, 
ERCC-00136 
438 … 532 
reverse AATCGATCGGAA
TCACGCCG 
20 60 
Spike-in 5 forward CATAAGCGGAGA
AAGAGGGAATGA
C 
25 59 103 Synthetic, 
ERCC-00145 
15 … 117 
reverse GCTAAATAGAGA
GCATCCACACCT
C 
25 58 
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Spike-in 12 forward AGACTGGCATTC
CCGTGATA 
20 57 97 Synthetic, 
ERCC-00170 
222 … 318 
reverse GCTAAAACCCCT
GCCTGCAA 
20 60 
ACTB forward ACTCTTCCAGCC
TTCCTTCC 
20 62 102 Gene ID: 60, 
NC_000007.14 
Homo sapiens 
chromosome 7 
Reference 
GRCh38.p12 
2,299 … 
2,495 
reverse TACAGGTCTTTG
CGGATGTC 
20 60 
HSPA1A forward GATCTTCACCAC
CTACTCCGACA 
23 59 86 Gene ID: 3303, 
NC_000006.12  
Homo sapiens 
chromosome 6 
Reference 
GRCh38.p12 
31,817,03
4 … 
31,817,11
9 reverse GATTGTTGTCTT
TCGTCATGGCCC 
24 60 
 
 
Table 9. CDK9as screening: PCR and sequencing primers. 
Sequences which do not map to the target locus are underlined. CDK9as screen (WQ) was designed by Dr. Weihua 
Qin (LMU Munich, Dept. of Biology II, group of Prof. Dr. Heinrich Leonhardt). 
 
Target 
name 
Direction Primer sequences 
5’>3’ 
Length 
(nt) 
Tm 
(°C) 
Amplicon 
size (bp) 
Genomic 
Sequence 
Amplified 
Region 
CDK9as 
screen 
(WQ) 
forward CCCCGTAGCT
GGTGCTTCCTC
G 
22 61 500 Gene ID: 1025, 
NC_000009 
Homo sapiens 
chromosome 9, 
GRCh38.p12 
127,787,74
8 … 
127,788,24
0 reverse CCCCAGCAGCC
TTCATGTCCCT
AT 
24 59 
CDK9as 
screen 
(SG-1) 
forward CCTCTTCTTAA
CTCAGATGGA
CCC 
24 58 412 Gene ID: 1025, 
NC_000009 
Homo sapiens 
chromosome 9, 
GRCh38.p12 
127,787,69
3 … 
127,788,10
4 reverse GTGGATGTAG
TAGAGGCCGT
TAAG 
24 59 
CDK9as 
screen 
(SG-2) 
forward GTGAAGGAAG
GAACAGACAG
ATGC 
24 59 388 Gene ID: 1025, 
NC_000009 
Homo sapiens 
chromosome 9, 
GRCh38.p12 
127,787,81
2 … 
127,788,19
9 reverse AGAGTGGGTC
CTTTAGTGACA
TCC 
24 60 
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Table 10. Other oligonucleotides used in this study. 
The listed oligonucleotides were designed Dr. Weihua Qin (LMU Munich, Dept. of Biology II, group of Prof. Dr. 
Heinrich Leonhardt). See Table 7 and subsection 2.3.1 for experimental details. 
 
Name Sequence 5’>3’ 
HDR template: A103 is underlined, 
BstUI cutting site in small letters 
AAAGTGTGTTGGGTGTGGTTTTCTTGACTTTTTCTTCTTTCTAT
TCCTGCCTCAGCTTCCCCCTATAACCGCTGCAAGGGTAGTATAT
ACCTGGTcgcgGACTTCTGCGAGCATGACCTTGCTGGGCTGTTGA
GCAATGTTTTGGTCAAGTTCACGCTGTCTGAGATCAAGAGGGT
GATGCAGATGCTGCTTAACGGCCT 
Primers for sgRNA generation and 
screening: CDK9-sgRNA-F 
CACCGGCTCGCAGAAGTCGAACACC 
Primers for sgRNA generation and 
screening: CDK9-sgRNA 
AAACGGTGTTCGACTTCTGCGAGCC 
 
 
1.4 Antibodies for Western blot and IP 
 
Table 11. Primary antibodies used in this study. 
If available, Research Resource Identifiers (RRIDs) are listed. The serum of 3E10 and 3E8 was a kind gift of Prof. 
Dr. Dirk Eick (Helmholtz Center Munich, Dept. of Molecular Epigenetics). 
 
Target Host Dilution Reference Lot. # 
GAPDH (C 71.1) mouse 1:20,000 [A], G8795; 
RRID: AB_1078991 
067M4785V 
Histone H2B (C.362.2) mouse 1:2,000 [B], MA5-14835; 
RRID: AB_10982286 
RI2272615 
Histone H3, HRP-coupled rabbit 1:5,000 Abcam, ab21054; 
RRID: AB_880437 
GR261138-1 
POLR2A (hRPB1), C-
terminus unphosphorylated + 
phosphorylated (CMA601) 
mouse 3 µg/107 cells 
(IP) 
Biozol, MABI0601; 
RRID: AB_2728735 
15013 
POLR2A (hRPB1), C-
terminus Ser2P (3E10) 
rat 1:60 Gift of Dirk Eick Serum 
POLR2A (hRPB1), C-
terminus Ser2P (CMA602) 
mouse 5 µg/107 cells 
(IP) 
Biozol, MABI0602; 
RRID: AB_2747403 
15013 
POLR2A (hRPB1), C-
terminus Ser5P (CMA602) 
mouse 5 µg/107 cells 
(IP) 
Biozol, MABI0603; 
RRID: AB_2728736 
16003 
POLR2A (hRPB1), C-
terminus Ser5P (3E8) 
rat 1:60 Gift of Dirk Eick Serum 
POLR2A (hRPB1), hRPB1, 
N-terminus (F-12) 
mouse 1:100 Santa Cruz Biotechnology, 
sc-55492; RRID: AB_630203 
E2913 
POLR2C (hRPB3) rabbit 1:2,000 Bethyl Laboratories, A303-
771A; RRID: AB_11218388 
A303-771A-1 
U1 snRNP70, C-terminus 
(C-3) 
mouse 1:200 Santa Cruz Biotechnology, 
sc-390899 
D0114 
mouse IgG (mock control) mouse 3 µg/107 cells 
(IP) 
Abcam, ab37355; 
RRID:AB_2665484 
NA 
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Table 12. HRP-coupled secondary antibodies used for Western blotting in this study. 
 
Target Host Dilution Reference 
Rabbit IgG donkey WB: 1:5,000 GE Healthcare, NA934 
Mouse IgG goat WB: 1:3,000 Abcam, ab5870 
Rat IgG goat WB: 1:5,000 [A], A9037 
 
 
1.5 Cell culture: cell lines, medium and consumables 
 
Table 13. Human cell lines used in this study. 
If available, Research Resource Identifiers (RRIDs) are listed. 
 
Species Cell line Reference Identifiers Additional information 
Homo sapiens; 
male 
Raji B 
lymphocyte 
DSMZ Cat# ACC-319; 
RRID:CVCL_0511 
Epstein-Barr virus-related 
Burkitt lymphoma 
Homo sapiens; 
male 
Raji B 
(CDK9as) 
lymphocyte 
This study 381 NA Homozygous mutation of F103A 
at the CDK9 gene 
Homo sapiens; 
female 
K562 erythro-
leukemia 
DSMZ Cat# ACC-10; 
RRID:CVCL_0004 
Chronic myelogenous leukemia, 
BCR-ABL1 positive 
 
 
Table 14. Growth and freeze medium composition used in this study. 
 
Cell lines Medium Components Supplier, 
identifier 
Final concentration Used for 
Raji B, Raji B 
(CDK9as) 
Growth RPMI-1640 [B], 31870-074 90 % v/v This 
study 381 Heat inactivated FBS bio-sell 10 % v/v 
L-glutamine [B] 200 µM 
(Pen/Strep [B] 1 x 
Raji B (CDK9as), 
K562 
Growth RPMI-1640 [B], 31870-074 90 % v/v This 
study Heat inactivated FBS [B], 10500-064 10 % v/v 
GlutaMAX [B], 35050061 1 x 
Raji B, Raji B 
(CDK9as), K562 
Freeze Heat inactivated FBS [B], 10500-064 90 % v/v This 
study DMSO (cryoprotectant) [A], 2438 10 % v/v 
Raji B, Raji B 
(CDK9as), K562 
Wash DPBS, no calcium, no 
magnesium 
[A] NA This 
study 
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Table 15. Cell culture consumables used in this study. 
 
Instrument Supplier Identifier 
Fungizide WAK-Chemie WAK-ZF-1 
Acryl Aqua Clean, Microbiocidal Additive for Water Soluble 
Heating Bath Fluids 
WAK-Chemie WAK-AQA-250-50l 
Plasmo Test Mycoplasma Detection Kit InvivoGen rep-pt1 
Serological pipettes (50 mL, 25 mL, 10 mL, 5 mL, 1 mL) Sarstedt Ref 86.1254.001 
Tissue culture plates 6-well, 12-well, 24-well, 96-well Sarstedt 83.1836 
Trypan blue solution (0.4 %) [A] T8154 
Cell culture T25/T75/T175/T225 flask for suspension cells 
(standard TC surface treatment) 
Greiner Bio-One NA 
Sterile cryovial (1.2 mL) Kisker CV11-1 
Sterile cryovial (2 mL) Kisker CV11-2 
Tubes 50 mL, 15 mL, 2 mL, 1.5 mL Greiner Bio-One NA 
 
 
1.6 Buffers 
 
Table 16. Western blot: buffers used in this study. 
 
Buffer Component Final concentration Step 
4 x LB Laemmli Sample Buffer (4 x) 4 x Western blot 
β-mercaptoethanol 10 % v/v 
Ponceau S staining Ponceau S 0.1 % w/v Western blot 
Acetic acid 5 % v/v 
10 x PBS stock NaCl 1.37 M Western blot 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 pH 7.4 18 mM 
MOPS running buffer MOPS buffer (20 x) 1 x Western blot 
Transfer buffer NuPAGE Transfer Buffer (20x) 1 x Western blot 
Ethanol 10 % v/v 
PBS-T PBS 1 x Western blot 
Tween20 0.05 % v/v 
Blocking solution Milk powder 5 % w/v Western blot 
PBS 1 x 
Tween20 0.05 % v/v 
Binding solution Milk powder 2 % w/v Western blot 
PBS 1 x 
Tween20 0.05 % v/v 
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Table 17. TT-seq: solutions and buffers used in this study. 
 
Solution / buffer Component Final concentration Stored at Step 
50 mM 4sU 4-thiouridine 50 mM -20 °C Labeling 
RNase-free H2O - 
EZ-Link Biotin-HPDP EZ-Link Biotin-
HPDP 
1 mg/ml 4 °C, -20 °C Biotinylation 
DMF - 
10 x biotinylation 
buffer 
Tris HCl pH 7.4 100 mM 4 °C Biotinylation 
EDTA pH 8.0 10 mM 
µMACS washing 
buffer (RT) 
Tris HCl pH 7.4 100 mM Prepare freshly, 
degas for 
>10min, RT 
Pull-down of 
labeled RNAs EDTA pH 8.0 10 mM 
NaCl 1 M 
Tween20 0.1 % v/v 
µMACS washing 
buffer (65 °C) 
Tris HCl pH 7.4 100 mM Prepare freshly, 
degas for 
>10min, 65 °C 
Pull-down of 
labeled RNAs EDTA pH 8.0 10 mM 
NaCl 1 M 
Tween20 0.1 % v/v 
 
 
Table 18. mNET-seq: solutions and buffers used in this study. 
 
Solution / buffer Component Final concentration Stored at Step 
10 x PhosSTOP PhosSTOP tablet 10 x -20 °C Buffers 
1 x MNase buffer 
(1 mL/10 samples) 
10 x MNase reaction 
buffer 
1 x Prepare freshly Chromatin wash 
100 x BSA 1 x 
Chromatin digest 
buffer 
(1 mL/10 samples) 
10 x MNase reaction 
buffer 
1 x Prepare freshly Chromatin digest 
100 x BSA 1 x 
MNase 50 U 
PNKT buffer 
(460 µL/replicate) 
T4 PNK buffer 1 x -20 °C RNA 
phosphorylation Tween 0.1 % v/v 
Cell lysis buffer 
(Ørom) 
(4 mL/10 samples) 
Tris-HCl pH 7.4 10 mM Prepare freshly Fractionation 
NaCl 150 mM 
NP-40 0.15 % v/v 
PhosSTOP 1 x 
Protease Inhibitor 1 x 
Sucrose buffer 
(Ørom) 
(10 mL/10 samples) 
Tris-HCl pH 7.4 10 mM Prepare freshly Fractionation 
NaCl 150 mM 
Sucrose 24 % w/v 
PhosSTOP 1 x 
Protease Inhibitor 1 x 
Glycerol buffer 
(Ørom) 
(2.5 mL/10 samples) 
Tris-HCl pH 7.4 20 mM Prepare freshly Fractionation 
NaCl 75 mM 
EDTA 0.5 mM 
Glycerol 50 % v/v 
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PhosSTOP 1 x 
Protease Inhibitor 1 x 
Nuclear lysis buffer 
(Ørom) 
(2.5 mL/10 samples) 
Tris-HCl pH 7.4 10 mM Prepare freshly Fractionation 
NaCl 300 mM 
EDTA 0.2 mM 
MgCl2 7.5 mM 
NP-40 1 % v/v 
Urea 1 M 
PhosSTOP 1 x 
Protease Inhibitor 1 x 
Dynabeads wash 
(DW) buffer 
DPBS, no Ca2+, no 
Mg2+ 
 Prepare freshly IP 
BSA 0.1 % v/v 
EDTA 2 mM 
IP buffer 
(15 mL/replicate) 
Tris-HCl pH 7.4 50 mM Prepare freshly IP 
NaCl 150 mM 
NP-40 0.05 % v/v 
Empigen BB (~30 %) 1 % v/v 
PhosSTOP 1 x 
Protease Inhibitor 1 x 
7 M urea LB 
(10 µL/replicate) 
Urea 7 M RT RNA size selection 
7 M urea LB with 
tracking dyes 
Urea 7 M RT RNA size selection 
Bromophenol blue 0.05 % w/v 
Xylene cyanol 0.05 % w/v 
Elution buffer 
(1 mL/replicate) 
Sodium acetate pH 5.2 1 M Prepare freshly RNA size selection 
EDTA 1 mM 
6 % PAGE (10 mL) Urea 7 M Prepare freshly RNA size selection 
40 % bis-acrylamide 
(19:1) 
6 % v/v 
10 x TRIS borate - 
EDTA (TBE) buffer 
solution 
1 x 
TEMED 10 µL 
10 % w/v ammonium 
persulfate (APS) 
50 µL 
Part II – Materials and Methods 
 
   30 
1.7 Software and databases 
 
Table 19. Overview of software and databases used in this thesis. 
 
Software Developer Version Ref 
Mac OS High Sierra Apple, USA 10.13.6  
Adobe Illustrator CS6 Adobe Systems Inc., USA 16.0.0  
Microsoft Word and Excel for Mac Microsoft Corp., USA 16.16.8  
Fiji / Image J Open source 2.0.0 398 
qPCRsoft Analytik Jena, Germany 3.4.6.0  
ChemoStar Imager Intas v.0.3.39  
NanoDrop Software Peqlab   
4200 TapeStation Analysis 
Software 
Agilent Technologies Inc. A.02.01  
PROSize Data Analysis Software 
(Fragment Analyzer) 
Agilent Technologies Inc. 3.0  
SonoLab 7 (Covaris S220) Covaris, USA 7.2.1.0  
Primer3 HHMI, open source software for high-
throughput primer design, USA 
v.0.4.0  399 
NCBI U.S. National Library of Medicine, USA NA  
Integrative Genomics Viewer, IGV 
desktop application 
Broad Institute and the Regents of the 
University of California 
2.4.10 400 
Endnote X8 Clarivate Analytics X8.2  
Bcl2fastq Illumina 2.20.0.422  
fastQC Babraham Institute Bioinformatics 0.11.5 401 
Cutadapt Marcel Martin 1.9.1 402 
STAR Open source 2.3.0 403 
Samtools John Marshall and Petr Danecek 1.3.1 404 
HTSeq EMBL Heidelberg, Genome Biology Unit 0.6.1 405 
R/Bioconductor https://www.r-project.org/ 3.1.2 406 
Cyberduck David Kocher, Yves Langisch 6.6.2  
Clustal Omega  EMBL-EBI, Wellcome Genome Campus 1.2.4 407 
Optimized CRISPR design  Web tool, Feng Zhang 
http://crispr.mit.edu/ 
NA  
SnapGene GSL Biotech LLC 3.3.4  
KInhibition, kinase inhibitor 
selection tool 
Fred Hutch online portal to search publicly 
available datasets 
NA 408 
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2. Methods 
 
This section lists methods used in this thesis. If applicable, a detailed list of contributions can 
be found at the beginning of each subsection or paragraph (in italic). 
 
 
2.1 General methods 
 
2.1.1 Maintenance of human hematopoietic cell lines 
 
Growth conditions. I cultured K562 and Raji B (wildtype or CDK9as) cells (Table 13) in 
accordance with the DSMZ Cell Culture standards in RPMI 1640 medium containing 10 % 
heat inactivated fetal bovine serum (FBS), and L-glutamine or 1 x GlutaMAX supplement at 
37 °C in a humidified 5 % CO2 incubator (Table 14). For short term storage, cells were stored 
at -80 °C. For long term storage, cells were stored in liquid nitrogen. The freezing medium is 
described in Table 14. For each working stock, a growth curve was generated. Cell morphology 
was frequently controlled by light microscopy. All three cell lines used in this study displayed 
the phenotypic properties, including morphology and proliferation rate, that have been 
described in literature. 
 
Authentication. K562, Raji B wildtype and Raji B (CDK9as) cell lines were verified by 
Dr. Wilhelm Dirks (Leibniz Institute DSMZ, Molecular Biology group). DNA profiling was 
carried out using 18 different and highly polymorphic short tandem repeat (STR) loci. All 
three cell lines were derived of pure human cell cultures and had full-matching STR profiles, 
as indicated by a search of databases of cell banks ATCC (USA), JCRB (Japan), RIKEN 
(Japan), KCLB (Korea), and DSMZ (Germany) (international STR reference database) 409. 
The respective STR electropherograms are shown in Figure 5. 
 
Mycoplasma testing. Tests were performed in-house by Dr. Anna Sawicka (MPI-bpc, Dept. 
of Molecular Biology). K562, Raji B wildtype and Raji B (CDK9as) cells were verified to be 
free of mycoplasma contamination using Plasmo Test Mycoplasma Detection Kit according 
to manufacturer’s instructions. The kit provides a cellular assay for colorimetric detection 
using HEK-Blue™-2 cells in detection medium as sensor. 
 
Cell counting and biological replicates. I counted cells using a hemocytometer (Neubauer 
counting chamber) in 3 technical replicates, or by a Scepter™ 2.0 Cell Counter (Merck KGaA) 
according to manufacturer’s instructions. Biological replicates were cultured independently. 
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Figure 5. STR electropherograms of human hematopoietic cell lines used in this study. 
Shown are the STR profiles of human K562 cells (a), Raji B wildtype (b), and Raji B (CDK9as) (c) cells. 
Authentication of cell lines was performed by Dr. Wilhelm Dirks (Leibniz Institute DSMZ, Molecular Biology 
group). See main text for additional information. 
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2.1.2 Quantitative reverse transcription PCR of RNA in a two-step assay 
 
I established a qPCR assay to screen for optimal inhibitor concentrations and determine the 
best time points for subsequent TT-seq, RNA-seq and mNET-seq analysis. This approach 
makes use of RNA spike-ins for normalization 410 and targets introns of highly expressed and 
rapidly degraded transcripts (the selection is based on half-lives measured in K562 cells 168), 
or treatment-specific up- or downregulated transcripts (based on literature). 
 
Total RNA isolation and DNase treatment. I harvested 3-4 x 106 cells at 3,000 x g for 2 min 
for each time point and biological replicate (n>2). Total RNA was isolated with QIAzol 
according to manufacturer’s instructions except for the addition of 10 ng RNA spike-in mix 
168 together with QIAzol. To remove possible genomic DNA contamination, isolated RNA 
(10 µg) was treated with TURBO DNase according to manufacturer’s instructions. 
 
Reverse transcription (RT). For RT, I used random hexamer priming (5’-d(NNNNNN)-3’, 
N = G, A, T, or C) according to manufacturer’s instructions. Briefly, 1 µg of DNase-treated 
RNA, Random Hexamer primers (final concentration of 5 ng/µL), dNTPs mix (final 
concentration of 0.5 mM) were mixed and incubated at 65 °C for 5 min. Subsequently, 
Maxima H Minus Reverse Transcriptase (final concentration of 200 U) and 5 x Maxima RT 
buffer were added (+RT reaction). For DNA contamination control, cDNA synthesis was 
performed without enzyme (-RT reaction; substituted with water). The (-/+) RT reactions 
were incubated in a PCR cycler at 25 °C for 10 min, 50 °C for 30 min, and 85 °C for 5 min. 
 
Primer design. I designed primers for quantitative PCR (qPCR) by using the online primer 
design software Primer3 v.0.4.0 399. Criteria that differ to default settings were the following: 
product size ranges ‘80-150 100-200’; primer size optimum ‘25’; primer Tm minimum ‘60’, 
optimum ‘64’, maximum ‘70’; maximum Tm difference ‘2’, table of thermodynamic parameters 
‘SantaLucia 1998’; product Tm optimum ‘50’; primer GC minimum ‘35’, optimum ‘65’, 
maximum ‘80’; salt correction formula ‘SantaLucia 1998’; concentration of divalent cations 
‘3.5 mM’; concentration of dNTPs ‘0.2 mM’. Primer specificity (single product peak) was 
validated by melting profiles. Primer sequences, length, annealing temperature, amplicon 
length and position on target are reported in Table 8. 
 
Quantitative PCR (qPCR). cDNAs (50 ng) were amplified with SYBR® Select Master Mix 
according to manufacturer’s instruction with a final primer concentration of 400 nM. PCR 
reactions were run in 96-well optical plates sealed with optical adhesive cover on a qTOWER 
2.0/2.2 instrument. The following thermal cycling conditions were used (SYBR Select Master 
Mix reference, standard cycling mode): 50 °C for 2 min, 95 °C for 2 min, 40 cycles of 95 °C 
for 15 sec and 60 °C for 1 min. Three synthetic RNA spike-ins were used for normalization. 
The 2(-ΔΔCt) method was applied to calculate the normalized target gene expression fold 
change, with the amplification efficiency (E) for each target gene, slope of standard curve (S) 
and mean threshold cycle (Ct) 411. 
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2.1.3 Western blotting 
 
I performed Western blotting to determine the quality of cellular fractionation by enrichment 
of marker proteins in cytoplasm (GAPDH), nucleoplasm (U1 snRNP0), and chromatin 
(H3/H2B, phosphorylated POLR2A). 
 
The protocol consists of the following steps: sample preparation, protein separation, protein 
electrotransfer to a membrane, detection of marker proteins including blocking, probing with 
primary antibody and subsequently, with secondary horseradish peroxidase (HRP) conjugated 
antibody (subsection 1.4), chemiluminescence detection, and band quantification. Buffer 
compositions are listed in Table 16. 
Protein samples were denatured in 1 x Laemmli buffer at 70 °C for 10 min. Samples 
were stored at -20 °C, or directly applied to polyacrylamide gel electrophoresis (PAGE). 
NuPAGE™ 4-12 % Bis-Tris Protein Gels and MOPS buffer 412 were used according to 
manufacturer’s instructions. Briefly, proteins were separated at 200 V for 50 min. A PVDF 
membrane was cut to the size of the gel, activated in 100 % ethanol for 30 sec, and 
subsequently equilibrated in transfer buffer. After 50 min, NuPAGE was removed from the 
cassette, placed onto a filter paper and assembled in a XCell II Blot Module (semi-wet transfer 
unit) according to manufacturer’s instructions. Transfer of a single NuPAGE onto PVDF 
membrane was performed in transfer buffer at 30 V for 1 h. 
Membrane was stained with Ponceau S staining solution to visualize successful protein 
transfer 413. Membrane blocking was performed in 5 % milk PBS-T on a rocking surface for at 
least 1 h. Primary antibody was added overnight. A list of primary antibodies used in this 
study can be found in Table 11. Three washes of the membrane were performed using PBS-
T, each with incubation on a rocking surface for 5 min. Secondary antibody was added on a 
rocking surface for 1 h. A list of HRP-coupled secondary antibodies used in this study can be 
found in Table 12. Three washes were performed using PBS-T, each with incubation on a 
rocking surface for 5 min. 
ECL working solution of SuperSignal West Pico PLUS Chemiluminescent Substrate was 
prepared by mixing equal parts of the Stable Peroxide Solution and the Luminol/Enhancer 
Solution. After the last PBS-T wash, the membrane was rinsed several times with ECL 
working solution. Marker proteins were visualized by chemiluminescence detection on INTAS. 
Band quantification was performed by Fiji / Image J. 
 
2.1.4 Figures 
 
All figures in this work were generated in Adobe Illustrator. Genome browser views were 
generated in R/Bioconductor or using the Integrative Genomics Viewer. Metagene plots were 
generated in R/Bioconductor. Bar plots were generated in Excel. 
All plots were subsequently modified for visual purposes in Adobe Illustrator. The respective 
programs are listed in Table 19. 
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2.2 Multi-omics 
 
2.2.1 In vitro transcription (IVT) of RNA spike-ins 
 
Six synthetic RNA spike-in controls (Table 20) were selected and established by Dr. Katja 
Lidschreiber (MPI-bpc, Dept. of Molecular Biology) as previously published 168. Cloning of the 
selected spike-in sequence into a pUC19 cloning vector and verification was done by Dr. Anna 
Sawicka and Dr. Kristina Žumer (MPI-bpc, Dept. of Molecular Biology). 
 
 
Table 20. Characteristics of 4sU-labeled and unlabeled RNA spike-ins. 
Full-length sequences of the respective spike-in and plasmid maps are listed in the Appendix. Molecular mass (M) 
is calculated as described in section 2.2.4, and rounded to first decimal place. For 4sU-labeled spike-ins, 10 % of U 
is substituted with 4sU (τ = 0.1). 
 
Name 
Derived from 
ERCC ID 
Length Li 
[nt] 
Nucleotide composition 
%GC 𝛕 M [g/mol] 
A U C G 
2-4sU ERCC-00043 985 354 297 127 207 34 0.1 318,331.0 
12 ERCC-00170 949 323 296 114 216 35 0 306,481.8 
4-4sU ERCC-00136 1,014 314 268 189 243 43 0.1 327,586.2 
5 ERCC-00145 1,015 286 264 207 258 46 0 327,385.0 
8-4sU ERCC-00092 1,079 233 287 265 294 52 0.1 347,569.7 
9 ERCC-00002 1,037 226 263 272 276 53 0 333,378.4 
 
 
For IVT template generation, 3 µg of plasmid (Table 6, Table 20) was linearized using 
EcoRV-HF (blunt end cut) digestion mix containing 1 x CutSmart buffer and 1 µL of EcoRV-
HF enzyme (final volume 50 µL). I incubated the digestion mix at 37 °C for 1 h and 
terminated the reaction by adding 1/20 volume of 0.5 M EDTA. Subsequently, DNA was 
precipitated in 1/10 volume of 3 M sodium acetate pH 5.2, and 2 volumes of 100 % ethanol 
at -20 °C for 15 min. DNA was collected by centrifugation at 4 °C and 16,000 x g for 15 min. 
The pellet was washed twice using 75 % ethanol. DNA was air-dried and resuspended in 5 µL 
of H2O at a concentration of 0.1-1.0 µg/µL (quantified by NanoDrop). In vitro transcription 
(IVT) was performed using the MEGAscript T7 kit following manufacturer’s instruction. For 
IVT of 4sU-labeled spike-ins, 10 % of UTP was substituted with 4-thio-UTP. This is to ensure 
at least similar 4sU incorporation rates in the IVT as has been observed in human cell lines 
414-416. IVT reactions were incubated at 37 °C. After 4 h, reaction volume was filled up with 
H2O to 40 µL, then 2 µL of TURBO DNase was added and incubated at 37 °C for additional 
15 min. RNA spike-ins were purified with RNAClean XP beads following manufacturer’s 
instructions. RNA was quantified using NanoDrop and 5 % denaturing PAGE (see Figure 37 
for representative PAGE). The final RNA spike-in pool contained equal amounts (1 ng/µL 
per spike-in) of all six RNA spike-ins and was stored in aliquots at -80 °C. The same batch of 
spike-in pool was used for all of my TT-seq an RNA-seq experiments (Table 21, Table 23). 
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Figure 6. Detailed experimental workflow of TT-seq and mNET-seq experiments. 
See text of section 2.2.2 (TT-seq, RNA-seq) (a) and 2.2.3 (mNET-seq) (b) for details. (c) This diagram depicts 
the major (pre-)processing steps and corresponding tools (in dark blue). Steps unique to either mNET-seq, or TT-
seq and RNA-seq are highlighted with asterisk symbol(s). The output format is highlighted in green. For details 
see Supplementary Information V.2.1. Abbreviations: quality controls (QC), Integrative Genomics Viewer (IGV). 
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2.2.2 Transient transcriptome sequencing (TT-seq) 
 
I optimized the experimental conditions for labeling of hematopoietic (suspension) cell lines 
(K562, Raji B wildtype, Raji B CDK9as) upon different treatments (see also subsection 2.1.2) 
based on a protocol published by the Cramer lab 168. I performed all TT-seq experiments 
(listed in Table 21 and Table 23). 
 
 
 
The methods presented in subsection 2.2.2 are currently under peer review for publication: 
 
S. Gressel *, K. Lidschreiber * et al. Transient transcriptome sequencing: experimental 
protocol to monitor genome-wide RNA synthesis including enhancer transcription.  
Methods Mol Biol, in revision 
(* joint first authorship) 
 
 
The TT-seq protocol 168 (Figure 6 a) consists of the following steps: (1) RNA spike-in pool 
preparation, (2) cell treatment and 4sU labeling of cellular RNA, (3) RNA spike-in addition 
and total RNA extraction (protocol based on 417), (4) mild RNA fragmentation, (5) 
biotinylation of labeled RNA using HPDP-biotin (protocol based on 365), (6) pull-down of 
labeled RNA using magnetic streptavidin beads, (7) labeled and total fragmented RNA clean-
up including DNase I digest, (8) next-generation sequencing library preparation including 
random priming, cDNA fragmentation, rRNA depletion, and determination of PCR 
amplification cycle number, (9) quality control and Illumina sequencing. Buffer compositions 
are listed in Table 17. 
 
(1) RNA spike-ins. Six synthetic RNA spike-in controls (three unlabeled and three 4sU 
labeled spike-ins) were established for validation of labeled RNA enrichment, global 
normalization and for estimating possible cross-contamination from unlabeled RNA 
fragments 168. The spike-ins are derived from selected RNAs of the ERCC RNA Spike-in 
Mix. For a detailed protocol see subsection 2.2.1 and Table 20. 
 
(2) Cell treatment and 4sU labeling. Cells were diluted 48 h before the labeling experiment 
was performed. Growth medium was exchanged 24 h before labeling. Prior to 4-thiouridine 
(4sU) labeling, cells were counted and treatments were performed (subsection 2.3.2 or 
2.4.1). The exact cell count is required to calculate the corresponding amount of RNA 
spike-ins. For labeling, 4sU was added to ~3.5 x 107 cells in 50 mL of growth medium to 
a final concentration of 500 µM, and incubated at 37 °C, 5 % CO2 for 5 min. Exactly after 
5 min of labeling, cells were centrifuged at 37 °C and 3,000 x g for 2 min. The cell pellet 
was vortexed with 5 mL of QIAzol lysis reagent, incubated for 5 min, and stored at  
-80 °C. 
 
(3) Total RNA extraction. Lysates were thawed and 150 ng of RNA spike-in pool (~43 ng/107 
cells) was added, mixed and incubated for 5 min. Per 1 mL of Qiazol 0.2 mL of chloroform 
(1 mL) was added, mixed for 15 sec and incubated for 5 min. Lysates were centrifuged at 
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4 °C and 13,000 x g for 15 min. Aqueous phase was transferred to new 15 mL centrifuge 
tube, an equal volume of isopropanol was added, mixed, and incubated for 10 min. To 
precipitate total RNA, samples were centrifuged at 4 °C and 13,000 x g for 10 min. The 
RNA pellet was washed twice using 75 % ethanol at 4 °C and 13,000 x g for 10 min. The 
pellet was dissolved in 600 to 1,000 µL H2O (aiming for a final concentration of 
≥ 750 ng/μL). Concentration and purity of total RNA was determined by NanoDrop 
spectrophotometer. Total RNA was stored at -80 °C. 
 
(4) Mild RNA fragmentation. Total fragmented RNA should be in a range between 0.2 to 
15 kbp. Two-times 150 µg of total RNA in a volume of 130 µL were transferred to 130 µL 
microTUBE AFA Fiber Snap-Cap tubes. The following settings were used on 
Covaris S220: water level 12, temperature 7 °C, peak incident power 100 W, duty factor 
1 %, cycles per burst 200, treatment time 10 sec. 
 
(5) Biotinylation. EZ-link HPDP-biotin is pyridyldithiol-activated and allows thiol-specific 
biotinylation of labeled RNA. Total fragmented RNA was incubated at 65 °C for 10 min, 
then placed on ice for 5 min. If RNA-seq was performed, 5 µL of total fragmented RNA 
were saved for DNase I digest. RNA was splitted into two 2 mL PP microtubes 
(150 µg/reaction) and processed in parallel. Water was added up to 700 µL. Subsequently, 
100 µL of 10 x biotinylation buffer, 200 µL of EZ-link HPDP-Biotin stock solution were 
added. Samples were incubated in the dark with rotation for 2 h. RNA was extracted and 
unbound biotin was removed using MaXtract High Density tubes following manufacturer’s 
instructions. For RNA precipitation, 1/10 volume of 5 M NaCl and an equal volume of 
isopropanol was added, mixed and centrifuged at 4 °C and 13,000 x g for 30 min. The 
RNA pellet was washed twice using 75 % ethanol at 4 °C and 13,000 x g for 10 min. The 
pellet was dissolved in 100 µL H2O per biotinylation reaction. The two RNA samples 
processed in parallel were pooled. 
 
(6) Pull-down of labeled RNA. µMACS wash buffer (3 mL per sample) was heated to 65 °C, 
or kept at room temperature (3 mL per sample). µMACS streptavidin beads were added 
to RNA sample (200 µL) in a ratio of 1:2, and incubated at 4 °C for 15 min. In the 
meantime, µMACS columns were equilibrated with 100 µL of nucleic acids equilibration 
buffer. Elution buffer (0.1 M DTT) was prepared freshly. RNA-bead-mix was transferred 
to the µMACS column, the flow-through was collected in LoBind tubes and reapplied 
twice. Columns were washed 3-times with 900 µL of wash buffer (65 °C), and 3-times with 
900 µL of wash buffer (RT). Labeled RNA was eluted twice in 100 µL of 0.1 M DTT (final 
volume of 200 µL). 
 
(7) RNA clean-up. Labeled RNA (TT-seq) and 1 µg of total fragmented RNA (RNA-seq) 
were processed in parallel. RNA was purified using either RNAClean XP beads or 
miRNeasy Micro Kit according to manufacturer’s instructions (as recommended, buffer 
RWT was prepared with isopropanol instead of ethanol). RNA was quantified by Qubit 
High Sensitivity RNA kit. Labeled RNA enrichment was controlled by RT-qPCR (see 
subsection 2.1.2) using primer pairs for RNA spike-ins (Table 8) to estimate labeled 
enrichment. For total fragmented RNA, the Ct values of labeled and unlabeled RNA 
spike-ins were very similar. Labeled RNA showed a Ct value difference of >5 for labeled 
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and unlabeled RNA spike-ins (Figure 7). 
 
 
 
 
Figure 7. Labeled spike-ins are enriched in TT-seq compared to RNA-seq samples. 
Bar plot depicts enrichment (∆∆Ct) of labeled spike-in for TT-seq (5 min of 4sU labeling; blue) and total RNA-
seq samples (grey) collected in Raji B (CDK9as) or K562 cells. Conditions are listed in the table at the bottom. 
RT-qPCR was performed as described in subsection 2.1.2 using primers for spike-ins 12 and 4 (Table 8). 
Corresponding normalized Ct values (∆Ct) and enrichment values (∆∆Ct) can be found in Table 30. 
 
 
(8) Library preparation. Input RNA (100 ng) was treated with HL-dsDNase and used for 
strand-specific library preparation according to the Ovation Universal RNA-Seq System 
with minor modifications. For ‘First Strand Primer Pre-mix Preparation’, only Random 
primer mix was used (poly-d(T) primers were substituted with 0.4 µl H2O). The User 
guide’s instructions were followed from ‘First Strand Synthesis Using DNase-treated RNA’ 
to ‘Second Strand cDNA Synthesis’. For fragmentation, Covaris S220 and 130 µL 
microTUBE AFA Fiber Snap-Cap tubes were used with the following settings: water level 
12, temperature 7 °C, peak incident power 145 W, duty factor 10 %, cycles per burst 200, 
treatment time 50 sec. The User guide’s instructions were followed from ‘cDNA 
Concentration After Fragmentation’ to ‘Adaptor Cleavage’. During ‘Ligation’ unique 
indexes (barcodes) were used per library (Table 21, Table 23). To avoid over-
amplification, the precise number of PCR cycles was determined by the KAPA HIFI 
Library Amp Real Time kit following manufacturer’s instructions. As input, 4.2 µL 
(~10 %) of the library, 5 µL of 2x Kapa HiFi Hot Start Master Mix and 0.8 µL 
Amplification Primer Mix P2 were used. For ‘PCR amplification’ of the remaining ~45 µL 
of library the determined number of PCR cycles (usually 10-15 cycles) were used following 
the User guide’s instructions for amplification as described in the Appendix ‘Using qPCR 
to determine the Number of PCR Cycles’. The User guide’s instructions were followed 
from ‘Bead Purification of the Amplified Material’ to ‘Quantitative and Qualitative 
Assessment of the Library’. Library cDNA concentration was measured by Qubit HS RNA 
kit. 
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(9) Quality control and Illumina sequencing. The size of the purified cDNA libraries was 
determined on a Fragment Analyzer. A representative size distribution of TT-seq and 
RNA-seq libraries prior to Illumina sequencing is depicted in Figure 8 a-b. Clustering and 
sequencing were performed on a HiSeq 1,500 or 2,500 (Illumina) in paired-end mode with 
50 bp read length 381, or on a NextSeq 550 (Illumina) in paired-end mode with 75 bp read 
length. An overview of generated libraries and sequencing statistics can be found in Table 
22 and Table 25. 
 
(10) Data processing. Data processing was performed by Dr. Björn Schwalb (MPI-bpc, Dept. 
of Molecular Biology) as previously published 168,381. For details see Supplementary 
Information V.2.1.1 and Figure 6 c. 
 
 
 
 
Figure 8. Size distribution of cDNA libraries generated in this study. 
Digital electropherograms show distribution of cDNA fragments size (library size includes both, adapters and 
insert). Purified cDNA libraries were analyzed by monitoring the relative fluorescence unit (RFU) intensity during 
capillary electrophoresis separation (size range 0.1-6 kbp) using Fragment Analyzer. The Fragment Analyzer run 
was performed in-house by Sigurd Hille, Kerstin Maier or Petra Rus (MPI-bpc, Dept. of Molecular Biology). 
(a) TT-seq cDNA library. (b) RNA-seq cDNA library. (c) mNET-seq cDNA library. 
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2.2.3 Mammalian native elongating transcript sequencing (mNET-seq) 
 
I established a protocol for human hematopoietic (suspension) cell lines (K562, Raji B CDK9as) 
based on protocols published by the Proudfoot lab 350,388 and performed all mNET-seq 
experiments (listed in Table 21 and Table 23). 
 
The final mNET-seq protocol (Figure 6 b) consists of the following steps: (1) cell fractionation 
(protocol based on 418) and chromatin digestion, (2) immunoprecipitation (IP) of total Pol II 
including Empigen BB detergent (protocol based on 391), (3) RNA phosphorylation, (4) RNA 
precipitation and size selection (protocol based on 419), (5) next-generation sequencing library 
preparation including 3’ and 5’ RNA adapter ligation, reverse transcription, cDNA library 
amplification, size selection and purification, and (6) quality control and Illumina sequencing. 
Buffer compositions are listed in Table 18. 
 
(1) Cell fractionation. Cells were diluted 48 h before the experiment was performed, and 
growth medium was exchanged 24 h before the experiment. Cells were counted and 
treatments were added (see subsection 2.3.2 or 2.4.1). Cells were collected in a swing-
bucket centrifuge at 4 °C and 200 x g for 5 min. Cells were washed using 10 mL of DPBS 
and centrifuged at 4 °C and 200 x g for 5 min. The cell pellet was resuspended at 107 cells 
per mL in DPBS and transferred to 1.5 mL tubes (i.e. for 108 cells, ten-times 1 mL). Per 
replicate, samples were processed in parallel for fractionation and MNase digest, and 
pooled before the IP step. Cells were centrifuged in a fixed-angle benchtop centrifuge at 
4 °C and 200 x g for 2 min. The supernatant was removed, the cell pellet was gently 
resuspended in 400 µL of cell lysis buffer, and incubated on ice for 5 min. The cell lysate 
was overlaid on top of 1 mL sucrose buffer, and centrifuged at 4 °C and 2,000-3,500 x g 
for 10 min. The resulting supernatant contains the cytoplasm (kept for fractionation 
control), and the pellet contains cell nuclei. During the centrifugation step, MNase was 
added to the chromatin digest buffer to a final concentration of 50 U, and warmed up to 
37 °C. Cell nuclei were resuspended in 250 µL of glycerol buffer and 250 µL of nuclear 
lysis buffer, and incubated on ice for 2 min. To precipitate the chromatin-Pol II-RNA 
complex, samples were centrifuged at 4 °C and 13,000 x g for 2 min. The resulting 
supernatant contains the nucleoplasm (kept for fractionation control). The pellet was 
washed once with 100 µL of 1 x MNase buffer (without MNase). To digest the chromatin-
RNA pellet, 100 µL of pre-warmed chromatin digest buffer as added at 37 °C and 
1,400 rpm for 90-120 sec (K562: 120 sec; Raji B CDK9as: 90 sec). For a reproducible digest 
it is critical to control temperature of the thermomixer. The digest was stopped by adding 
11 µL of 250 mM EGTA (final concentration 25 mM) and transfer to ice. Samples were 
centrifuged at 4 °C and 13,000 x g for 5 min. Supernatant of all samples per replicate were 
pooled (i.e. for 108 cells, ~1 mL). The quality of cell fractionation was controlled by 
Western blot of marker proteins. 
 
(2) IP of total Pol II with 1 % v/v Empigen BB (~30 % active substance). Chromatin-
Pol II-RNA complexes were 8-fold diluted with IP buffer. Antibody-conjugated Dynabeads 
M-280 Sheep anti-mouse IgGs were prepared based on manufacturer’s instructions. 
Briefly, for 108 cells 250 µL of Dynabeads (~10 mg/mL) were washed three-times with 
DW buffer. 30 µg of Pol II POLR2A total CTD (all isoforms) antibody (CMA601) was 
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added, and coupled by slow rotation at 4 °C and 8 rpm for 2 h or overnight. Antibody-
conjugated Dynabeads were washed three-times with DW buffer, resuspended in IP buffer 
and added to diluted chromatin-Pol II-RNA complexes. IP was incubated on a rotating 
wheel at 4 °C and 12 rpm for 1 h. The tube was transferred to a big magnet for 5 min, 
the supernatant removed by decanting, and the remaining beads were transferred to a 
new 1.5 mL LoBind tube using 1 mL of IP buffer. Beads were washed six times with 1 mL 
IP buffer. For each wash, solution was transferred to the magnet for 1 min before 
supernatant was removed. Beads were resuspended in 300 µL of PNKT buffer. 
 
(3) RNA phosphorylation. To control RNA size distribution, 1/10 volume of IP 
(corresponding to 107 cells) was subjected to 32P-g-ATP labeling in the hot lab according 
to MPI-bpc safety regulations. For 32P-g-ATP labeling, beads were resuspended in 10 µL 
PNK hot reaction mix containing 8.5 µL of PNKT, 0.5 µL of T4 polynucleotide kinase 
(PNK) 3’ phosphatase minus (20 U/µL) and 1 µL of fresh 32P-g-ATP. For ATP labeling, 
beads were resuspended in 200 µL of PNK reaction mix containing 160 µL PNKT, 10 µL 
of T4 PNK 3’ phosphatase minus (20 U/µL) and 30 µL of 10 mM ATP. Reactions were 
incubated at 37 °C and 800 rpm for 10 min. Beads were washed with 1 mL IP buffer, 
resuspended in 1 mL of TRIzol reagent and incubated for 5 min. Samples were stored at 
-20 °C. 
 
(4) RNA precipitation and size selection (25-110 nt). Samples were thawed, 200 µL of 
chloroform was added, mixed by vortexing and incubated for 2 min. Subsequently, 
samples were centrifuged at 4 °C and 16,000 x g for 15 min. The upper aqueous phase 
(~0.5 mL) was transferred to a new 1.5 mL tube. 1 µL of GlycoBlue co-precipitant and 
equal volume (~0.5 mL) of isopropanol were added, mixed and incubated for 10 min. RNA 
was precipitated by centrifugation at 4 °C and 16,000 x g for 10 min. RNA pellets were 
air-dried for ~3 min and dissolved in 10 µL of 7 M urea LB. Denaturing 6 % 
polyacrylamide gel solution (PAGE) was prepared, poured into a 1 mm cassette with a 
15-well comb and polymerized for at least 30 min. The comb was removed and PAGE was 
pre-run in electrophoresis tank with 1 x TBE buffer at 200 V for 30 min. Wells were 
washed with a syringe to remove urea before sample loading. 7 M urea LB containing 
0.05 % bromophenol blue and 0.05 % xylene cyanol dyes was used to follow sample 
migration. In a 6 % PAGE, bromophenol blue migrates at ~25 nt and xylene cyanol at 
~110 nt (Figure 39). Samples were run at 200 V for 30 min. For 32P-g-ATP labeled RNA, 
size distribution was visualized by phosphorimaging on a Typhoon FLA 9500 instrument. 
For ATP labeled RNA, the gel was cut above the bromophenol blue band and above the 
xylene cyanol band. RNA was extracted by crush-and-soak. Briefly, 2 mL tubes were 
prepared for RNA recovery by inserting a 0.5 mL tube which was pierced several times 
with a 22 gauge syringe needle. Gel slices were transferred to 0.5 mL tube and centrifuged 
at 16,000 x g for 2 min. The 0.5 mL tube was removed, 500 µL of elution buffer was added 
to the gel fragments and rotated at 12 rpm for 3 h. Samples were centrifuged at 16,000 x g 
for 1 min, and the elution was repeated from the gel fragments. Supernatant was 
transferred to a spin-X column with cellulose acetate membrane and centrifuged at 
16,000 x g for 1 min. Flow-through was transferred to new 2 mL tube, 0.5 µL of GlycoBlue 
co-precipitant and 2.5 volumes of 100 % ethanol were added and incubated at -20 °C for 
30 min. Samples was centrifuged at 4 °C and 16,000 x g for 10 min. RNA pellets were air-
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dried for ~5 min. The first pellet was dissolved in 5 µL of H2O, and then transferred to 
the RNA pellet of the second elution (final volume 5.5 µL). RNA was stored at -80 °C. 
 
(5) Library preparation. Input RNA (5 µL) was used for strand-specific library preparation 
according to the TruSeq Small RNA Library Prep Kit (Illumina) with modifications 
described below. The Reference Guide’s instructions were followed from ‘Ligate 3’ 
Adapter’ to ‘Amplify Libraries’. During amplification (15 cycles) unique PCR primer 
barcodes of Indices A or D Box (sequences 1-12, or 37-48) were used per library according 
to Illumina’s Pooling Guidelines. cDNA size selection (150-230 nt) was performed using 
4 % E-Gel High-ReSolution agarose gels, loading a maximum of two libraries per gel. Gels 
were loaded with TrackIt 25 bp DNA ladder, HRL ladder, CRL ladder, 25 µL of library 
in two wells, and 20 µL of H2O in all empty wells. Gels were run in iBase Power system 
using program 2 at maximum run time (40 min). Bands were visualized on a 
transilluminator by exposure to UV light. Libraries were cut using sterile disposable 
scalpels no. 23. Libraries were purified using QIAquick MinElute Gel Extraction Kit 
according to manufacturer’s instructions. The kit recovers ~80 % of DNA (70 bp – 4 kbp). 
cDNA was eluted in 11 µL.  
 
(6) Quality control and Illumina sequencing. The size of the purified cDNA libraries was 
determined on a Fragment Analyzer. A representative size distribution of mNET-seq 
libraries is depicted in Figure 8 c. Clustering and sequencing were performed on a HiSeq 
1,500 or 2,500 (Illumina) in paired-end mode with 50 bp read length 381, or on a NextSeq 
550 (Illumina) in paired-end mode with 75 bp read length. An overview of generated 
libraries and sequencing statistics can be found in Table 22 and Table 25. 
 
(7) Data (pre-)processing. Data processing was performed by Dr. Björn Schwalb (MPI-bpc, 
Dept. of Molecular Biology) as published 381. For details see Supplementary Information 
V.2.1.2 and Figure 6 c. 
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2.2.4 Kinetic modeling (I, d), pause site n* and the ‘pause-initiation limit’ 
 
Kinetic modeling was designed in collaboration with Dr. Björn Schwalb (MPI-bpc, Dept. of 
Molecular Biology) who also performed the final analysis. 
 
 
 
The methods presented in subsection 2.2.4 have been published: 
 
S. Gressel *, B. Schwalb * et al. CDK9-dependent RNA polymerase II pausing controls 
transcription initiation. Elife 6, doi:10.7554/eLife.29736 (2017). 
(* joint first authorship) 
 
 
Detection of pause sites. For all expressed (c)TUs or RefSeq-TUs (exceeding 10 kbp in length 
with one unique TSS given all RefSeq annotated isoforms (UCSC RefSeq GRCh38)) i the 
pause site 𝑛∗was calculated for all bases m in a window of 350 bp downstream of the GRO-
cap refined TSS, or in a window from the TSS to the end of the first exon (excluding the last 
5 bp) via maximizing the function 
𝜌0 = max4 𝑝04, 
 
where 𝜌0 needed to exceed 5 times the median of the signal strength 𝑝04 for all non-negative 
antisense bias corrected mNET-seq coverage values. In order to maximize the chances of 
finding the most likely pause site, two replicate tracks were constructed by taking the 
maximum of each nucleotide over the first and second replicates, respectively, regardless of 
treatment. We defined the pause site at the active site based on structural information 307 
(Figure 2 a). The RNA-DNA hybrid within the paused polymerase is in the so-called tilted 
state that hinders nucleotide addition at the active site. Thus, the subsequent nucleotide is 
not added yet. We defined the pause site to be the position in line with the 'post-translocated' 
RNA rather than with the 'pre-translocated' DNA. In conclusion, the pause site was calculated 
as 𝑛∗ = 𝑚∗ + 1, where m* is the argument that maximizes 𝜌0. 
 
Molecular weight conversions. The known sequence and mixture of the utilized spike-ins 
allows to calculate a conversion factor to RNA amount per cell [cell-1] given their molecular 
weight assuming perfect RNA extraction. The number of spike-in molecules per cell N [cell-1] 
was calculated as 
𝑁 =
𝑚
𝑀𝑛
𝑁: 
with the mass m 25∙10-9 [g] per spike-in (in this study, pool with equal mass per spike-in), the 
number of cells n (first study: 3.27∙107 Raji B CDK9as cells; second study: 3.8∙107 for K562, 
3.4∙107 for RajiB CDK9as) the Avogadro constant NA 6.02214085774∙1023 [mol-1] and molar-
mass (molecular weight) of the spike-ins M [g mol-1] calculated as 
 
𝑀 = 𝐴= ∙ 329.2 + (1 − 𝜏) ∙ 𝑈= ∙ 306.2 + 𝐶= ∙ 305.2 + 𝐺= ∙ 345.2 + 	τ ∙ 𝑈= ∙ 322.26 + 159 
 
where An, Un, Cn, and Gn are the number of each respective nucleotide within each spike-in 
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polynucleotide. τ is set to 0.1 in case of a labeled spike-in and 0 otherwise. The addition of 
159 to the molecular weight considers the molecular weight of a 5' triphosphate (see Table 
20). Provided the above, the conversion factor to RNA amount per cell 𝜅 [cell-1] can be 
calculated as 
𝜅 = mean
	
Nmedian
0
N
𝑡𝑏0
𝐿0 ∙ 𝑁
TT 
 
for all labeled spike-in species i with length Li. Note that imperfect RNA extraction efficiency 
would lead to an underestimation of cellular labeled RNA in comparison to the amount of 
added spike-ins and thus to an underestimation of initiation frequencies. In case of a strong 
underestimation however the real initiation frequencies would lie above the pause-initiation 
limit, which is theoretically impossible. Thus, we assume this effect to be insignificant. 
 
Estimation of the productive initiation frequency I. The antisense bias corrected number of 
transcribed bases 𝑡𝑏0UV=WXVY was calculated on all expressed (c)TUs or expressed RefSeq-TUs 
(exceeding 10 kbp in length with one unique TSS given all RefSeq annotated isoforms (UCSC 
RefSeq GRCh38)) i. For each (c)TU or RefSeq TU i the productive initiation frequency 
Ii [cell-1 min-1], which corresponds to the pause release rate, was calculated as 
 
𝐼0 =
1
𝜅
∙
𝑡𝑏0[V=WXVY
𝑡 ∙ 𝐿0
 
 
with labeling duration t = 5 [min] and length Li. Note that for RefSeq-TUs, 𝑡𝑏0[V=WXVY and Li 
were restricted to regions of non-first constitutive exons (exonic bases common to all isoforms) 
located in the first 25 kbp. Given a 30 min treatment, we expect only the first 35 kbp to be 
significantly affected by changes in initiation frequency assuming an average elongation 
velocity of 2.4 kbp/min. Additionally, changes in splicing rate upon heat shock treatment 209,420 
should not influence constitutive exonic regions. This is to ensure, not to be biased by 
alternative splicing. 
 
Estimation of pause duration d. For all expressed (c)TUs or expressed RefSeq-TUs 
(exceeding 10 kbp in length with one unique TSS given all RefSeq annotated isoforms (UCSC 
RefSeq GRCh38)) i the pause duration di [min] was calculated as the residing time of the 
polymerase in a window +/- 100 bases m around the pause site (see above) as 
 
𝑑0 =
∑ 𝑝04^/`	abb
𝐼0
∙ median
0
c
𝑣0
𝐼0𝑣0(𝑡∗ − 𝑡)/∑ 𝑝04XefgV=fe	h0=iVh
j 
 
with pause release rate 𝐼0 and the number of polymerases 𝑝04 (antisense bias corrected mNET-
seq coverage values in a window +/- 100 bases around the pause site. For pause sites below 
100 bp downstream of the TSS the first 200 bp of the TU were considered.  Note that the 
right part of the formula is restricted to mNETseq instances above the 50% quantile for 
robustness and adjusts di to an absolute scale by comparing the CDK9 derived elongation 
velocities	𝑣0 with those derived from combining mNET-seq and TT-seq data in the response 
window [200, 𝑣0(𝑡∗ − 𝑡)]. The productive initiation frequency represents the ‘true’ initiation 
frequency if the fraction of Pol II terminating within the pause window is insignificant 
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(unknown fraction of early termination). The pause duration d obtained in this way reflects 
the effective pause between two initiation events that successfully lead to productive 
elongation of a transcript and thus the relevant transcriptional outcome. 
 
Pause-initiation limit. The previously derived inequality from 315 
 
𝑣
𝐼
≥ 50	[𝑏𝑝] 
states that new initiation events into productive elongation are limited by the velocity of the 
polymerase in the promoter-proximal region and that steric hindrance occurs below a distance 
of 50 bp between the active sites of the initiating Pol II and the paused Pol II. Given the 
calculations of pause duration 𝑑 and (productive) initiation frequency 𝐼 above, we can 
reformulate this inequality to 
200	[𝑏𝑝]
𝑑 ∙ 𝐼
≥ 50	[𝑏𝑝] 
with 200 [bp] being the above defined pause window. 
 
 
2.3 CDK9-dependent Pol II pausing controls transcription initiation 
 
 
The methods presented subsections 2.3.1 (first paragraph), 2.3.4 and 2.3.5 have been 
published: 
 
S. Gressel *, B. Schwalb * et al. CDK9-dependent RNA polymerase II pausing controls 
transcription initiation. Elife 6, doi:10.7554/eLife.29736 (2017). 
(* joint first authorship) 
 
 
2.3.1 CRISPR/Cas9 engineering of human Raji B analog-sensitive CDK9 cell line 
 
The human Raji B (CDK9as) cell line was generated and validated by Dr. Weihua Qin (LMU 
Munich, Dept. of Biology II, group of Prof. Dr. Heinrich Leonhardt). 
 
CRISPR/Cas9 engineering. Analog sensitive CDK9 (CDK9as) contains a point mutation of 
the so-called gatekeeper residue that enables the kinase active site to accept bulky ATP 
analogs as 1-NA-PP1 (Figure 3 d-e). To identify the gatekeeper residue 339, the amino acid 
sequence of the human CDK9 kinase (UniProt, P50750-1) was aligned with sequences of 
previously characterized kinases carrying analog sensitive mutations. Multiple sequence 
alignment was performed with the web tool Clustal Omega 1.2.4 407. For the canonical isoform 
of CDK9, phenylalanine (F) 103 was identified as the gatekeeper residue and selected for 
mutation to alanine (A). Mutation of F103 at the CDK9 gene loci in Raji B cells was 
performed using the CRISPR/Cas9 system 344,345 as described 421 with minor modifications 
(Figure 9 a). Briefly, the single guide RNA (sgRNA) for editing CDK9 was designed by using 
the web tool Optimized CRISPR design (http://crispr.mit.edu/), and was incorporated to 
pSpCas9(BB)-2A-GFP (PX458) vector by BpiI restriction sites (Addgene plasmid #48138) 397 
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(Table 7, see Appendix for plasmid map). For nucleotide replacement (gttc to cgcg), 200 nt 
single-stranded DNA oligonucleotides (ssODNs) were synthesized by Integrated DNA 
Technologies and used as homology-directed repair (HDR) template (Table 10). A BstUI 
cutting site was incorporated into the HDR template for screening. The vector and HDR 
template were introduced into human Raji B cells by using Amaxa Mouse ES Cell 
Nucleofector® Kit according to the manufacturer’s instructions. Two days after transfection, 
GFP positive cells were single cell sorted into 96 well plates using FACS Aria II instrument. 
After two weeks, individual colonies were expanded for genomic DNA isolation. 
 
Genomic DNA (gDNA) extraction. 105 Raji B wildtype or Raji B (CDK9as) cells were used 
for gDNA extraction. Medium was aspirated and cells washed once with DPBS. Cell lysis and 
gDNA extraction was performed using 100 µL of Quick Extraction solution per 105 cells 
according to manufacturer’s instructions. Briefly, the lysate was incubated at 65 °C for 15 min 
and subsequently at 95 °C for 10 min. The final DNA concentration was measured by 
NanoDrop. 
 
Target DNA PCR amplification and purification. Per reaction, 100 ng of gDNA template 
were used. PCR amplification was performed using AccuPrime GC-Rich DNA Polymerase 
according to manufacturer’s instructions. Briefly, forward and reverse primers (final 200 nM 
each) (Table 9), buffer A (GC-rich template, 2 mM MgSO4), AccuPrime DNA polymerase 
(1 U) were added to gDNA template. Reactions were run using the following program in a 
thermal cycler with a lid temperature of 99 °C. The PCR product was analysed on a 2 % 
agarose gel containing SYBRsafe. Bands were visualized on a transilluminator by exposure to 
UV light. DNA band was cut using sterile disposable scalpels no. 23 (Swann-Morton) and 
purified using QIAquick MinElute Gel Extraction Kit according to manufacturer’s 
instructions. DNA was eluted in 11 µL. DNA concentration was measured by NanoDrop. 
 
Step Temperature Time Cycle 
1 95 °C 3 min 1 x 
2 95 °C 30 sec 
25-30 x 3 (Tm of primers – 5 °C) 30 sec 
4 72 °C 30 sec 
5 72 °C 10 min 1 x 
6 4 °C hold  
 
BstUI digest. For restriction digest, purified PCR product (200 ng) was digested using 49 µL 
of BstUI digestion mix containing 1 x CutSmart buffer and 1 µL of BstUI enzyme. The 
digestion mix was incubated at 60 °C for 15 min and terminated by adding 1 volume of gel 
loading dye at 70 °C for 10 min. Samples (wildtype, CDK9as) were analyzed on a 2 % agarose 
gel containing SYBRsafe. Bands were visualized on a transilluminator by exposure to UV 
light. 
 
Sanger cycle sequencing using capillary electrophoresis. 1 µg of purified PCR product was 
submitted for Sanger sequencing. Sequencing primers are listed in Table 9.
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Figure 9. CRISPR/Cas9 engineering of analog-sensitive CDK9 in human Raji B cells. 
(a) Detailed experimental workflow of CRISPR/Cas9 engineering of the CDK9as cell line. See Method 2.3.1 for 
details. (b) IGV400 browser shot of TT-seq data (Table 21) at the CDK9 locus (top: entire gene; bottom: zoomed 
to exon 4 carrying F103A mutation in CDK9as). Reads containing mutated residues (gttc to cgcg) (>2 mismatches 
per 50 bp read) cannot be mapped to the reference genome (highlighted by red box). 
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2.3.2 Cell treatment: CDK9as inhibition 
 
Optimization of 1-NA-PP1 concentration was performed by Dr. Tim M. Decker (Helmholtz 
Center Munich, Dept. of Molecular Epigenetics, group of Prof. Dr. Dirk Eick) as published 381. 
 
Based on the cell proliferation (MTS) assay and Pol II CTD phosphorylation data we chose 
5 µM of 1-NA-PP1 and 15 min as treatment conditions for the TT-seq and mNET-seq analysis 
of Raji B (CDK9as) cells. 
 
2.3.3 Multi-omics experiments 
 
TT-seq and mNET-seq experiments were performed as described (section 2.2). I performed all 
TT-seq and mNET-seq experiments. For four TT-seq experiments (Table 21, no. 1-4), 
Dr. Tim M. Decker (Helmholtz Center Munich, Dept. of Molecular Epigenetics, group of Prof. 
Dr. Dirk Eick) contributed to steps (2) to (7) (see section 2.2.2, steps 2-7). 
 
 
Table 21. Information on experimental conditions used in this study. 
 
No. Assay Cell type Condition name 
Replicate 
no. 
Treatment 
1 TT-seq Raji B (CDK9as) Ctrl 1 0.05 % v/v DMSO, 15 min. 
2 TT-seq Raji B (CDK9as) Ctrl 2 0.05 % v/v DMSO, 15 min. 
3 TT-seq Raji B (CDK9as) CDK9 inhibited 1 5 µM 1-NA-PP1, 15 min. 
4 TT-seq Raji B (CDK9as) CDK9 inhibited 2 5 µM 1-NA-PP1, 15 min. 
5 TT-seq Raji B Ctrl 1 0.05 % v/v DMSO, 15 min. 
6 TT-seq Raji B Ctrl 2 0.05 % v/v DMSO, 15 min. 
7 TT-seq Raji B CDK9 inhibited 1 5 µM 1-NA-PP1, 15 min. 
8 TT-seq Raji B CDK9 inhibited 2 5 µM 1-NA-PP1, 15 min. 
9 mNET-seq Raji B (CDK9as) Ctrl 1 0.05 % v/v DMSO, 15 min. 
10 mNET-seq Raji B (CDK9as) Ctrl 2 0.05 % v/v DMSO, 15 min. 
11 mNET-seq Raji B (CDK9as) CDK9 inhibited 1 5 µM 1-NA-PP1, 15 min. 
12 mNET-seq Raji B (CDK9as) CDK9 inhibited 2 5 µM 1-NA-PP1, 15 min. 
 
For TT-seq pre-processing and global spike-in normalization, as well as mNET-seq pre-
processing see Supplementary Information V.2.1. 
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2.3.4 Analysis of CDK9 response ratio 
 
Data analysis was performed by Dr. Björn Schwalb (MPI-bpc, Dept. Molecular Biology). 
 
Size factor normalization. We first checked that no significant global shifts were detected in 
a comparison of two TT-seq replicates with 1-NA-PP1 (CDK9as inhibitor) treatment against 
two TT-seq replicates with DMSO treatment (control) in the described spike-ins 
normalization strategy (V.2.1.1). Then all samples were subjected to an alternative, more 
robust normalization procedure. For each sample j the antisense bias corrected number of 
transcribed bases tbj was calculated on all expressed TUs i exceeding 125 kbp in length. 50 kbp 
were truncated from each side of the selected TUs to avoid influence of the response to CDK9as 
inhibition 302. On the resulting intervals, size factors for each sample j were determined as 
𝜎o = median0 p
𝑡𝑏0o
q∏ 𝑡𝑏0o4sta u
a/4v 
where m denotes the number of samples. This formula has been adapted 422 and was used to 
correct for library size and sequencing depth variations. 
 
Calculation of response ratios. For each condition j (control or CDK9as inhibited) the 
antisense bias corrected number of transcribed bases 𝑡𝑏0
o was calculated on all expressed TUs 
i exceeding 10 kbp in length. Of all remaining TUs only those were kept harboring one unique 
TSS given all Refseq annotated isoforms (UCSC RefSeq GRCh38). Response ratios were 
calculated for a window from the TSS to 10 kbp downstream (excluding the first 200 bp) for 
each TU i as 
𝑟0 = 1 −
𝑡𝑏0	[x.y	,zx	{|}]
U~	0=00Wei
𝑡𝑏0	[x.y	,zx	{|}]
UV=WXVY  
where negative values were set to 0. 
 
Estimation of robust common elongation velocity. For each condition j (control or CDK9as 
inhibited) the antisense bias corrected number of transcribed bases 𝑡𝑏0
o was calculated on all 
expressed TUs i with a given response ratio 𝑟0, excluding the first 200 bp. All TUs were 
truncated by 5 kbp in length from the 3’ end prior to calculation to avoid influence of some 
alterations in signal around the pA site after CDK9as inhibition 302. A robust common 
elongation velocity estimate was calculated by finding an optimal fit for all TUs i between 25 
to 200 kbp in length Li, i.e. minimizing the function 
𝑙𝑜𝑠𝑠 = median
0
c1 −
𝑡𝑏0U~
	0=00Wei
𝑡𝑏0UV=WXVY
−
𝑟0𝑣(𝑡∗ − 𝑡)
𝐿0
j 
on the interval [0,10000] with inhibitor treatment duration t* = 15 [min] and labeling duration 
t = 5 [min], given that 
𝑡𝑏0U~
	0=00Wei − 𝑡𝑏0UV=WXVY = 𝑟0
𝑡𝑏0UV=WXVY
𝐿0
𝑣0(𝑡∗ − 𝑡) 
, i.e. the difference of transcribed bases obtained by the CDK9as inhibitor treatment equals 
the number of transcribed bases per nucleotide 𝑡𝑏0UV=WXVY/𝐿0 times the number of nucleotides 
traveled 𝑣0(𝑡∗ − 𝑡) in 𝑡∗ − 𝑡 minutes corrected by the amount of the response 𝑟0. 
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Estimation of gene-wise elongation velocity. For each condition j (control or CDK9as 
inhibited) the antisense bias corrected number of transcribed bases 𝑡𝑏0
o was calculated on all 
expressed TUs i exceeding 35 kbp in length, excluding the first 200 bp. All TUs were truncated 
by 5 kbp in length from the 3’ end prior to calculation to avoid influence of some alterations 
in signal around the pA site after CDK9as inhibition 302. Of all remaining TUs only those were 
kept harboring one unique TSS given all Refseq annotated isoforms (UCSC RefSeq GRCh38). 
For each TU i with 𝑟0 > 0.25 the elongation velocity vi [kbp/min] was calculated as 
 
𝑣0 =
𝑡𝑏0UV=WXVY − 𝑡𝑏0	U~
	0=00Wei
𝑡𝑏0UV=WXVY ∙
𝑟0
𝐿0
(𝑡∗ − 𝑡)
 
with inhibitor treatment duration t* = 15 [min] and labeling duration t = 5 [min]. 
 
2.3.5 Analysis of human promoter-proximal pause sites 
 
Data analysis was performed by Dr. Björn Schwalb (MPI-bpc, Dept. Molecular Biology). 
 
mNET-seq data normalization. mNET-seq coverage tracks were size factor normalized on 
260 TUs that showed a response of less than 5% (ri<0.05) in the TT-seq signal upon 1-NA-
PP1 (CDK9as inhibitor) treatment. The response ratio ri was determined as described (2.3.4) 
including also TUs with multiple TSS to extend the number of TUs for normalization. Note 
that variation of the response ratio cutoff and thereby the number of TUs available for 
normalization does virtually not change the normalization parameters. Coverage tracks for 
further analysis were restricted to the last nucleotide incorporated by the polymerase in the 
aligned mNET-seq reads. 
 
DNA-RNA and DNA-DNA melting temperature calculation. The gene-wise mean melting 
temperature of the DNA-RNA and DNA-DNA hybrid was calculated from subsequent melting 
temperature estimates of 8-base pair DNA-RNA 423 and DNA-DNA 424 duplexes tiling the 
respective area. 
 
In vivo RNA secondary structure (DMS-seq). The gene-wise DMS-seq coverage 425 for a 
window of [-15, -65] bp upstream of the pause site was normalized by subtraction from the 
respective DMS-seq coverage (denatured) allowing for maximal 5% negative values which 
were set to 0 (sequencing depth adjustment). The gene-wise mean values were subsequently 
normalized by dividing with the initiation frequency. Note that the latter normalization has 
an insignificant effect. 
 
Prediction of RNA secondary structure (in silico). The gene-wise mean minimum free energy 
for a window of [-15,-65] bp upstream of the pause site was calculated from subsequent 
minimum free energy estimates of 13-base pair RNA fragments tiling the respective area using 
RNAfold from the ViennaRNA package 426. 
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2.3.6 Illumina sequencing and data availability 
 
For this study, Illumina sequencing was performed at the Genomics research unit of 
Dr. Helmut Blum at Gene Center Munich (LAFUGA) by Dr. Stefan Krebs, and at the Deep-
Sequencing Facility at UMG Göttingen (TAL). 
 
The sequencing data and processed files were deposited in the GEO database under accession 
code GSE96056 381. A detailed overview of sequencing data and processed files is depicted in 
Table 22. Experimental conditions are listed in in Table 21. 
 
 
Table 22. Sequencing statistics of 12 libraries generated in this study. 
All libraries were sequenced on an Illumina HiSeq 1,500 or 2,500 sequencing platform in 50 bp paired-end mode. 
Numbers refer to experimental conditions listed in Table 21. Correlation of replicates is calculated as Spearman’s 
rho rounded to second decimal place. Sequenced fragments were determined by FastQC, uniquely mapped 
fragments were counted after mapping using STAR 2.3.0 403. 
 
No. Barcode GEO no. 
Fragment numbers 
Duplicates 
(%) 
Replicate 
correlation 
(RPKs) Sequenced 
Mapped 
uniquely 
Replicates 
combined 
1 GGAGAA GSM2528067 314,918,545 268,871,103  12.1  
2 AGCATG GSM2528068 309,157,897 263,833,832 532,704,935 12.7 1.00 
3 GAGTCA GSM2528066 306,381,221 252,242,142  12.2  
4 CGTAGA GSM2528069 297,142,421 238,445,837 490,687,979 9.7 1.00 
5 AAGAGG GSM2728731 47,534,035 44,476,779  16.7  
6 GGAGAA GSM2728732 54,910,285 50,449,470 94,926,249 25.2 0.99 
7 AGCATG GSM2728733 53,643,687 49,779,461  49.2  
8 GAGTCA GSM2728734 41,709,549 38,712,626 88,492,087 44.9 1.00 
9 GCCAAT GSM2728735 115,716,948 44,550,953  35.1  
  GSM2728736 155,873,045 96,105,747  46.9  
10 TGACCA GSM2728737 249,818,334 28,847,051 169,503,751 36.6 0.98 
11 CTTGTA GSM2728738 86,286,005 38,611,242  37.0  
  GSM2728739 135,015,202 82,905,554  48.4  
12 ACTTGA GSM2728740 185,224,474 26,036,620 147,553,416 50.7 0.95 
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Figure 10. Correlations and fragment sizes of cDNA libraries (Raji B cells). 
(a) TT-seq experiments were performed from two independent biological replicates for control (DMSO, 15 min), 
or CDK9as inhibition (5 µM 1-NA-PP1, 15 min) in Raji B (CDK9as) cells (Table 21). Scatter plots show the density 
of reads of 11,384 RefSeq GRCh38 annotated genes. Both axes depict reads per kilobase (RPK). The color scale 
corresponds to the density of points. Correlation of replicates is calculated as Spearman’s rank correlation 
coefficient (rho) rounded to second decimal place (shown in each plot). (b) TT-seq experiments were performed 
from two independent biological replicates for control (DMSO, 15 min), or CDK9as inhibition (5 µM 1-NA-PP1, 
15 min) in Raji B wildtype (WT) cells (Table 21). Scatter plots show the density of reads of 10,363 RefSeq 
GRCh38 annotated genes. (c) mNET-seq (with Empigen BB treatment) experiments were performed from two 
independent biological replicates for control (DMSO, 15 min), or CDK9as inhibition (5 µM 1-NA-PP1, 15 min) in 
Raji B (CDK9as) cells (Table 21). Scatter plots show the density of reads of 10,040 RefSeq GRCh38 annotated 
genes. (a-c) Right: size distributions [nt] of library inserts. 
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2.4 The pause-initiation limit restricts transcription activation 
 
 
The methods presented in section 2.4 are currently under peer review for publication: 
 
S. Gressel *, B. Schwalb * et al. The pause-initiation limit restricts transcription activation 
in human cells. Nature communications, in revision. 
(* joint first authorship) 
 
 
2.4.1 Cell treatment: heat shock 
 
To determine the optimal time-points for the multi-omics analysis, I performed a time-course 
in which K562 or Raji B (CDK9as) cells were exposed to 42 °C in a water bath. Transcriptional 
changes were analyzed by RT-qPCR (see subsection 2.1.2), and cell viability was checked by 
tryphan blue exclusion assay (see below) and MTS assay (data not shown). 
 
Heat shock treatment. To avoid transcriptional changes by freshly added growth medium 427, 
fresh growth medium was added ~24 h prior to heat shock treatments. Heat shock treatments 
of K562 or Raji B (CDK9as) cells were performed in T175 flasks in a volume of 50 mL at 0.6 
x 106 cells/mL in a water bath at 42 °C. Temperature was monitored by thermometer. It took 
5 min until the cell suspension reached 42 °C. For RT-qPCR and cell viability assessment, 
cells were treated for a time-course of 0 to 75 min. For TT-seq, RNA-seq and mNET-seq 
experiments, cells were treated for 0 (Ctrl), 15 (HS15) or 30 min (HS30). 
 
Tryphan blue exclusion. Cell viability levels were evaluated by the trypan blue exclusion 
method as described by 428. Cell viability assessment was performed with two biological 
replicates. Briefly, 5 x 105 cells were treated as above for 0, 15, 30, 45, 60, or 75 min. Cells 
were pelleted at 200 x g for 5 min and resuspended in 1 mL DPBS prior to counting. Equal 
volumes of cell suspension and 0.4 % trypan blue solution were mixed and incubated for 2 min. 
The solution was applied to a hemacytometer and viable cells were counted using light 
microscopy. For each treatment time, the cell count was duplicated (dilution factor for trypan 
blue) and the average value was obtained. Cell viability was calculated as the ratio of viable 
cells upon heat shock (15-75 min) to viable cells of control (0 min). 
 
2.4.2 Multi-omics experiments 
 
TT-seq and mNET-seq experiments were performed as described (section 2.2). I performed all 
TT-seq, RNA-seq and mNET-seq experiments in this study (Table 23). 
 
For TT-seq pre-processing and global spike-in normalization, as well as mNET-seq pre-
processing see Supplementary Information V.2.1. 
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Table 23. Information on experimental conditions used in this study. 
Abbreviations used: control (Ctrl), heat shock (HS), analog sensitive CDK9 (CDK9as). 
 
No. Assay Cell type Condition name 
Replicate 
no. 
Treatment 
1 mNET-seq K562 Ctrl 1 - 
2 mNET-seq K562 Ctrl 2 - 
3 mNET-seq K562 HS15 1 42 °C, 15 min. 
4 mNET-seq K562 HS15 2 42 °C, 15 min. 
5 mNET-seq K562 HS30 1 42 °C, 30 min. 
6 mNET-seq K562 HS30 2 42 °C, 30 min. 
7 TT-seq K562 Ctrl 1 - 
8 TT-seq K562 Ctrl 2 - 
9 TT-seq K562 HS15 1 42 °C, 15 min. 
10 TT-seq K562 HS15 2 42 °C, 15 min. 
11 TT-seq K562 HS30 1 42 °C, 30 min. 
12 TT-seq K562 HS30 2 42 °C, 30 min. 
13 RNA-seq K562 Ctrl 1 - 
14 RNA-seq K562 Ctrl 2 - 
15 RNA-seq K562 HS15 1 42 °C, 15 min. 
16 RNA-seq K562 HS15 2 42 °C, 15 min. 
17 RNA-seq K562 HS30 1 42 °C, 30 min. 
18 RNA-seq K562 HS30 2 42 °C, 30 min. 
19 TT-seq Raji B (CDK9as) Ctrl Solvent 1 0.05 % v/v DMSO, 35 min. 
20 TT-seq Raji B (CDK9as) Ctrl Solvent 2 0.05 % v/v DMSO, 35 min. 
21 TT-seq Raji B (CDK9as) 
Ctrl CDK9 
inhibited 
1 5 µM 1-NA-PP1, 35 min. 
22 TT-seq Raji B (CDK9as) 
Ctrl CDK9 
inhibited 
2 5 µM 1-NA-PP1, 35 min. 
23 TT-seq Raji B (CDK9as) HS Solvent 1 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
24 TT-seq Raji B (CDK9as) HS Solvent 2 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
25 TT-seq Raji B (CDK9as) HS CDK9 inhibited 1 
5 µM 1-NA-PP1, 35 min; 
after 5 min: 42 °C, 30 min. 
26 TT-seq Raji B (CDK9as) HS CDK9 inhibited 2 
5 µM 1-NA-PP1, 35 min; 
after 5 min: 42 °C, 30 min. 
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mNET-seq data pre-processing and normalization. We first identified a subgroup of RefSeq-
TUs with unchanged behavior over the response to heat shock in the spike-ins normalized 
TT-seq data via k-means clustering. On the resulting 3,416 RefSeq-TUs i, size factors for each 
sample j were determined as 
𝜎o = median0 p
𝑝0o
q∏ 𝑝0o4sta u
a/4v 
where m denotes the total number of antisense corrected mNET-seq samples (𝑝0o). This 
formula has been adapted 422 and was used to correct for library size and sequencing depth 
variations. 
 
 
2.4.3 Heat shock treatment response ratio 
 
Calculation of response ratios (for calibration of pause duration). For each condition j 
(control or heat shock 15 minutes) the antisense bias corrected number of transcribed bases 
𝑡𝑏0
o was calculated on all expressed RefSeq-TUs i (exceeding 35 kbp in length with one unique 
TSS given all Refseq annotated isoforms (UCSC RefSeq GRCh38)). Response ratios were 
calculated for a window from the TSS to 10 kbp downstream (excluding the first 200 bp) for 
each RefSeq-TU i as 
𝑟0 = 1 −
𝑡𝑏0	[x.y	,zx	{|}]
eW	fV[
𝑡𝑏0	[x.y	,zx	{|}]
[V=WXVY  
where negative values were set to 0 and values above 1 were set to 1. 
 
Estimation of gene-wise elongation velocity (for calibration of pause duration). For each 
condition j (control or heat shock 15 minutes) the antisense bias corrected number of 
transcribed bases 𝑡𝑏0
o was calculated on all expressed RefSeq-TUs i (exceeding 35 kbp in length 
with one unique TSS given all Refseq annotated isoforms (UCSC RefSeq GRCh38)), excluding 
the first 200 bp. All TUs were truncated by 5 kbp in length from the 3’ end prior to calculation 
to avoid influence of some alterations in signal around the pA site after heat shock. For each 
TU i with 𝑟0 > 0.1 the elongation velocity vi [kbp/min] was calculated as 
𝑣0 =
𝑡𝑏0[V=WXVY − 𝑡𝑏0	eW	fV[
𝑡𝑏0[V=WXVY ∙
𝑟0
𝐿0
(𝑡∗ − 𝑡)
 
with heat shock treatment duration t* = 15 [min] and labeling duration t = 5 [min]. 
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2.4.4 Major transcript classes annotation 
 
Annotation was performed by Dr. Björn Schwalb (MPI-bpc, Dept. Molecular Biology) based 
on 168,177. 
 
Transcription units based on UCSC RefSeq genome assembly. For each annotated gene, 
transcription units were defined as the union of all existing inherent transcript isoforms (UCSC 
RefSeq GRCh38). 
 
Definition of isoform-independent exonic regions (constitutive exons). Isoform-independent 
exonic regions were determined using a model for constitutive exons 429 based on UCSC RefSeq 
annotation (GRCh38). 
 
Transcription units based on GenoSTAN (TUs, K562 and Raji). Annotation of different 
transcript classes was done as in 168 with minor differences. In brief, genome-wide coverage 
was calculated from all TT-seq fragment midpoints in consecutive 200 bp bins throughout the 
genome. In order to create a comprehensive annotation independent of heat shock induced 
length differences, two replicate tracks were constructed by taking the maximum of each bin 
over the first and second replicates, respectively, regardless of treatment. A two-state hidden 
Markov model with a Poisson-Log-Normal emission distribution was learned in order to 
segment the genome into ‘transcribed’ and ‘untranscribed’ states. Consecutive ‘transcribed’ 
states were joined, if its gaps were smaller than 200 bp, within a validated GENCODE mRNA 
or lincRNA (version 22) or showed uninterrupted coverage supported by all TT-seq samples. 
Subsequently, TU start and end sites were refined to nucleotide precision by finding borders 
of abrupt coverage increase or decrease between two consecutive segments in the four 200 bp 
bins located around the initially assigned start and stop sites via fitting a piecewise constant 
curve to the TT-seq coverage profiles for both replicates using the segmentation method from 
the R/Bioconductor package "tilingArray" 430. 
 
GRO-cap TSS refinement of TUs (cTUs, K562). For all TUs i, the GRO-cap refined 
transcription start site tss* was determined as the closest non-zero GRO-cap signal 50 in a 
window of 500 bp around the start of the TUs. Note that all TUs without an assigned GRO-
cap site were not used. It was recently shown that upon 1 h heat shock TSS architecture 
remains mostly unchanged 247. Thus, we assume changes of TSS architecture upon 30 min of 
heat shock to be insignificant. 
 
Transcript sorting (K562 and Raji). We sorted each gene (cTU for K562, TU for Raji) into 
one of the following seven classes: eRNA, sincRNA, asRNA, conRNA, uaRNA, lincRNA and 
mRNA. First, (c)TUs reciprocally overlapping by at least 50% with a validated GENCODE 
mRNA or lincRNA (version 22) on the same strand were classified as mRNAs and lincRNAs. 
(c)TUs reciprocally overlapping by less than 50% with a validated GENCODE mRNA or 
lincRNA (version 22) on the same strand were not classified. Next, (c)TUs located on the 
opposite strand of either a mRNA or lincRNA were classified as asRNA if the TSS was located 
> 1 kbp downstream of the sense TSS on the opposite strand, as uaRNA if its TSS was 
located < 1 kbp upstream of the sense TSS, and as conRNA if its TSS was located < 1 kbp 
downstream of the TSS on the opposite strand. For K562, each of the remaining cTUs was 
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classified as sincRNA. Every ncRNA (sincRNA, asRNA, conRNA or uaRNA) was re-classified 
as eRNA if its TSS fell into a K562 enhancer state 177. This resulted in 11,324 non-ambiguously 
classified RNAs in K562 cells (Table 24). For Raji, each of the remaining TUs was classified 
into eRNA – if its TSS exhibited a high (>1) ratio H3K4me1/H3K4me3 – or as sincRNA – if 
its TSS exhibited a low (<1) ratio of H3K4me1/H3K4me3. This resulted in 16,452 non-
ambiguously classified RNAs (Table 24). 
 
 
Table 24. Annotation of RNA classes in human hematopoietic cell lines (K562, Raji B). 
For details see Methods and Figure 1 e. Abbreviations: capped (c) transcription unit (TU). 
 
Class Class Definition cTUs in K562 TUs in Raji B 
mRNA messenger RNA GENCODE annotation (>50 % 
overlap) 
6,549 6,990 
lincRNA intergenic RNA GENCODE annotation (>50 % 
overlap); promoter state 
239 243 
asRNA antisense RNA located on opposite strand of mRNA or 
lincRNA, TSS located >1 kbp 
downstream of sense TSS; promoter 
state 
564 1,398 
uaRNA upstream 
antisense RNA 
located on opposite strand of mRNA or 
lincRNA, TSS located <1 kbp 
upstream of sense TSS; promoter state 
1,064 565 
conRNA convergent RNA located on opposite strand of mRNA or 
lincRNA, TSS located <1 kbp 
downstream of sense TSS; promoter 
state 
502 326 
sincRNA short intergenic 
noncoding RNA 
promoter state 1,581 3,479 
eRNA enhancer RNA location as asRNA, uaRNA, or 
conRNA; enhancer state 
825 3,451 
Total   
 
11,324 16,452 
 
 
2.4.5 Illumina sequencing and data availability 
 
For this study, all Illumina sequencing was performed in-house by Kerstin Maier and Petra 
Rus (MPI-bpc, Dept. of Molecular Biology). 
 
The sequencing data and processed files were deposited in the GEO database under accession 
code GSE123980. Transcript annotations were deposited as supplementary GTF file 
(GSE123980_transcript.annotation). A detailed overview of sequencing data and processed 
files is depicted in Table 25. Experimental conditions are listed in Table 23. 
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Table 25. Sequencing statistics of 26 libraries generated in this study. 
All libraries were sequenced on a NEXTseq 550 sequencing platform in 75 bp paired-end mode. Numbers refer to 
experimental conditions listed in Table 23. Correlation of replicates is calculated as Spearman’s rho rounded to 
second decimal place. Sequenced fragments were determined by FastQC, uniquely mapped fragments were counted 
after mapping using STAR 2.3.0 403. 
 
No. Barcode GEO no. 
Fragment numbers 
Duplicates 
(%) 
Replicate 
correlation 
(RPKs) 
Sequenced Mapped 
uniquely 
Replicates 
combined 
1 CGGAAT GSM3518117 159,190,513 118,817,488  54.1  
2 CTAGCT GSM3518118 173,587,084 130,654,902 249,472,390 54.5 1.00 
3 GACGAC GSM3518119 164,964,729 117,933,814  48.0  
4 TAATCG GSM3518120 151,647,527 111,634,549 229,568,363 44.3 1.00 
5 TCATTC GSM3518121 202,842,209 151,118,454  52.9  
6 TCCCGA GSM3518122 180,695,911 134,847,488 285,965,942 47.5 1.00 
7 AAGCCT GSM3518105 149,673,334 134,367,932  7.2  
8 GTCGTA GSM3518106 151,253,343 136,351,777 270,719,709 11.5 1.00 
9 AAGAGG GSM3518107 161,455,492 145,506,316  8.4  
10 GGAGAA GSM3518108 157,619,872 141,621,200 287,127,516 11.3 1.00 
11 AGCATG GSM3518109 147,638,717 132,928,558  8.1  
12 GAGTCA GSM3518110 170,970,259 153,960,400 286,888,958 16.2 0.99 
13 AACCAG GSM3518111 102,213,680 84,822,615  35.6  
14 TGGTGA GSM3518112 107,355,413 89,846,989 174,669,604 33.7 1.00 
15 AGTGAG GSM3518113 100,709,060 84,896,024  35.4  
16 GCACTA GSM3518114 105,407,471 88,182,473 173,078,497 41.8 1.00 
17 CACAGT GSM3518115 108,465,109 90,694,343  35.6  
18 TTGGCA GSM3518116 105,327,756 88,593,759 179,288,102 41.2 1.00 
19 AACCAG GSM3518123 57,249,175 52,426,514  5.3  
20 TGGTGA GSM3518124 76,191,286 69,811,550 122,238,064 6.3 1.00 
21 AGTGAG GSM3518125 70,801,390 64,421,316  15.1  
22 GCACTA GSM3518126 67,661,931 61,817,282 126,238,598 10.2 1.00 
23 ACCTCA GSM3518127 70,180,248 64,629,409  6.5  
24 GTGCTT GSM3518128 74,373,094 68,428,032 133,057,441 8.5 1.00 
25 AAGCCT GSM3518129 82,625,021 75,042,304  21.7  
26 GTCGTA GSM3518130 77,366,563 70,613,758 145,656,062 14.4 1.00 
Part II – Materials and Methods 
 
   60 
 
Figure 11. Correlations and fragment sizes of cDNA libraries (K562 cells). 
TT-seq (a, top; b, left), RNA-seq (a, bottom; b, right), and mNET-seq (with Empigen BB treatment) (c, d) 
experiments were performed from two independent biological replicates for control (37 °C), or heat shock (42 °C) 
conditions for 15 min (HS15) and 30 min (HS30) (Table 23). (a, c) Scatter plots with color-coded density of reads 
for 12,315 RefSeq GRCh38 annotated genes. Both axes depict reads per kilobase (RPK). The color scale 
corresponds to the density of points. Correlation of replicates is calculated as Spearman’s rank correlation 
coefficient (rho) rounded to second decimal place (shown in each plot). (b, d) Size distributions of library inserts 
of TT-seq, RNA-seq (b) and mNET-seq (d) in K562 cells treated as described in (a). 
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Figure 12. Correlations and fragment sizes of TT-seq libraries (Raji B). 
(a) TT-seq experiments were performed from two independent biological replicates for control (37 °C), or heat 
shock conditions for 30 min (42 °C) with solvent (DMSO, 35 min) or CDK9 inhibition (5 µM 1-NA-PP1, 35 min) 
(Table 23). Scatter plots show the density of reads of 10,294 RefSeq GRCh38 annotated genes. Both axes depict 
reads per kilobase (RPK). The color scale corresponds to the density of points. Correlation of replicates is calculated 
as Spearman’s rank correlation coefficient (rho) rounded to second decimal place (shown in each plot). (b)  Size 
distributions of library inserts of TT-seq in Raji B (CDK9as) treated as described in (a). 
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III. Results 
 
 
 
 
 
 
1. Establishing mNET-seq in human suspension cells 
 
The mNET-seq protocol can be divided into five main steps: (i) cellular fractionation, 
(ii) chromatin solubilization, (iii) immunoprecipitation of polymerase (Pol) II, (iv) RNA 3’ 
end phosphorylation and size selection, (v) preparation of cDNA libraries and Illumina 
sequencing. In an effort to establish a reproducible mNET-seq protocol in human 
hematopoietic suspension cells (K562 and Raji B), I revisited most steps of the protocol 
published by the Proudfoot lab 350,388 (Figure 13 a). 
 
Here, I briefly summarize the critical steps (i-iv) which have been optimized for mNET-seq 
application in human hematopoietic suspension cells. 
 
 
Table 26. Comparison of three cellular fractionation protocols. 
 
Step Mayer’s protocol 431 Ørom’s protocol 418 Nojima’protocol 388 
Mild cell lysis 10 mM Tris-HCl pH 7.0 
150 mM NaCl 
0.15 % v/v NP-40 
10 mM Tris-HCl pH 7.4 
150 mM NaCl 
0.15 % v/v NP-40 
10 mM Tris-HCl pH 7.5 
10 mM NaCl 
0.5 % v/v NP-40 
2.5 mM MgCl2 
Sucrose cushion 10 mM Tris-HCl pH 7.0 
150 mM NaCl 
25 % w/v sucrose 
10 mM Tris-HCl pH 7.4 
150 mM NaCl 
24 % w/v sucrose 
10 mM Tris-HCl pH 7.4 
10 mM NaCl 
10 % w/v sucrose 
0.5 % NP-40 
2.5 mM MgCl2 
Glycerol 20 mM Tris-HCl pH 8.0 
75 mM NaCl 
0.5 mM EDTA 
50 % v/v glycerol 
20 mM Tris-HCl pH 7.4 
75 mM NaCl 
0.5 mM EDTA 
50 % v/v glycerol 
20 mM Tris-HCl pH 7.9 
75 mM NaCl 
0.5 mM EDTA 
50 % v/v glycerol 
Nuclear lysis 20 mM HEPES pH 7.5 
300 mM NaCl 
1 M urea 
0.2 mM EDTA 
1 % v/v NP-40 
10 mM Tris-HCl pH 7.4 
300 mM NaCl 
1 M urea 
0.2 mM EDTA 
1 % v/v NP-40 
7.5 mM MgCl2 
20 mM HEPES-KOH pH 7.6 
300 mM NaCl 
1 M urea 
0.2 mM EDTA 
1 % v/v NP-40 
7.5 mM MgCl2 
Processing time ~45 min ~45 min ~60 min 
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Cellular fractionation. Due to differences in cell size and chromatin compaction of adherent 
and suspension cells, the efficiency of a cellular fractionation protocol differs. In general, cells 
are lysed with mild detergent (NP-40), and centrifuged through a sucrose cushion to yield 
purified nuclei. Then, the nuclear envelop is disrupted by NP-40 and urea, and the chromatin 
is precipitated by centrifugation 390. I compared three fractionation protocols (Table 26) with 
respect to processing time, quality and reproducibility of the fractionation. The quality and 
reproducibility were verified by Western blotting of marker proteins (Figure 38 a). One 
protocol failed to resolve clean fractions of hematopoietic cells (Figure 38 b) while the other 
two performed equally well. Since short processing time was also an important aspect, Ørom’s 
protocol 418 worked best in steady state and after perturbations (CDK9 inhibition, or heat 
shock) (Figure 13 b-c). 
 
Chromatin solubilization. Cellular fractionation is followed by solubilization of the chromatin 
fraction by a DNase. Micrococcal nuclease (MNase) has the propensity to cleave double 
stranded DNA, within internucleosomal linker regions, and single stranded RNA 432-434 
resulting in solubilization of Pol II-RNA complexes from chromatin. However, overly harsh 
MNase digestion affects nascent RNA length. I found that short incubation times (<180 sec) 
with 50 U MNase yield sufficient solubilization of Pol II-RNA complexes, and RNA fragment 
lengths corresponding to the desired RNA size range of 25 to 110 nt (Figure 13 e). 
 
Immunoprecipitation (IP) of POLR2A with Empigen BB. I tested two commercial antibodies 
for the subsequent IP step. Both immunoprecipitate total Pol II by targeting the largest 
subunit of human Pol II, POLR2A. Specifically, one binds to the N-terminus of POLR2A 
(Santa Cruz, clone F12), and the other targets the unphosphorylated and phosphorylated 
CTD of POLR2A (MBL, clone CMA601) (Table 11). By comparing the IP efficiency, the 
MBL antibody performed with ~10-fold higher yield compared to the F12 antibody (Figure 
13 d). Thus, the MBL antibody was used for IP. A crucial improvement for the IP step was 
the addition of the strong detergent Empigen BB to the IP reaction and subsequent washing 
steps to weaken protein-protein interactions of Pol II with RNA processing complexes. 
Consistent with observations by recent studies 391,392, strong peaks at the end of exons were 
lost upon Empigen BB addition (Figure 13 f). These peaks originate from non nascent RNA 
intermediates with 3’-OH groups such as spliceosome or microprocessor complex associated 
RNAs. 
 
RNA size selection. I tested different acrylamide percentages (5-8 %) for RNA size selection 
with the aim to monitor RNA size distribution by the migration of two blue dyes 
(bromophenol blue and xylene cyanol blue), without radioactive labeling. The use of 6 % 
denaturing urea polyacrylamide gel electrophoresis (PAGE) allowed to select the target size 
(25-110 nt) by cutting between the two dyes (Figure 39). A few month ago the Proudfoot lab 
also decreased the acrylamide concentration from 8 % (used in 2015 to 2017 350,388,391) to 
6 % 392,435 in order to monitor the RNA size by the two tracking dyes. 
 
The optimized mNET-seq protocol for suspension cells is described in detail in the methods 
section II.2.2.3. 
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Figure 13. Establishing mNET-seq of total Pol II in human hematopoietic cell lines. 
(a) Left: experimental workflow of mNET-seq. Right: several steps were optimized for application in hematopoietic 
cells. (b-c) Western blot analysis ( INTAS imager) of cytoplasm (CP), nucleoplasm (NP) and solubilized chromatin 
(Chr) fractions (Ørom’s protocol 418) from Raji B (CDK9as) (b) or K562 cells (c) using indicated antibodies. 
Antibodies are listed in Materials II.1.4. (b) Cells were treated with solvent control (DMSO) or CDK9 inhibition 
(5 µM 1-NA-PP1) for 15 min prior to fractionation (Table 21, no. 9, 11). Chromatin of Raji B (CDK9as) cells was 
digested for 90 sec. (c) Cells were subjected to standard growth conditions (Ctrl), 15 or 30 min of heat shock (HS) 
at 42 °C prior to fractionation (Table 23, no. 1, 3, 5). Chromatin of K562 cells was digested for 2 min. 
(d) Comparison of two POLR2A antibodies after 1 h of IP using digested chromatin of 107 K562 cells as input. 
Uncropped images can be found in Figure 40. (e) Library insert size after sequencing of mNET-seq libraries 
generated in Raji B (CDK9as) cells. Left: trials using 3 min digest time. Right: final conditions using 90 sec of 
MNase digest. (f) Representative genome browser view of mNET-seq data at the MYC gene locus on chromosome 
8 (plus strand) (IGV, version 2.4.10; human hg38) 400. Shown is the strand-specific Pol II occupancy with single 
nucleotide resolution. Top panels: two biological replicates of mNET-seq in Raji B (CDK9as) cells without Empigen 
BB. Bottom panels: two biological replicates of mNET-seq in Raji B (CDK9as) cells with 1 % v/v Empigen BB 
(~30 % active substance) treatment. Empigen BB sensitive peaks are marked by red arrows. 
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2. CDK9-dependent Pol II pausing controls transcription 
initiation 
 
 
 
 
The results presented in chapter 2 have been published: 
 
S. Gressel *, B. Schwalb * et al. CDK9-dependent RNA polymerase II pausing controls 
transcription initiation. Elife 6, doi:10.7554/eLife.29736 (2017). 
(* joint first authorship) 
 
A detailed list of author contributions can be found on page VII. 
 
 
 
Chapter summary 
 
Gene transcription can be activated by decreasing the duration of RNA polymerase II pausing 
in the promoter-proximal region, but how this is achieved remains unclear. Here we use a 
‘multi-omics’ approach to demonstrate that the duration of polymerase pausing generally 
limits the productive initiation frequency of transcription initiation in human cells (‘pause-
initiation limit’). We further engineer a human cell line to allow for specific and rapid 
inhibition of the P-TEFb kinase CDK9, which is implicated in polymerase pause release. 
CDK9 activity decreases the pause duration but also increases the productive initiation 
frequency. This shows that CDK9 stimulates release of paused polymerase and activates 
transcription by increasing the number of transcribing polymerases and thus the amount of 
mRNA synthesized per time. CDK9 activity is also associated with long-range chromatin 
interactions, suggesting that enhancers can influence the pause-initiation limit to regulate 
transcription. 
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2.1 CRISPR/Cas9 engineered mutation allows for specific CDK9 
inhibition 
 
 
 
 
Figure 14. Inhibition of the human CDK9as kinase activity specific to CRISPR/Cas9 engineered cells. 
(a) Experimental design. TT-seq was carried out in Raji B (wildtype, or CDK9as) cells after treatment with 0.05 % 
v/v solvent DMSO (control) or 5 µM 1-NA-PP1 (CDK9as inhibited) for 15 min (including 5 min of 4sU labeling). 
(b-c) Log fold change upon 1-NA-PP1 treatment (5 µM for 15 min) versus normalized mean read count across two 
biological replicates and conditions for wildtype Raji B cells (b) and Raji B (CDK9as) cells (c). Significantly up- 
or downregulated genes (adjusted p-value < 0.01) are marked in red. 
 
 
To specifically inhibit CDK9, we used a chemical biology approach 338,339 that circumvents off-
target effects of standard CDK9 inhibitors 337. We introduced a CDK9 analog sensitive 
mutation (CDK9as) into human Raji B cells by CRISPR/Cas9 (Methods II.2.3.1; Figure 9). 
This allows for rapid and highly specific CDK9 inhibition with the adenine analog 1-NA-PP1 
338,339, which does not have any effect on wild type cells (Figure 14 b-c). CDK9 protein levels 
were unchanged in CDK9as mutant cells compared to wild type cells (Figure 41 a). After 72 h 
of incubation with 1-NA-PP1, growth of CDK9as cells ceased, whereas wild type cells grew 
normally (Figure 41 b). 
 
2.2 TT-seq monitors immediate response to CDK9 inhibition 
 
We treated CDK9as cells with 5 μM of 1-NA-PP1 for 10 min and monitored changes in RNA 
synthesis by TT-seq 168 (Methods II.2.2.2; Figure 6 a), using an RNA labeling time of 5 min 
(Figure 15 a-b). TT-seq data were highly reproducible (Figure 10 a; Spearman correlation 
coefficient 1) and monitored transcription activity before and after CDK9 inhibition (Figure 
15). CDK9 inhibition resulted in reduced TT-seq signals at the beginning of genes, indicating 
that less Pol II was released into gene bodies (Figure 15 c-e). This gave rise to a ‘response 
window’ revealing the distance traveled by Pol II during 10 min inhibitor treatment (Figure 
15 c-d). Downstream of the response window, the TT-seq signal was largely unchanged, 
indicating continued RNA synthesis from Pol II elongation complexes that had been released 
before CDK9 inhibition. To determine the relative response of genes to CDK9 inhibition, we 
calculated response ratios for those transcribed units based on the UCSC RefSeq genome 
assembly GRCh38 (RefSeq-TUs; referred to as ‘genes’ in chapter 2) (Methods II.2.3.4) that 
synthesized RNA, harbored a single TSS, and exceeded 10 kbp in length (2,538 genes). The 
response ratio of genes varied between 0 % to 100 % (fully responding genes) with a median 
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of 58 % (Figure 15 f). A remaining TT-seq signal in the response window likely reflects the 
proportion of polymerases that move to productive elongation without CDK9 kinase activity, 
but we cannot exclude that it stems from incomplete CDK9 inhibition. However, based on 
the assumption that the inhibitor is evenly distributed across cells and within, the portion of 
CDK9 that has not been fully inhibited must be very low (see also Figure 42). 
 
 
 
 
Figure 15. Decrease of RNA synthesis in the 5’-region of genes upon CDK9 inhibition is gene-specific. 
(a) Experimental design. TT-seq was carried out in Raji B (CDK9as) cells after treatment with 0.05 % v/v solvent 
DMSO (control) or 5 µM 1-NA-PP1 (CDK9as inhibited) for 15 min (including 5 min of 4sU labeling) (Table 21, 
Table 22, Figure 10). (b) TT-seq signal before (black) and after (red) CDK9 inhibition at the CYB5R4 gene locus 
(107,781 [bp]) on chromosome 6. Two biological replicates were averaged. The grey box depicts the transcript body 
from the transcription start site (TSS, black arrow) to the polyA site (pA). (c) Schematic representation of changes 
in TT-seq signal showing the definition of the response window. The decrease of RNA synthesis in the 5’ region of 
a gene corresponds to the response [%]. Colors are as in (b). (d) Metagene analysis comparing the average TT-seq 
signal before and after CDK9 inhibition. The TT-seq coverage was averaged for 954 out of 2,538 investigated genes 
that exceed 50 [kbp] in length. Genes were aligned with their TSS. Shaded areas around the average signal (solid 
lines) indicate confidential intervals. (e) Violin plot showing the relative response to CDK9 inhibition for 2,538 
investigated genes defined as 1 - (CDK9as inhibited / Control) ∙ 100 [%] for a window from the TSS to 10 [kbp] 
downstream, excluding the first 200 [bp] (c). The red line indicates the median response (58 %). 
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2.3 Pol II elongation velocity is gene-specific 
 
The width of the response window differs between genes (Figure 15 c-d) and informs on Pol II 
elongation velocity (Methods II.2.2.4). The average width of the response window was 23 kbp 
which would correspond to an average elongation velocity of 2.3 kbp/min (Figure 16 a). This 
is in agreement with gene-specific elongation velocity measurements (Figure 16 b, combined 
2.3 kbp/min; Figure 16 c, mean 2.7 kb/min, median 2.4 kb/min). This also agrees with 
previous estimates 129,130,335,336. Gene-specific elongation velocities (Figure 16 c) were 
significantly higher in genes with longer first introns (Figure 16 d; Wilcoxon rank sum test, 
p-value < 1.916·10-11), consistent with faster transcription of introns 130. Elongation velocity 
correlated positively with nucleosome density, and negatively with the stability of the DNA-
RNA hybrid, CpG density and topoisomerase occupancy (Figure 16 e, Table 31). 
 
 
 
 
Figure 16. Pol II elongation velocity is gene-specific. 
(a) Schematic representation of observed response window of TT-seq signal upon CDK9 inhibition (red) or control 
(black) for genes of three different length classes (short < 25 [kbp], medium-length 25-50 [kbp] and long > 
100 [kbp]). (b) Scatter plot of the ratio of transcribed bases (CDK9as inhibited/control) against the length of the 
genes in nucleotides [kbp] revealed that the schematic representation in (a) holds true for 2,443 investigated genes. 
The ratio is corrected for response of individual genes. Modeling of the observed relation allows estimation of a 
robust combined elongation velocity of 2.3 [kbp/min] (solid black line). (c) Distribution of gene-wise elongation 
velocity (1,027 genes) depicted as a histogram (mean 2.7 [kbp/min], median 2.4 [kbp/min]). (d) Distribution of 
elongation velocity [kbp/min] depicted for 513 genes with short first intron (< 50 % quantile, left) and 514 genes 
with long first intron (> 50 % quantile, right). (e) Color encoded Spearman correlation coefficients (-0.45 in blue 
to 0.21 in red) of elongation velocity [kbp/min] against genomic features and measures of transcriptional context 
(all data sets are listed in Table 31). Note that the conclusions we draw across different cell lines are all based on 
metagene analysis, involving 500 up to more than 2,000 genes. Thus, we assume cell-line specific differences to 
have an insignificant influence and that the tendencies we observe rather suggest strong conservation. 
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Figure 17. Characteristics of the promoter-proximal pause site 
(a) Histogram depicts the distribution of pause sites (n*) with respect to RefSeq annotated TSS for 2,135 
investigated genes (mean 128 [bp], median 112 [bp], mode 84 [bp]). Two biological mNET-seq replicates were 
averaged (Table 21, Table 22, Figure 10). (b) Position weight matrix (PWM) logo representation of bases at 
positions –10 to +10 [bp] around the pause site (position 0, n*). (c) Mean basepairing energy [kcal mol-1] (right y-
axis, in red) of the DNA-RNA hybrid aligned at the pause site n*. The DNA-RNA hybrid in the active center of 
Pol II is highlighted in grey. (d) Mean melting temperature [°C] (left y-axis, in orange) of the DNA duplex aligned 
at the pause site n*. The downstream DNA duplex is highlighted in grey. Shaded areas around the average signal 
(solid lines) indicate confidence intervals. 
 
 
2.4 Characteristics of the promoter-proximal pause site 
 
To study the kinetics of CDK9-dependent Pol II pause release, we generated mNET-seq data 
that map the RNA 3’ end of engaged Pol II and extracted the position of paused polymerases 
(Methods II.2.2.3; Figure 6 b). mNET-seq data were highly reproducible (Figure 10 c; 
Spearman correlation coefficient >0.95). Of the above genes, 2,135 (84 %) showed mNET-seq 
signal peaks above background. The called pause sites n* were distributed around a maximum 
located 84 bp downstream of the RefSeq-annotated TSS (Figure 17 a). We asked how 
sequence content (DNA sequence at the pause site) and energetic properties (RNA-DNA 
hybrid in the active site of Pol II, downstream DNA duplex) contribute to pausing at human 
genes. At pause sites, we detected an enrichment for G/C-C/G dinucleotides with a strongly 
conserved cytosine at the RNA 3’-end (Figure 17 b). We observed a minimum of the predicted 
basepairing energy of the DNA-RNA hybrid immediately upstream of the pause site in the 
active site of Pol II (Figure 17 c, highlighted in grey). A weak DNA-RNA hybrid in the active 
center of Pol II is known to destabilize the elongation complex 436, and could be a major 
determinant for establishing the paused state. The DNA duplex downstream of the pause site 
shows a local minimum of the DNA-DNA melting temperature but appears to have a minor 
impact on the pause (Figure 17 d, highlighted in grey). 
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2.5 Multi-omics analysis provides pause duration d and initiation 
frequency I 
 
To quantify pausing, we defined the pause duration d as the time a polymerase needs to pass 
through a 200 bp ‘pause window’ located +/- 100 bp around the pause site. The pause 
duration d can now be derived from a combination of mNET-seq and TT-seq data. In 
particular, the mNET-seq signal corresponds to the number of polymerases in the pause 
window, which is determined by d and by the initiation frequency I (Figure 18 a) 315. Thus, 
d is proportional to the ratio of the mNET-seq signal over I. To calculate I we integrated TT-
seq signals over exons, excluding the first exon (Methods II.2.2.4). This provides the 
‘productive initiation frequency’, i.e. the number of polymerases that initiate and successfully 
exit from the pause window. We use the term ‘productive’ because we do not know whether 
there is a small fraction of polymerases terminating within the pause window. Finally, to 
derive absolute values of d, we scaled the reciprocal of d (the elongation velocity in the pause 
window) according to the elongation velocity obtained from CDK9 inhibition. 
We obtained a mean productive initiation frequency of 2.7 polymerases cell-1min-1, and pause 
durations in the range of minutes, with strong variations between genes. The pause durations 
are generally consistent with reported half-lives of paused Pol II in mouse 130 and Drosophila 
cells 355,357 but slightly shorter. Pause durations were also consistent with kinetic modeling of 
TT-seq data alone. At genes with long pause durations we observed less labeled RNA in the 
short region between the TSS and the pause site. This confirms that indeed initiation 
frequencies are altered. It also indicates that the fraction of Pol II enzymes that terminate 
within the pause window is low, in agreement with previous findings 355 (see Supplementary 
Note 1). For strongly CDK9-responding genes, we obtained a significantly longer pause 
duration (Figure 18 b; Wilcoxon rank sum test, p-value < 10-12) and lower initiation 
frequencies (Figure 18 c, highlighted in grey). 
 
 
2.6 Human genes have a ‘pause-initiation limit’ 
 
These results prompted us to ask whether the pause duration is generally related to the 
initiation frequency. We indeed found a robust anti-correlation between I and d in normally 
growing cells, and an upper boundary for combinations of I and d which we call ‘pause-
initiation limit’ (Figure 18 d; Methods II.2.2.4). Thus, genes with shorter pausing show higher 
initiation frequencies and more RNA synthesis. In conclusion, independent mNET-seq and 
TT-seq data led to independent measures of pause duration and productive initiation 
frequency for each gene, which were then observed to be globally anti-correlated. 
These findings now allowed us now to test directly whether longer pause durations lead to 
lower initiation frequencies, by analyzing TT-seq data after CDK9 inhibition. CDK9 inhibition 
resulted in significantly reduced labeled RNA in the short region between the TSS and the 
pause site (Figure 19 a, c; Wilcoxon rank sum test, p-value < 10-16). Productive initiation 
frequencies were significantly downregulated after CDK9 inhibition (Figure 19 b-c; Wilcoxon 
rank sum test, p-value < 10-16). Because CDK9 specifically targets paused Pol II, and not 
initiating polymerase, these results show that pausing limits initiation, and not the other way 
around. Thus, human genes have a ‘pause-initiation limit’. 
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To monitor the occupancy of engaged Pol II we generated mNET-seq data before and after 
CDK9 inhibition (Methods II.2.2.3). CDK9 inhibition resulted in increased mNET-seq signal 
at the beginning of genes and decreased signal in the gene body, indicating that less Pol II 
was released from the pause site (Figure 20 a). Indeed, calculation of pause durations from 
mNET-seq and TT-seq data after CDK9 inhibition showed that Pol II resides significantly 
longer at the pause site after CDK9 inhibition (Figure 20 b; Wilcoxon rank sum test, p-value 
< 10-16). Taken together, CDK9 inhibition increases the pause duration and decreases the 
initiation frequency at human genes (Figure 20 c). 
 
 
 
 
Figure 18. Pol II pausing generally limits transcription initiation (‘pause-initiation limit’). 
(a) Schematic representation of polymerase flow in the promoter-proximal region. The mNET-seq signal (top) is 
the ratio of the productive initiation frequency I over the elongation velocity v. The TT-seq signal (bottom) 
corresponds to the productive initiation frequency I. Thus, v can be derived from the ratio of the TT-seq over the 
mNET-seq signal, and the reciprocal of v in the pause window corresponds to the pause duration d. 
(b) Distributions of gene-wise pause duration d [min] for genes with a CDK9 response ratio > 75 % quantile (574 
genes) and genes with a response ratio < 25 % quantile (469 genes). (c) Distributions of gene-wise initiation 
frequency I [cell-1min-1] for genes with a CDK9 response ratio > 75 % quantile (635 genes) and genes with a response 
ratio < 25 % quantile (635 genes). (d) Scatter plot between the initiation frequency I [cell-1min-1] and the pause 
duration d [min] for 2,135 common genes with color-coded density estimation. The grey shaded area depicts 
impossible combinations of I and d according to published kinetic theory315 and assuming that steric hindrance 
occurs below a distance of 50 bp between the active sites of the initiating Pol II and the paused Pol II (Figure 
2 b). 
Part III – Results 
 
   72 
 
 
Figure 19. Increasing Pol II pause duration decreases the frequency of transcription initiation. 
(a) Boxplot comparing distributions of gene-wise mean TT-seq signals (labeled RNA) in the region between the 
TSS and the pause site, before (control) and after CDK9 inhibition for 2,135 genes, normalized to the initiation 
frequency I before CDK9 inhibition. (b) Boxplot comparing distributions of gene-wise initiation frequencies before 
(control) and after CDK9 inhibition. (c) Schematic summary of observed decrease in TT-seq signal upon CDK9 
inhibition, upstream (analyzed in (a)) and downstream (analyzed in (b)) of the pause site (n*) (Figure 2 a). The 
grey box depicts the transcript body from the transcription start site (TSS, black arrow) to the polyA site (pA). 
(d) Schematic representation of labeled RNA coverage ratio calculation for strong (red solid line) and weak (red 
dashed line) CDK9 response. (e) Distributions of gene-wise uridine content in the region between the TSS and the 
pause site for genes with a strong response ratio (>75% quantile, 603 genes) and genes with a weak response ratio 
(<25% quantile, 527 genes). (f) Distributions of gene-wise mean real TT-seq signal in the region between the TSS 
and the pause site normalized to initiation frequency for subsets as in (e). 
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Figure 20. CDK9 inhibition leads to increased pause duration. 
(a) Metagene analysis comparing the average mNET-seq signal before and after CDK9 inhibition. Two biological 
replicates were averaged (Table 21, Table 22, Figure 10). The mNET-seq coverage was averaged for 2,538 
investigated genes. Genes were aligned with their TSS. Shaded areas around the average signal (solid lines) indicate 
confidentiality intervals. (b) Distributions of gene-wise pause duration d [min] before (control) and after CDK9 
inhibition for 2,135 genes. (c) Scatter plot between the initiation frequency I [cell-1 min-1] and the pause duration 
d [min] after CDK9 inhibition for 2,135 genes with color-coded density estimation. The grey shaded area depicts 
impossible combinations of I and d 315 assuming that steric hindrance occurs below a distance of 50 [bp] between 
the active sites of the initiating Pol II and the paused Pol II (Figure 2 b). 
 
 
 
2.7 Determinants of promoter-proximal pausing 
 
To investigate possible reasons for polymerase pausing and its consequences, we compared 
different properties of genes with long and short pause durations. For the 5’ region of genes 
with longer pause durations, the transcript adopts more RNA secondary structure in vivo 425 
(Figure 21 a-b; Wilcoxon rank sum test, p-value < 10-16) and in silico 426 (Figure 21 c 
Wilcoxon rank sum test, p-value < 10-8). Genes with longer pause durations were also enriched 
for hyper-methylated CpG islands 144 upstream of the pause site (Figure 21 d), consistent 
with a previous report 256. 
Comparison of strongly and weakly CDK9-responding genes around the pause site showed 
that genes that responded strongly to CDK9 inhibition showed a higher tendency to establish 
long-range chromatin interactions (Figure 21 f) as observed by Hi-C 437. This is consistent 
with the idea that interactions of an enhancer with its target promoter can stimulate Pol II 
pause release 240,438. This tendency however seems to be independent of the pause duration as 
comparing genes with long and short pause durations leads to no observable difference in Hi-
C signal. Finally, we investigated which factors preferentially occupy pause windows with 
longer pause durations. This is now possible because ChIP-seq signals can be normalized with 
the productive initiation frequency. Without such normalization, ChIP-seq derived factor 
occupancies are artificially high in pause windows with long pause durations 315. Correlation 
of such normalized ChIP-seq signals in the pause window with pause durations (Figure 21 e) 
resulted in a positive correlation for Pol II phosphorylation at sites that are associated with 
elongation, and also for NELF-E, CDK9, and Brd4, which are all factors involved in Pol II 
pausing and release. 
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Figure 21. Determinants of long promoter-proximal pause duration d. 
(a) Secondary structure of a 50 nt long RNA fragment (-15 to -65 bp) upstream of pause site (position 0, n*) is 
compared for genes with long d to genes with short d. RNA secondary structure is read out by in vivo DMS-seq, 
or in silico (minum free energy, MFE [kcal mol-1]). (b) Distribution of gene-wise mean in vivo DMS-seq signals 425 
for a window defined in (a) for genes with long d (d > 75 % quantile, 534 genes) and with short d (d < 25 % 
quantile, 534 genes) normalized to denatured DMS-seq coverage 425. (c) Distributions of gene-wise MFE 426 as in 
(b). (d) Metagene analysis comparing the average Bisulfite-seq signal for subsets as in (b) aligned at the pause site 
(n*) (red, long d, and black, short d). Shaded areas around the average signal (solid lines) indicate confidence 
intervals. (e) Heatmap showing the pairwise Spearman correlation (color encoded, −0.19 in blue to 0.22 in red) of 
534 genes with long d against ChIP-seq measurements in the pause window (n* ± 100 bp, or TSS + 200 bp) of 
factors involved in pausing: Brd4 439, CDK9 439,440, and NELF-E 144 in K562 cells. ChIP-seq signal is shown as raw 
(top), or normalized by total Pol II occupancy 440 (middle), or by initiation frequency I (bottom). (f) Metagene 
analysis comparing the average Hi-C signal 437 (detecting long-range chromatin interactions) for strongly CDK9-
responding genes (red, response ratio > 75% quantile, 552 genes) and weakly CDK9-responding genes (black, 
response ratio < 25% quantile, 440 genes) aligned at the pause site (n*). All data sets are listed in Table 31. 
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3. The pause-initiation limit restricts transcription 
activation 
 
 
 
 
The results presented in chapter 3 are currently under peer review for publication: 
 
S. Gressel *, B. Schwalb * et al. The pause-initiation limit restricts transcription activation 
in human cells. Nature Communications, in revision. 
(* joint first authorship) 
 
A detailed list of author contributions can be found on page VII. 
 
 
 
Chapter summary 
 
Eukaryotic gene transcription is often controlled at the level of RNA polymerase II (Pol II) 
pausing in the promoter-proximal region. Pausing Pol II limits the frequency of transcription 
initiation (‘pause-initiation limit’), predicting that the pause duration must be decreased for 
transcriptional activation. To test this prediction, we conducted a genome-wide kinetic 
analysis of the heat shock response in human cells. We show that the pause-initiation limit 
restricts transcriptional activation at most genes. Gene activation requires the activity of the 
P-TEFb kinase CDK9, which decreases the duration of Pol II pausing and thereby enables an 
increase in the productive initiation frequency. The transcription of enhancer elements is 
generally not pause-limited and can be activated without CDK9 activity. Our results define 
the kinetics of Pol II transcriptional regulation in human cells at all gene classes during a 
natural transcription response. 
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Figure 22. Multi-omics analysis and annotation of different gene classes in human K562 cells. 
(a) Experimental schematic of multi-omics approach. Human K562 cells were subjected to TT-seq to estimate the 
productive initiation frequency I [cell-1 min-1]. By combining TT-seq data with mNET-seq the pause duration d 
[min] is calculated 381. (b) Schematic overview of capped transcription unit (cTU) annotation in K562 cells. First, 
TT-seq data (n=6) were subjected to the genomic segmentation algorithm GenoSTAN 177. The transcription start 
sites (TSSs) were further refined by published GRO-cap data generated in K562 cells 50. To call promoter-proximal 
pause sites mNET-seq data (n=6) generated in K562 cells were used (Table 23, Table 25, Figure 11). 
(c) Distribution of pause site distance [bp] for 12,160 investigated cTUs measured by mNET-seq depicted as a 
histogram with respect to GRO-cap refined TSS (mean 131 [bp], median 100 [bp], mode 50 [bp]). (d) Genome 
browser view of a 847 kbp region located in chromosome 13 (chr13:51,209,291-52,060,003) visualized with the 
Integrative Genomics Viewer (IGV, version 2.4.10; human hg38) 400. From top to bottom, tracks represent: TT-
seq coverage in K562 cells (n=6) on respective plus (+) or minus (-) strand, GRO-cap data 50, new cTU annotation, 
RefSeq GRCh38 annotation. cTUs missing in the RefSeq GRCh38 annotation are highlighted in a green. RefSeq 
transcript not present in K562 cells is highlighted in red. 
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3.1 Multi-omics analysis and annotation of transcription units 
 
We first aimed at defining genome-wide Pol II kinetic parameters during steady state 
conditions. To obtain the productive initiation frequency I and the promoter-proximal pause 
duration d 381, we carried out TT-seq and mNET-seq of total Pol II (with Empigen BB) in 
human K562 cells (Figure 6, Figure 22 a). We generated TT-seq data for two independent 
biological replicates after 5 min of metabolic labeling with 4sU (Figure 11 a; Spearman 
correlation rho = 1.00) as well as mNET-seq data for two independent biological replicates 
(Figure 11 c; Spearman correlation rho = 0.99) (Table 23). We then used the TT-seq data 
to create a genome-wide transcription unit (TU) annotation with the segmentation algorithm 
GenoSTAN 177 (Figure 22 b, Figure 45). As a strategy for identifying accurate transcription 
start sites (TSSs) for the TT-seq derived TUs, we used published GRO-cap data 50, which 
recovers nascent RNAs with 5' caps of transcriptionally engaged RNA Pol II. To be eligible 
for further analysis, annotated TUs needed a GRO-cap signal in a window of 250 bp around 
the GenoSTAN-derived start site, and an expression of >5 reads per base in the sum of both 
replicates of the TT-seq signal. We then sorted each capped TU (cTU) into one of the 
following seven classes using GENCODE annotation, respective location and chromatin state 
annotation 177 for enhancer and promoter classification (Figure 23 a; Methods II.2.4.4): 
protein-coding (m), long intergenic noncoding (linc), antisense (as), convergent (con), 
upstream antisense (ua), short intergenic noncoding (sinc), and putative enhancer (e) RNAs.  
 
Subsequently, we used the mNET-seq data to extract the position of paused polymerases for 
all cTUs in each class that showed mNET-seq signal peaks above background (Methods 
II.2.4.4). The called pause sites were distributed around a maximum located ~50 bp 
downstream of the TSS (Figure 22 c), in contrast to the pause sites that were previously 
derived based on the TSS annotation from RefSeq, which were located ~30 bp further 
downstream (Figure 2 a; Figure 48 c). This agrees well with recently published data in K562 
cells 247. We did not observe any substantial differences in the positions of called pause sites 
among the different classes. This resulted in a total of 10,363 expressed cTUs, for which a 
pause site call was successful, encoding 604 eRNAs, 471 asRNAs, 1,314 sincRNAs, 965 
uaRNAs, 445 conRNAs, 209 lincRNAs and 6,355 mRNAs (Figure 22 b-d, Figure 23 a). Below 
we will refer to these cTUs simply as ‘genes’ or with the respective RNA transcript class they 
give rise to. 
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Figure 23. Transcription kinetics of different gene classes in steady state. 
(a) Schematic representation of seven major transcript classes annotated in this study: 604 eRNAs (in light red), 
471 asRNAs, 1,314 sincRNAs, 965 uaRNAs, 445 conRNAs (in different shades of grey), 209 lincRNAs (in purple), 
6,355 mRNAs (in green), depicted on plus (dark blue) or minus (light blue) strand (Methods II.2.4.4). (b-
c) Boxplots of productive initiation frequency I [cell-1 min-1] (b) or pause duration d [min] (c) for transcript classes 
defined in (a). Black bars represent medians, boxes span from upper to lower quartiles, whiskers represent 1.5 
times the inter-quartile range. (d) Plot shows the median productive initiation frequency I [cell-1 min-1] depicted 
against the median pause duration d [min] for all transcript classes (circles) in log scale. The two solid perpendicular 
lines define the inter-quartile range, the dotted whiskers represent 1.5 times the inter-quartile range of the 
respective estimates for the entire transcript class. The grey shaded area depicts impossible combinations of I and 
d 315,381. Striped area shows confidence intervals of the pause-initiation limit. The dotted line defines an 8-fold 
possible fold change until a gene would be restricted by the pause-initiation limit. (e) Boxplots of minimum free 
energy MFE [kcal mol-1]. MFE was calculated in a window of [-15,-65] bp upstream of the pause site to predict 
RNA secondary structure 426 (Figure 21 a) for each transcript in a transcript class. 
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3.2 Transcription kinetics differ between gene classes 
 
We next used our TT-seq and mNET-seq data in combination with our previously described 
kinetic modeling 381 to derive estimates of I and d for all annotated genes (Figure 23 a). We 
observed a reciprocal behavior of I and d for all classes of genes except enhancers (Figure 
23 b-d). When I was high, d was generally low, and the other way around, consistent with an 
anti-correlation between these two parameters 381. Protein-coding and lincRNAs showed the 
highest I value (with median initiation events of 1 and 0.3 cell-1 min-1) and the lowest d values 
(median 1 and 2.7 min), consistent with high expression levels (Figure 23 b, d; Figure 46). 
On average, lincRNAs show significantly longer pausing compared to mRNAs (Figure 23 c; 
Wilcoxon rank sum test, p-value < 2.2·10-16), in contrast to a recent study 391. Thus, genes 
encoding lincRNAs initiate on average about half as frequently as protein-coding genes, and 
smaller mNET-seq peaks for these genes indicate longer pause durations, which is 
counterintuitive but clearly revealed by the kinetic analysis (Supplementary Note 2). 
Generally, all noncoding (nc) RNA classes (except eRNAs) showed high d values, with a 
median ranging around 4-6 minutes, explaining their low levels of expression. The low pause 
durations at enhancers might be explained by the fact that eRNAs do generally not adopt 
stable secondary structure in the nascent RNA exiting from the polymerase (Figure 23 e), 
which is associated with pausing 381. However, other chromatin features and factor availability 
at different loci might contribute to pausing as well. A particularly long pause duration was 
observed for upstream antisense RNAs (median 6 min), and this could impair initiation events 
in the noncoding direction of bidirectional promoters (Figure 23 c). 
 
3.3 Monitoring transcription kinetics during a natural transcription 
response 
 
We next investigated how transcription activation kinetics change upon response to heat 
shock (Figure 24). The optimal time points were determined by quantitative reverse 
transcription PCR (RT-qPCR) of the major cell stress protein HSPA1A (human Hsp70) and 
cell viability assays (Figure 47; Methods II.2.1.2 and II.2.4.1). We performed TT-seq, RNA-
seq and mNET-seq in K562 cells that were maintained under optimal growth conditions at 37 
°C (control), or placed in a 42 °C water bath for 15 or 30 min (heat shock) (Figure 24 b). 
TT-seq, RNA-seq and mNET-seq libraries were prepared in two biological replicates that were 
highly reproducible (TT-seq: rho >0.99 for all time points; RNA-seq: rho >0.99 for all time 
points; mNET-seq: rho >0.99 for all time points) (Table 23, Table 25, Figure 11). In order 
to capture global changes in transcription profiles, we used a spike-in normalization strategy 
168. This revealed that 899 genes were significantly upregulated, whereas 2,614 genes were 
downregulated after 30 min of heat shock (Figure 25 a). To normalize the respective mNET-
seq signals in the heat shock conditions versus the control, we identified 3,416 genes that were 
unchanged in their TT-seq signal, and globally calibrated the mNET-seq data to show no 
change on these genes during the heat shock response (Methods V.2.1.2). 
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3.4 The pause-initiation limit restricts transcription activation 
 
Next, we calculated the productive initiation frequency I and the pause duration d for all 
genes after 15 min and after 30 min of heat shock. Our results show that upon heat shock, 
activated genes generally show increased I and decreased d (Figure 24 c, Figure 48 f), 
suggesting that gene activation requires a decrease in pause duration, which in turn allows for 
higher productive initiation frequencies. This behavior is even more evident at protein-coding 
genes linked to heat shock (Figure 24 c). This can be exemplified at the HSPA1A (HSP70) 
gene which is a prominent model gene for the heat shock response (Supplementary Fig. 4 b). 
The pause duration d of HSPA1A changes from ~30 min at steady state to ~0 min upon 
30 min of heat shock which agrees well with literature estimates 356. Consistent with an anti-
correlation between d and I, I increased upon heat shock to 87 productive initiation events 
(cell-1 min-1). The results also revealed that downregulated genes exhibited decreased I and 
increased d (Figure 24 d, Figure 48 e). Thus, this multi-omics analysis reveals that the pause-
initiation limit restricts gene regulation at genes which are located close to the limit in steady 
state. The use of TT-seq in this respect is critical because it directly monitors RNA synthesis 
activity and productive initiation frequency (see also Supplementary Note 2, Figure 43). 
 
 
 
 
Figure 24. Regulation of transcription upon heat shock time-course in human K562 cells. 
(a) Illustration of the regulatory changes (red arrows) at a model gene upon heat shock. Pol II is depicted in silver, 
decorated with initiation, pausing or elongation factors (dark grey). (b) Experimental set-up of the heat shock 
(HS) time-course (0 to 30 min at 42 °C) in human K562 cells. TT-seq and mNET-seq experiments were performed 
in two independent biological samples (Table 23, Table 25, Figure 11). (c) Pause-initiation trajectories upon heat 
shock time-course. Shown are 706 significantly upregulated cTUs (in grey), and 33 significantly upregulated 
RefSeq-TUs (in red) of overrepresented GO categories linked to heat shock (unfolded protein binding, regulation 
of cellular response to heat, response to unfolded protein, chaperone binding) (Figure 26). Median estimates per 
time point (0, 15 and 30 min) are depicted as circles. The two solid perpendicular lines define the inter-quartile 
range, the dotted whiskers represent 1.5 times the inter-quartile range of the respective estimates for the entire 
transcript class. The grey shaded area depicts impossible combinations of I and d 381. Striped area shows confidence 
intervals of the pause-initiation limit. (d) Pause-initiation trajectories as in (c) upon heat shock time-course of 
1,907 significantly downregulated cTUs (in grey). 
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Figure 25. DE analysis of transcript classes and kinetics of HSPA1A upon heat shock. 
(a) Transcript classes as annotated in this study (Figure 22; Methods II.2.4.4). Boxplots show differential 
expression (DE) analysis of upregulated (light red), downregulated (dark blue), and unchanged genes (grey) in 
human K562 cells upon 30 min of heat shock (42 °C). Heat shock samples (HS30) were compared to respective 
control (Ctrl). Spike-in normalized TT-seq data were analyzed for DE of all genes (cTUs), mRNAs (green frame), 
eRNAs (light red frame), conRNAs (black frame), lincRNAs (purple frame), asRNAs, uaRNAs, sincRNAs (frame 
in different shades of grey). A minimum fold change of 1.5 in all conditions and a maximum adjusted p-value of 
0.1 was set for calling a significant expression change. (b) Plot shows the median productive initiation frequency I 
[cell-1 min-1] depicted against the median pause duration d [min] for hsp70 (HSPA1A) (red) for 0, 15, and 30 min 
at 42 °C (in red). The grey shaded area depicts impossible combinations of I and d. 
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Figure 26. GO analysis of differentially expressed RefSeq-TUs upon heat shock. 
Gene Ontology (GO) analysis 441 of significantly overrepresented categories linked to upregulated (a) or 
downregulated (b) categories in heat shock for human K562 or Raji B (CDK9as) cells. For K562 cells, heat shock 
samples (HS15, or HS30) were compared to respective control (Ctrl). For Raji B (CDK9as) samples, solvent heat 
shock sample (HS30) was compared to solvent control, while CDK9 inhibited heat shock sample (PP1+HS30) was 
compared to CDK9 inhibited control. Two biological replicates were averaged per condition and time-point. 
 
 
3.5 CDK9 activity lowers the pause-initiation limit for gene activation 
 
Our kinetic modeling revealed that the activation of genes restricted by the pause-initiation 
limit requires a decrease in the pause duration. To corroborate this, we utilized the highly 
specific and rapid inhibition of an analog-sensitive CDK9 Raji B cell line using the bulky ATP 
analog 1-NA-PP1 381 (Figure 27 a). Raji B and K562 cell lines are predicted to show a 
conserved response to heat shock with respect to timing of HSPA1A upregulation, cell viability 
(Figure 26) and GO terms of up- or downregulated TUs (Figure 47). 
We generated TT-seq data for two independent biological replicates after 5 min of metabolic 
labeling with 4sU to measure changes in I upon specific inhibition of the P-TEFb kinase CDK9 
prior and during heat shock (Table 23, Table 25). TT-seq data were highly reproducible 
(Figure 12 a; Spearman correlation rho = 1.00) and CDK9 kinase inhibition was very rapid 
(Figure 44). We again annotated TUs genome-wide with GenoSTAN (Figure 49), and this 
resulted in 6,990 mRNAs, 3,451 eRNAs, 243 lincRNAs, 1,398 asRNAs, 326 conRNAs, 565 
uaRNAs, and 3,479 sincRNAs. We now tested our hypothesis by investigating the changes in 
I upon heat shock after CDK9 inhibition (Figure 27). We derived estimates of the productive 
initiation frequency I for all 12,958 expressed, non-ambiguously classified genes after spike-in 
normalization. Changes in I for upregulated genes confirmed a strong dependence of 
transcription activation on CDK9 kinase activity. Genes were significantly less inducible 
during heat shock when CDK9 was inhibited (Figure 27 b, left; Wilcoxon rank sum test, p-
value = 9·10-9), confirming an obligatory decrease in pause duration for upregulation of the 
productive initiation frequency. Productive initiation events of genes encoding mRNAs 
decreased to 75 % after CDK9 inhibition (Figure 27 c, left). Downregulation of genes was 
overall stronger upon CDK9 inhibition (Figure 27 b, right; Wilcoxon rank sum test, p-value 
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< 2.2·10-16), indicating less possible initiation events (33 % for mRNAs) due to even longer 
pause durations compared to downregulation upon heat shock alone (Figure 27 c, right). 
Thus, CDK9 activity lowers the pause duration to allow for high gene activation that is 
restricted by the pause-initiation limit. 
 
 
 
Figure 27. Enhancer transcription is generally not pause limited and less dependent on CDK9. 
(a) Experimental set-up. The adenine analog 1-NA-PP1 allows for rapid and highly specific inhibition of analog 
sensitive CDK9 338,339 in CRISPR/Cas9 engineered human Raji B (CDK9as) cells 381 (Figure 12 b). CDK9 was 
inhibited using 5 µM 1-NA-PP1 (CDK9 inhibition) in combination with heat shock at 42 °C for 30 min in human 
Raji B (CDK9as) cells. DMSO was used as solvent control. (b) Boxplots of productive initiation frequency I fold 
change before (in white) and after CDK9 kinase inhibition (in dark blue). Shown are 241 significantly upregulated 
genes (left boxplot), and 2,795 significantly downregulated genes (right boxplot) annotated in Raji B (CDK9as) 
cells (Figure 49 b). (c) Left: bar plot comparing productive initiation frequency I change (ΔI) with and without 
CDK9 inhibition for 92 significantly upregulated mRNAs (in green), and 54 significantly upregulated eRNAs (in 
red) annotated in Raji B (CDK9as) cells. ΔI upon upregulation between heat shock with CDK9 inhibition (CDK9 
inhibited HS30) and heat shock with solvent control (Solvent HS30) is shown in percentage [%]. Grey arrow 
indicates that less productive initiation events occur compared to solvent control. Right: bar plot comparing 
productive initiation frequency I change (ΔI) with and without CDK9 inhibition for 2,210 significantly 
downregulated mRNAs (in green), and 223 significantly downregulated eRNAs annotated in Raji B (CDK9as) cells. 
ΔI upon downregulation between heat shock with CDK9 inhibition (CDK9 inhibited HS30) and heat shock with 
solvent control (Solvent HS30) is shown in percentage [%]. Grey arrows indicate that less productive initiation 
events occur for mRNAs, or more productive initiation events for eRNAs compared to solvent control. (d) Log2 
fold change of pause duration d and initiation frequency I for 336 significantly upregulated mRNAs (in green), and 
67 significantly upregulated eRNAs (in light red) in K562 cells upon 30 min of heat shock (HS30) (Figure 25 a). 
Dashed lines represent HSF1 driven subsets of 91 mRNAs and 20 eRNAs. (e) Log2 fold change of pause duration 
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d and initiation frequency I for 1,101 significantly downregulated mRNAs (in green), and 99 significantly 
downregulated eRNAs (in light red) in K562 cells upon 30 min of heat shock (HS30) (Figure 25 a). 
 
 
3.6 Enhancer transcription is generally not pause limited 
 
Amongst all seven gene classes, enhancers showed the greatest distance from the pause-
initiation limit at steady state in K562 cells, thus forming a notable exception from other gene 
classes (Figure 23 d). Enhancers showed a median pause duration of only 2.2 min and a 
median productive initiation frequency of only one initiation event every 6-7 min. This 
indicated that enhancers were generally not restricted by the pause-initiation limit, i.e. I could 
increase several-fold without any change in pause duration, until the pause-initiation limit 
would be reached. Indeed, upon heat shock, the productive initiation frequency I for enhancers 
was increased 1.5-fold more than for mRNAs given the same change in pause duration d 
(Figure 27 d). This difference is even stronger when comparing heat shock factor 1 (HSF1) 
targeted mRNAs and eRNAs. HSF1 is a major activator in heat shock induced transcription 
upregulation. HSF1 driven eRNAs can be activated without a change in pause duration, while 
HSF1 driven mRNAs still require a shortening of the pause duration. 
Another implication of this exceptional kinetic behavior is that enhancer transcription can 
generally only be reduced by a strong increase (>8-fold, Figure 23 d) of the pause duration 
d. However, downregulation of enhancer transcription is in line with the general observation 
of prolonged pausing to inhibit new initiation events, as is the case for mRNA synthesis 
(Figure 27 e). In conclusion, enhancers differ from protein-coding genes, because their 
productive initiation frequency appears generally not to be restricted by the pause duration. 
 
3.7 Enhancer transcription is less dependent of CDK9 
 
Although enhancer transcription is generally not limited by pausing in K562 cells at steady 
state (Figure 23 d), it remained unclear whether enhancer transcription is controlled by P-
TEFb. Using mNET-seq data in Raji B (CDK9as) cells 381 we found that the median pause 
duration of all transcript classes and the exceptional role of eRNAs is conserved in 
unperturbed Raji B cells (Figure 28 a). We confirmed this also in the context of the 
upregulation of enhancer transcription upon heat shock in K562 cells. Enhancers showed 
higher initiation frequency fold-changes provided the same fold-change in pause duration as 
found for protein-coding genes (Figure 27 d). Consistent with the results in K562, activation 
of enhancer transcription in Raji cells was only reduced by 11% upon CDK9 inhibition (Figure 
27 c, Figure 28 c).  
This shows that enhancer transcription can be activated even when CDK9 is inhibited. The 
overall behavior of impaired activation after CDK9 inhibition for all gene classes resembles 
the pause durations calculated for Raji cells 381 and strongly supports our estimates (Figure 
23 d, Figure 28 b). Surprisingly, downregulated enhancers were not repressed by inhibition 
of CDK9, consistent with our assumption that higher pause durations do not cause lower 
productive initiation frequencies at enhancers (Figure 27 c, Figure 28 d). Taken together, 
enhancer transcription and thus, eRNA synthesis can be up- and down-regulated to a large 
extent without changes in pause duration. 
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Figure 28. Gene classes vary in CDK9-induced pause duration changes upon heat shock. 
(a) Boxplots of pause duration d [min] for 498 eRNAs (in light red), 319 asRNAs, 504 sincRNAs, 462 uaRNAs (in 
different shades of grey), 254 conRNAs, 144 lincRNAs (in purple), and 5,967 mRNAs (in green) annotated in Raji 
B (CDK9as) cells (Methods II.2.4.4). By combining TT-seq data with published mNET-seq in Raji B (CDK9as) 
cells 381, d was calculated. Black bars represent medians, boxes span from upper to lower quartiles, whiskers 
represent 1.5 times the inter-quartile range. Note that the median pause duration (black bars) per transcript class 
in Raji B (CDK9as) cells resembles the median pause duration per transcript class in K562 cells (Figure 23 c). 
Thus, our data suggest strong conservation across human hematopoietic cell lines. (b) Fold change of pause 
duration d for different transcript classes (as in (a)) in Raji B (CDK9as) cells upon CDK9 inhibition using published 
TT-seq and mNET-seq data 381. CDK9 inhibited samples (5 µM 1-NA-PP1, 15 min) were compared to respective 
solvent control (DMSO, 15 min). Grey arrow indicates shift to longer pause durations upon CDK9 inhibition for 
all genes. (c) Bar plot comparing productive initiation frequency I change (ΔI) with and without CDK9 inhibition 
for significantly upregulated genes in Raji B (CDK9as) cells. From left to right: 55 eRNAs, 13 asRNAs, 51 
sincRNAs, 16 uaRNAs, 11 conRNAs, 3 lincRNAs, and 92 mRNAs annotated in this study (colors as in (a)) (Figure 
49 b). ΔI upon upregulation between heat shock with CDK9 inhibition (CDK9 inhibited HS30) and heat shock 
with solvent control (Solvent HS30) is shown in percentage [%]. Grey arrow indicates that less productive initiation 
events occur compared to solvent control. (d) Bar plot comparing productive initiation frequency I change (ΔI) 
with and without CDK9 inhibition for significantly downregulated genes in Raji B (CDK9as) cells. From left to 
right:  223 eRNAs, 45 asRNAs, 227 sincRNAs, 38 uaRNAs, 20 conRNAs, 35 lincRNAs, and 2,211 mRNAs 
annotated in this study (colors as in (a)) (Figure 49 b). ΔI upon downregulation between heat shock with CDK9 
inhibition (CDK9 inhibited HS30) and heat shock with solvent control (Solvent HS30) is shown in percentage [%]. 
Grey arrows indicate that less productive initiation events occur for mRNAs, or more productive initiation events 
for eRNAs (less downregulation) compared to solvent control. 
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IV. Discussion and Outlook 
 
 
 
 
 
 
In this part, I will review the results of my work with respect to the five questions 
(Introduction I.4) raised at the beginning of my graduate work (chapter 1). Furthermore, I 
included a chapter on current technical limitations of our multi-omics approach. I hope that 
this work will encourage further development of the methodology (TT-seq and mNET-seq) to 
address the technical limitations discussed in chapter 2. In the future, multiple challenges 
such as the general mechanism of Pol II pausing and (in)active P-TEFb recruitment have to 
be addressed. Thus, in a closing chapter, I will look beyond the current state to anticipate 
what might be the next exciting questions to tackle in the field of transcription regulation 
(chapter 3). 
 
 
1. Our contributions to the field 
 
1.1 A novel multi-omics approach 
 
Question 1. Can we measure the kinetic parameters initiation frequency, pause duration, and 
elongation velocity globally? 
 
Major open questions in systems biology relate to how cells control when and how much of 
the molecular information contained in their genome is transcribed into RNA. To capture the 
complexity of this regulation, a quantitative description of the transcriptional output and the 
kinetics of the transcription process itself is crucial. To date, methods are available to quantify 
RNA synthesis and degradation rates 368,442 (recently reviewed in 443). However, at the outset 
of this work, efforts to capture transcription kinetics revealed limitations: the number of 
initiating polymerases (initiation frequency) and the time a polymerase needs to pass through 
the promoter-proximal window (pause duration) could not be quantified. Consensus methods 
in the field measured elongation velocity (in units of distance [bp] per time [min]) for genes 
longer than 5 kbp, and estimated the degree of Pol II pausing as relative ratio of promoter-
proximal region and gene body occupancies of Pol II (see Introduction I.3.1). 
Here, we solve this challenge with the combination of two state-of-the-art sequencing 
methods (TT-seq, mNET-seq) and novel kinetic modeling (multi-omics). Our approach 
enables genome-wide measurements of the kinetic parameters elongation velocity v, productive 
initiation frequency I and pause duration d in human cells (Figure 18 a, Figure 22 a). 
Specifically, the TT-seq signal (transcribed bases, tb) in the exons of the gene body is 
proportional to the productive initiation frequency I (in units of molecules per cell per time 
[min-1]). Synthetic spike-ins allow for calculation of a conversion factor to RNA amount per 
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cell (see Methods II.2.2.4). The promoter-proximal pause site (PS) which is marked by a peak 
in Pol II occupancy can be determined by mNET-seq. The number of polymerases released 
into elongation (productive initiation frequency I) measured by TT-seq can be combined with 
Pol II occupancy profiles measured by mNET-seq. This allows for quantitative conclusions to 
be drawn about the pause duration d (in units of time [min]) which is the time a polymerase 
resides in the pause window (PS +/- 100 bp) (Figure 18 a). These efforts have led to a kinetic 
description of genes in steady state, upon pause release inhibition and natural stress (Figure 
29). Given that sufficient input material (number of cells) can be generated, our multi-omics 
approach enables for the calculation of kinetics in any cell line with minimal optimization 
(chapter 2). Ultimately, transcription kinetics are a critical building block in our 
understanding of transcriptional regulation which may enable us to develop novel treatments 
for diseases with transcriptional malignancies (chapter 3). 
 
 
 
 
Figure 29. Summary of the novel multi-omics analysis. 
(a) For simplicity, the kinetic parameters (I, d) are depicted for a model gene x in steady state (left) and upon 
upregulation (right, top) or downregulation (right, bottom). The multi-omics approach, allows us to follow the 
kinetic parameters of a specific gene, e.g. the HSPA1A (human HSP70) gene over the heat shock time-course 
(Figure 25 b). Furthermore, our multi-omics approach enables us to globally extract kinetic parameters of 
expressed genes (symbolized by shifted frames, see also Figure 18), or sets of genes (see Figure 23, Figure 24). 
Plots are ordered by transcription activity (see also Figure 1 b). (b) Kinetic analysis of 6,496 genes in steady state 
K562 cells. 
Part IV – Discussion and Outlook 
 
   88 
1.2 The pause-initiation limit 
 
 
Parts of the discussion presented in this subsection 1.2 has been published as: 
 
S. Gressel *, B. Schwalb * et al. CDK9-dependent RNA polymerase II pausing controls 
transcription initiation. Elife 6, doi:10.7554/eLife.29736 (2017). 
(* joint first authorship) 
 
 
Question 2. How can Pol II promoter-proximal pausing control the frequency of productive 
initiation and by that the amount of RNA synthesized per time? 
 
Taken together, our results show that Pol II pausing can control transcription initiation and 
demonstrate the central role of CDK9 in controlling pause duration and thereby the 
productive initiation frequency. Our results have implications for understanding gene 
regulation. Genes that show initiation frequencies below the pause-initiation limit may be 
activated by increasing the initiation frequency without changing the pause duration. 
However, activation of genes that are transcribed at the pause-initiation limit requires a 
decrease in pause duration, i.e. stimulation of pause release, to enable higher initiation 
frequencies. We suggest that pause-controlled initiation evolved because mutations in the 
promoter-proximal region can change pause duration, and thereby limit initiation, but do not 
compromise a high initiation capacity of the core promoter around the TSS. This may have 
enabled the evolution of genes that remain highly inducible but can be efficiently 
downregulated. 
 
After our work had been completed, a publication appeared in Nature Genetics that concluded 
that polymerase pausing inhibits new transcription initiation 444. The conclusion in this paper 
is consistent with our general finding of an interdependency of Pol II pausing and transcription 
initiation, but the two studies differ in three aspects. 
First, we used human cells whereas the published work was conducted in Drosophila cells. 
Second, our work uses a multi-omics approach to enable a kinetic description, whereas the 
published work is based on changes in factor occupancy. Third, we selectively inhibited CDK9 
using CRISPR/Cas9-based engineering and chemical biology, whereas the published work 
used small molecule inhibitors that may target multiple kinases (DRB, flavopiridol; see 
Introduction I.3.1.1). Despite these differences, the general conclusion that promoter-proximal 
pausing of Pol II sets a limit to the frequency of transcription initiation holds for both human 
and Drosophila cells and is likely a general feature of metazoan gene regulation. 
 
To understand genome function, the regulatory steps of gene transcription have to be defined 
and it is crucial to analyze under which conditions they become rate limiting. A rate-limiting 
step may be defined as the slowest molecular transition in the process that limits the overall 
progression and the transcriptional output (reviewed in 445,446). As outlined above, we and 
another group concluded that prolonged promoter-proximal pausing of Pol II impairs new 
initiation, and thus, reduces the amount of mRNA synthesized per time (‘pause-initiation 
limit’) 381,444. Mechanistically, however, it is not fully understood if steric hindrance by the 
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paused polymerase (Figure 2 b) is the only way to restrict initiation, or if promoter-proximal 
pausing additionally represses Pol II recruitment to the promoter or PIC assembly. In the 
future, the interdependence of Pol II pausing and initiation should be investigated further, 
e.g. by structural analysis. 
 
1.3 DNA sequence determines pause site but not pause duration 
 
Question 3. What are the determinants of long pause duration in human cells? 
 
Polymerase pausing is characterized by two parameters: the pause position or pause signal to 
enter the paused state, and the pause duration which is the dwell time until a Pol II molecule 
transitions from the promoter-proximal paused state to productive elongation. 
Across different organisms, promoter-proximal polymerase pause positions can be 
called from polymerase peaks downstream of the TSS using (m)NET-seq, PRO-seq, or CoPRO 
data (Figure 30 a). The first DNA sequence analysis of genes with promoter-proximal Pol II 
peaks was performed on ChIP-chip data generated in Drosophila melanogaster embryos. In 
this study an enrichment of cytosine (C) and guanine (G) was observed for a window of [-5, 
+ 50] around the TSS which the authors referred to as the pause button (PB) 256(Figure 
30 b). Technical advances in resolution by the development of PRO-seq defined the position 
of the Drosophila PB at ~40 bp downstream of the TSS 347. At the Drosophila Hsp70 promoter, 
it was shown that insertion of sequences upstream of the PB sequence shifted the pause site 
downstream of its original position (e.g. the addition of 5 bp shifted the pause site ~5 bp 
downstream) 347. This indicates that the PB defines the pause position in Drosophila. NET-
seq analysis of pause site sequences in Escherichia coli (E.coli) showed the following features: 
G/C immediately upstream of the DNA-RNA hybrid in the active site of the polymerase, 
C/T at the 3’ end of the RNA and G/C as the first incoming nucleotide (pause element, 
PE) 257,447 (Figure 30 c). Our work was the first study analyzing the pause sequence (PS) at 
human pause sites by mNET-seq. We found an enrichment for G/C-C/G dinucleotides with 
a strongly conserved C as the first incoming nucleotide (Figure 17 b). The strongly conserved 
C was also found in other mammalian cell lines – by re-analysis of published PRO-seq data 
(human K562 cells) 50 and by another recent study using CoPRO experiments (human K562 
cells and mouse embryonic fibroblasts) 247 (Figure 17 c). 
In summary, high-throughput sequencing of nascent RNAs found that C/G 
nucleotides are frequently enriched at polymerase pause sites in Drosophila, E.coli and 
mammalian cells. The conservation of DNA sequence elements at pause sites (PB, PE, or PS) 
across diverse species suggests that pausing might have evolved early and supports its key 
regulatory roles in prokaryotes and eukaryotes (reviewed in 46). Another contributing factor 
might be that CTP and GTP are the least frequent ribonucleotides 448 (Figure 17 d). However, 
pause durations in bacteria (~1 second 449) are much shorter than in Drosophila and 
mammalian cells (range of minutes, ~2.5 min in this study). This indicates that the pause 
duration must depend on stabilizing factors acting in trans such as NELF and DSIF which 
are not present in bacteria. Interestingly, the dependence on the P-TEFb kinase CDK9 for 
pause release varies significantly between human genes (Figure 15 e). Some genes (low 
responding) are capable of escaping the pause window independently of CDK9 while other 
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genes (high responding) are highly dependent on CDK9 (mean response ~60 %). Several 
important questions about the factors ‘timing’ the pause duration remain to be answered. 
 
 
 
 
Figure 30. Pause site specification by sequence in flies, bacteria and humans. 
(a) Pause site n* is defined at position 0 (see also Figure 2 a). The RNA 3’-end is depicted as dotted line. (b) Logos 
depict the level of sequence conservation (bits of information) at each position. In Drosophila melanogaster 
embryos, the pause button (PB) is enriched from [-5 to +55 bp]. Ab initio motif search 256 was performed on ChIP-
chip data 353 (logo modified from figure 2 a of 256). (c) In Escherichia coli, a consensus pause element (PE) was 
identified by NET-seq. Top: Larson et al. 257 aligned pause sequences at their 3’ end and performed motif analysis 
by weblogo.berkeley.edu 450 (logo modified from figure 2 a of 257). Bottom: Vvedenskaya et al. 447 analyzed pause 
sites by WebLogo 451 (logo modified from figure 1 a of 447). (d) In human cells, the pause sequence (PS) was 
identified by mapping the active site of Pol II along nascent RNA at the pause site n*. Left to right: mNET-seq 
of Raji B cells 381, PRO-seq of K562 cells (50, reanalyzed in this study), and CoPRO-seq of K562 cells 247. Position 
weight matrix (PWM) logo representation of bases -10 to +10 [nt] around the pause site n* (position 0). Tome et 
al. 247 analyzed sequences of the pause region (logo modified from figure 2 b of 247). (e) Average physiological 
concentration of ribonucleotides across mammalian tumor cell cultures (ATP in green, GTP in yellow, UTP in 
red, CTD in blue). The values for average concentration [µM] and the standard deviation are derived from table 
4, column ‘tumor cells’ of 448. 
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1.4 Transcription of enhancer elements is generally not pause-limited 
 
 
The discussion presented in subsection 1.4 and 1.5 is currently under peer review for 
publication: 
 
S. Gressel *, B. Schwalb * et al. The pause-initiation limit restricts transcription activation 
in human cells. Nature Communications, in revision. 
(* joint first authorship) 
 
 
Question 4. Are there differences with respect to average Pol II pausing and/or initiation 
behavior of coding compared to noncoding transcript classes? 
 
Changes in the kinetics of Pol II initiation and pausing had not been quantified genome-wide 
during a transcription response, which is required as definitive evidence that natural gene 
regulation is controlled by pausing kinetics. To test this assumption, we conducted a genome-
wide kinetic analysis of the heat shock response in human cells. 
We quantified transcription kinetics of protein-coding and noncoding genes in steady 
state and during the dynamic transcriptional response of human cells to heat shock. To this 
end, we annotated protein-coding RNAs (mRNAs), and six major long noncoding transcript 
classes, i.e. lincRNAs, asRNAs, eRNAs, uaRNAs, conRNAs, and sincRNAs in human 
hematopoietic cell lines (K562 and Raji B) (Figure 22 b-e, Figure 49 a). We then used our 
multi-omics approach to follow changes in productive initiation frequency I and pause 
duration d in a quantitative manner. In steady state, we observed a reciprocal behavior of I 
and d for genes encoding all transcript classes except eRNAs. Protein-coding and lincRNAs 
were among the classes with the shortest pause durations, consistent with their high 
transcription levels. The longest median pause duration was observed for upstream antisense 
RNAs (uaRNAs), presumably impairing initiation events in the noncoding direction of 
bidirectional promoters. Enhancers showed a median pause duration of 2.2 min and a median 
productive initiation frequency of only one initiation event every 6-7 min (Figure 23 c-d). 
Thus, enhancer elements are generally not pause-limited. We found that in contrast to the 
other transcript classes, the nascent eRNA upstream of the pause site does not adopt a stable 
secondary structure (Figure 23 e). This could be an explanation for the short pause durations. 
Furthermore, it might be that the absence of stabilizing factors at enhancer elements leads to 
shorter pause durations. 
 
1.5 Towards a model for gene activation 
 
Question 5. How are rapid and reversible changes in transcription upon stress achieved at a 
molecular level? Specifically, are changes refined by the pause-initiation limit? 
 
So far, a model was proposed where transcriptional regulation upon heat shock is coordinated 
at the single step of promoter-proximal pause release 219,231. Here we could show that this holds 
true for genes that are close to the pause-initiation limit such as protein-coding genes (Figure 
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24 c). Using the transcriptional response to heat shock, we show that upregulation of the 
productive initiation frequency is restricted by the P-TEFb kinase CDK9. Enhancers form a 
notable exception to this rule, because changes in pause duration do not cause changes in 
eRNA production during heat shock (Figure 27, Figure 28 c-d). 
More generally, upregulation of a gene requires an increase in initiation frequency, 
which leads to a higher number of polymerases loaded onto the gene, and a higher amount of 
RNA synthesis over time (Figure 29, top). At genes that are at the pause-initiation limit, 
pausing limits initiation, and a decrease in pause duration is required for upregulation of 
transcription by allowing for higher initiation frequencies. This is apparently often the case 
at protein-coding genes. In contrast, upregulation of enhancer transcription is often possible 
without changes in pause duration because enhancers are generally not pause-limited. These 
observations lead to a simple model for gene activation, which involves upregulation of 
enhancer transcription by an increase in productive initiation frequency, followed by a 
decrease in pause duration at the protein-coding target genes, which in turn allows for an 
increase of productive initiation frequency at the target genes. These mechanisms however 
rely on the availability of polymerases and transcription factors, and assume that transcription 
is generally processive. 
Considering the critical role of factors decreasing the pause duration for gene activation, 
the mechanisms of polymerase pause release should be studied further in the future. Despite 
the P-TEFb kinase CDK9, a role in pause release upon heat shock has been reported for other 
factors: the TFIIH-associated kinase CDK7 452-454, the elongation factor TFIIS 273, the DNA-
PK kinase, the ATM kinase, the 7SK snRNP recruitment factor TRIM28/KAP1 455, the pause 
stabilizing factor GRINL1A/GDOWN1 262, and the CTD phosphatase FCP1 456. These factors 
were mainly studied at selected model genes. It is however unclear if these factors reduce the 
pause duration directly, or if they operate indirectly, e.g. by recruitment of P-TEFb to 
activated genes. Methods developed here and elsewhere can now be used to dissect the 
involvement of these factors as well as the kinetics underlying the mechanisms of P-TEFb 
delivery and activation in a quantitative and genome-wide manner, ultimately unravelling the 
nature of gene regulation in mammalian cells. 
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2. Technical improvements 
 
Our multi-omics approach constitutes a systematic tool for measuring transcription rates in 
living cells. The current input requirements for TT-seq are 300 to 600 µg of total RNA to 
yield >100 ng of labeled RNA which is the optimal input for the cDNA library preparation. 
If sufficient input material is available, TT-seq can be applied in a broad range of cells 
including Drosophila and mammalian cells 168,374,457. For mNET-seq, ~1 x 108 of mammalian 
cells (K562, Raji B, HeLa S3, murine lymphoid cells) are required for a good coverage across 
the genome. Transferring the mNET-seq protocol to other cell lines may require optimization 
of two steps, cell fractionation and chromatin solubilization. If the number of cells is not 
available for mNET-seq experiments, mNET-seq can be replaced by another occupancy 
profiling technique which requires less input material (e.g. PRO-seq). However, it should be 
noted that PRO-seq does not monitor backtracked or arrested polymerases and may thus 
underestimate the total number of polymerases at a gene. 
As for every experimental approach, the two underlying techniques (TT-seq and mNET-seq) 
can be improved further to increase the efficiency (TT-seq, mNET-seq) and quantitative 
accuracy (mNET-seq) of the current protocols. 
 
2.1 TT-seq 
 
To date, the application of TT-seq is primarily limited by its need for large amounts of input 
material. This is required to perform metabolic labeling and subsequently, biochemical 
separation of newly synthesized from pre-existing RNAs. Depending on cell type specific 
parameters (doubling time, transcriptional activity, and amount of cellular RNA), between 
300 and 600 µg of total RNA is needed to isolate sufficient amounts of labeled RNA for 
sequencing. Typically, this corresponds to 1.5 to 5 x 107 cells. Overcoming these limitations 
would allow application of TT-seq in cases of rare cell populations and limited input material 
as those commonly obtained in clinical settings. To do so, either the metabolic labeling 
efficiency (not discussed here), or the efficiency of the biochemical separation step of 4sU-
labeled RNA fragments from unlabeled fragments must be increased. The separation step is 
essential to focus the sequencing capacity on newly synthesized RNA fragments which were 
transcribed during the 5 min labeling pulse (see Introduction I.3.2.1). The current protocol 
uses EZ-link HPDP-biotin which allows thiol-specific biotinylation of 4sU-labeled RNA. It 
was suggested that methylthiosulfonate-activated biotin (MTS-biotin) can be used as a more 
efficient alternative to HPDP-biotin 458. Our group performed extensive control experiments 
to evaluate the described use of MTS-biotin for our TT-seq protocol. To assess the specificity 
of both biotins, we used 4sU-free total cellular RNA spiked-in with 0.1 % of 4sU-labeled spike-
ins. When using MTS-biotin we found high levels of cross-contamination of the labeled RNA 
with unlabeled RNA (Katja Lidschreiber, unpublished). This is in agreement with Marzi et 
al. who detected 10-fold higher background levels for MTS-biotin compared to HPDP-
biotin 459. Recently, an improved MTS-biotin protocol including optimized biotin chemistry 
(MTS-resin) was developed 460. We have not tested this improved biotinylation protocol yet, 
but, if the new protocol overcomes the specificity issues it might offer an alternative to the 
currently used HPDP-biotin and could be a step towards overcoming the limitation of input 
material. 
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2.2 mNET-seq 
 
The three main technical challenges in mNET-seq are (i) the low efficiency (requirement of 
large amounts of input material) and imperfect specificity (heterogeneity of the target epitope) 
of the POLR2A antibody, (ii) the amplification bias (which might reduce quantitative 
accuracy), and (iii) the global normalization strategy (crucial for perturbation experiments). 
One of the critical steps in mNET-seq is the immunoprecipitation of the Pol II-RNA 
complex. Several antibodies are available for the largest subunit of Pol II, POLR2A. They 
target the C-terminal domain (CTD) of POLR2A, specifically, unphosphorylated CTD 
(8WG16), CTD with phosphorylation(s) at serine 2 (S2P) (MBL, clone CMA602), CTD with 
phosphorylation(s) at serine 5 (S5P) (MBL, clone CMA603), or total, unphosphorylated and 
phosphorylated CTD (MBL, clone CMA601) (Figure 31). Since the total number of Pol II 
molecules is required for kinetic modeling, the monoclonal MBL antibody (clone 
CMA601) 350,461 was used to immunoprecipitate total POLR2A. During the transcription cycle, 
the CTD is heavily phosphorylated and interacts with multiple transcription factors (see CTD 
code, Introduction I.1.1). The MBL antibody was validated by overall immunoreactivity in 
ELISA (enzyme-linked immunosorbent assay) 462 against purified peptides with and without 
phosphorylations (antigens) 350. ELISAs are limited by the provided antigen information and 
in vivo target epitopes of certain Pol II states might be masked by transcription factors leading 
to an underrepresentation in the mNET-seq data. However, comparison of Pol II occupancies 
measured by mNET-seq to published PRO-seq data which do not rely on Pol II antibodies 
(Introduction I.3.2.2) indicates that the fraction of Pol II that cannot be captured with a total 
CTD antibody must be very low. Two technical developments could circumvent the 
aforementioned problems: epitope tagging of POLR2A by CRISPR/Cas9 343, or the 
development of a novel N-terminal POLR2A antibody. Introducing an epitope tag may 
influence stability or interactions of Pol II with transcription factors and thus, differ from the 
wildtype Pol II and would affect the outcome of the mNET-seq experiment. As an alternative, 
the N-terminus of POLR2A would provide a less heterogenous target compared to the CTD, 
but to date no efficient antibody for IP is commercially available (Figure 31; see Figure 13 d 
for Santa Cruz’s antibody F12 raised against the N-terminus of POLR2A). The generation of 
a novel N-terminal POLR2A antibody would be advantageous 463, e.g. by collaboration with 
in-house Nanobodies experts (MPI-bpc, Dept. of Cellular Logistics, Prof. Dr. Dirk Görlich). 
Nanobodies are single-domain antibodies of camelid origin 464,465 which can be produced 
renewable as recombinant fusion proteins in bacteria without the need of immunizing and 
killing of animals 466. Epitope tagging or development of a novel antibody with higher 
efficiency would also allow to use less input material for the IP. 
 
Figure 31. Target regions of human POLR2A 
antibodies. 
The largest subunit of human Pol II, POLR2A 
(position highlighted by circle) is used as target for 
commercial antibodies. For the N-terminus, no 
efficient antibody for IP applications is available to 
date and the field would benefit from a novel N-
terminal antibody. Boxes show consensus repeat of 
YSPTSPS 107 and recognized phosphorylation sites 
(brown dots). 
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All current RNA-based Pol II profiling methods use amplification by PCR in their library 
strategy (i.e. GRO-seq 12-20 PCR cycles 467,468, PRO-seq 12-18 PCR cycles 347, mNET-seq 10-
15 PCR cycles 388). To correct for amplification bias, namely to distinguish seemingly identical 
fragments arising from distinct RNA molecules from copies arising through PCR amplification 
of the same RNA molecule, Unique Molecular Identifiers (UMIs) have been described for 
RNA-protein crosslinking methods or single-cell RNA-seq 469,470. UMIs are random 
oligonucleotide barcodes which make each RNA molecule unique and allow quantitative read 
counting after correction for amplification bias. For mNET-seq (and all current small RNA-
seq methods), overlapping or identical reads arising from distinct RNA molecules are expected 
in regions with a high number of polymerases or regions with slowly elongating polymerases. 
Thus, the majority of reads mapping to identical coordinates might not be due to PCR 
duplication but rather from biological distinct RNA molecules and should also be considered 
for quantification. It was recently shown by Fu et al. that for small RNA-seq data the majority 
of sequencing reads (~60 %) are counted as PCR duplicates. However, if UMIs were used to 
distinguish identical copies from unique RNAs from PCR duplicates only ~5 % were actual 
duplicates 471. Thus, removing PCR duplicates without UMIs would lead to a biased, 
unbalanced removal of identical but biological meaningful mNET-seq reads. The addition of 
UMIs in the cDNA library would improve the quantitative accuracy of mNET-seq Pol II 
occupancy changes. 
To compare Pol II occupancies reproducibly among experiments (control versus 
perturbation), normalization is required. There are a number of different normalization 
strategies, including normalization to sequencing depth, quantile normalization and other 
methods. In this study, we employed a set of ‘neutral’ genes which were defined by TT-seq 
(see Methods II.2.3.5 and II.2.4.2) for global normalization. However, certain perturbations 
might not allow for this normalization strategy. To address the problem of global 
normalization in these cases, IP spike-ins have been described 472,473. To this end, a constant 
number of Pol II-RNA complexes from another organism (e.g. Drosophila) is spiked-in prior 
to IP. The spike-in controls serve as internal calibrators for technical variations during IP and 
subsequent steps of the protocol. A crucial prerequisite of this approach is that IP antibodies 
are used that target conserved peptides across organisms. Unfortunately, the currently used 
MBL antibody does not recognize Drosophila or yeast Pol II due to sequence differences 
between their CTDs 474. Thus, a novel N-terminal antibody would allow immediate application 
of spike-ins during IP since the N-terminus of POLR2A is conserved across organisms. 
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3. Future explorations 
 
 
Box. Outstanding challenges in the pausing field. 
 
General pausing mechanism 
(1) What influences Pol II pause duration at pause sites? Is it a specific factor or the combinatorial action of 
multiple factors (regulatory network)? * 
(2) What transcription factors and chromatin regulators are involved in changing the pause duration in 
response to cellular signaling pathways? * 
(3) How is pause duration regulated in a gene or domain (e.g. TAD) specific manner? * 
(4) What are the consequences of pausing for development? How is paused Pol II established de novo at 
previously closed promoters during development (special pioneering factors)? 
(5) How do enhancers (and eRNAs) facilitate pause-release? * 
(6) Which steps are disrupted and lead to aberrant release of pausing in disease? * 
(7) How much non-productive initiation (promoter-proximal attenuation) occurs genome-wide upon steady 
state? ** 
 
P-TEF recruitment 
(8) How are the various recruitment mechanisms for P-TEFb coordinated and regulated? 
(9) How is the ratio of anchored Brd4-P-TEFb and anchored KAP1-7SK-snRNP-P-TEFb on chromatin? Are 
there sets of genes which have related and highly similar compositions? * 
(10) How is active P-TEFb recruited to specific promoters/enhancers? * 
(11) How is inactive, chromatin-anchored KAP1-7SK-snRNP-P-TEFb released on-site at specific 
promoters/enhancers? 
(12) How does P-TEFb after its release become part of SEC, and what is the link for SEC assembly (suggested 
for AFF1 and AFF4 475)? 
 
* covered in the main text (chapter 3); ** requires development of a novel method 
 
 
 
This work represents a detailed genome-scale picture of kinetic parameters and serves as a 
template for future studies measuring transcription kinetics. However, to arrive at a 
mechanistic understanding of the peculiar step of Pol II pausing in vivo it must be studied 
further by systems biology approaches (and as mentioned in the introduction, by other 
methods as well to arrive at a holistic understanding of the process). In systems biology, a 
four-step framework can be applied to most challenges  476. This requires (i) the knowledge of 
all components involved in the pausing step, (ii) systematic perturbations of pausing-related 
factors and monitoring changes in transcription kinetics or changes of components (e.g. by 
post-translational modifications), (iii) the development of one or several pausing model 
hypotheses, and (iv) to repeat the previous steps to expand, refine and test the pausing 
model(s) by experimental data which might depend on the development of novel techniques. 
In this perspective, I focus first on a strategy to identify the set of pausing factors at 
specific promoters (step i, subsection 3.1), and state-of-the-art tools to rapidly perturb 
pausing-related factors (step ii, subsection 3.2). Combining rapid perturbations with our 
multi-omics approach will provide answers to many of the outstanding challenges in the 
pausing field (listed in the Box above). At the end, I will briefly cover the requirements of a 
novel methodology to address promoter-proximal attenuation (step iv, subsection 3.3), and 
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the application of our multi-omics approach to study elongation velocity changes along the 
gene in the context of co-transcriptional processes such as splicing (subsection 3.4). 
Future studies of pausing promise many important discoveries: since de-regulation of 
pausing is involved in multiple diseases (e.g. MLL-fusion leukemia, HIV infection, cardiac 
hypertrophy; summarized in 250), an understanding of Pol II pausing regulation holds great 
promise for novel targeted therapies. Furthermore, cancers are an attractive target for multi-
omics studies of transcription kinetics because cancer is a disease of gene regulation (as 
discussed in an excellent recent review 477). 
 
3.1 Gene-specific identification of (un)known pausing factors 
 
Engineered DNA-binding molecule mediated chromatin immunoprecipitation (enChIP)478,479 
in combination with mass spectrometry (MS) offers a strategy to isolate physiologically 
relevant complexes within a specific genomic region. The protocol consists of a cell 
fractionation step 418, crosslinking of DNA and proteins within isolated nuclei 480, chromatin 
isolation and fragmentation by sonication (1-2 kbp fragments), as well as MS analysis (Figure 
32 a). Challenges for the development of a reproducible enChIP-MS protocol will be the 
identification of a suitable crosslinker, testing the efficiency and background of epitope tagged 
nuclease dead Cas9 protein with guide RNA 481 for the IP of the DNA at a specific locus, and 
identifying a suitable MS normalization strategy between samples. The characterization of 
factors enriched at pause sites of selected genes with long pause duration versus genes with 
short pause duration, and changes of the repertoire upon perturbation will provide new 
insights (Box, questions no. 1-3, 9). 
 
 
3.2 Perturbation tools with high kinetic resolution 
 
Combining the read-out of transcription kinetics by our multi-omics approach with a specific 
and rapid perturbation of pausing and elongation factors, or of chromatin architectural factors 
will be highly informative (Box, questions 1-2, 6, 8). To date, multiple perturbation strategies 
are available including genetic approaches (CRISPR/Cas9 system 482 and 
RNA interference 483), pharmacologic inhibitors (small molecules), and target(ed) protein 
degradation (TPD) (direct: Protacs 484, molecular glues 485; indirect: dTAG strategy 486, AID 
system 487). The strength and caveats of the different strategies were recently compared in an 
excellent technology review 488. 
As mentioned above, a specific and rapid perturbation is critical for our application 
to dissect the primary role of the respective factor. For this purpose, the indirect chemical-
genetic TPD approach performs best on a wide range of target proteins especially if structural 
information is available 488. Two strategies are commonly used, the degradation tag (dTAG) 
and the auxin-inducible degron (AID) system. Both strategies require engineering (addition 
of a tag for ligand binding) of the endogenous gene which encodes the protein of interest by 
CRISPR/Cas9 mediated knock-in. Once the tagged protein of interest is expressed and a 
standardized ligand is added to the cells, the ligand binds to the tag and re-directs the 
ubiquitination activity of ubiquitin E3 ligases to the target protein. Ubiquitination leads to a 
target-specific proteasomal degradation. The advantage of the dTAG system is that it employs 
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an endogenous E3 ligase complex (CRBN) while AID requires ectopic expression of a ligase 
complex (TIR1). The dTAG-ligand is a small molecule which can rapidly enter cells 486. The 
top five targets for perturbation in combination with multi-omics experiments (Figure 32 a) 
are the pausing factor NELF, the insulator CTCF, the PAF1 complex, the cap-binding 
complex (CBC) and the cyclin subunit of P-TEFb (CCNT1) (see also Table 35). 
Genome architecture and transcriptional activity are intimately linked: the 3D nuclear 
architecture governs when and to what extent the linear information might be accessed. In 
this study, we found that genes with high CDK9 responsiveness are also associated with long-
range chromatin interactions (Figure 21 f), suggesting that enhancers can influence the pause-
initiation limit at target genes to regulate transcription. Thus, it would be very interesting to 
dissect pause duration changes after perturbation of 3D chromatin loops. Hereby established 
enhancer-promoter interactions would be disrupted. These loop structures are formed by the 
interaction of DNA with two CTCF insulator proteins, and cohesin 489. Using the above 
introduced dTAG system, CTCF and cohesin might be interesting targets to disrupt the 
genome architecture. Knockdown (KD) experiments of CTCF suggested that CTCF is 
required for P-TEFb delivery at the model gene C-MYC 490 and a viral transcript 491. This 
supports our model that certain chromatin loops established by CTCF and cohesin allow for 
enhanced P-TEFb delivery to release paused Pol II, especially at genes with long pause 
durations. 
 
 
 
Figure 32. Future developments and applications of our multi-omics approach. 
(a) Identification of novel or gene-specific pausing factors in human cells. For details see main text. The 
experimental strategy was developed after a discussion with Prof. Dr. Henning Urlaub (MPI-bpc, Dept. 
Bioanalytical Mass Spectrometry). (b) Targeted protein degradation (TPD) using dTAG strategy in combination 
with our multi-omics approach. 
 
 
3.3 The ratio of non-productive to productive initiation frequency 
 
The TT-seq 168 protocol enables us to measure productive initiation frequencies in vivo. 
However, since TT-seq requires the incorporation of 4sU into newly synthesized RNA, shorter 
RNAs (<100 nt) have a higher probability to escape the labeled RNA purification. As a 
consequence, the coverage upstream of the pause site cannot be recovered fully (depending on 
its sequence composition and 4sU content). Our comparison of genes with long pause durations 
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to genes with short pause durations (both groups had similar U content) showed that less 
labeled RNA was recovered for genes with long pause durations (Figure 19). This suggests 
that the fraction of Pol II that might terminate in the pause window (promoter-proximal 
attenuation, see Supplementary Note 1) is generally low. However, it is technically 
challenging to quantify the extent of promoter-proximal attenuation (non-productive 
initiation frequency) (Figure 33). The combination of productive initiation frequency with 
the unknown fraction of non-productive initiation frequency yields the ‘true’ initiation 
frequency. As described in Supplementary Note 1, occupancy measurements are insufficient 
to define the fate of paused Pol II. Below, two ideas for novel approaches to tackle this 
challenge are listed: 
 
• Estimate the ‘true’ initiation frequency by capping events per time. 
Technical challenges: develop an in vivo cap-labeling approach, e.g. using cap analogs 
(NAD+ etc.). Optimize efficiency of metabolic uptake and incorporation of cap analog. 
• In vitro transcription assay to reconstitute the transition from initiation via promoter-
proximal pausing/attenuation to productive elongation. 
Technical challenge: identification, purification and complex assembly of essential pausing 
and release factors and Pol II.  
 
 
 
 
 
 
 
 
Figure 33. The challenge to quantify promoter-proximal attenuation. 
The figure is adapted from 357. 
 
 
3.4 Elongation velocity at high resolution across the gene 
 
In order to introduce the reader to the relevant information needed to understand the next 
paragraphs I will briefly revisit the human gene architecture (Figure 34 a). A gene consists 
of exons which code for the mature transcript, and introns which are removed by splicing (see 
also Introduction I.1.2). Introns of nascent RNAs are mostly spliced co-
transcriptionally 392,492,493. For each intron the spliceosome needs to assemble, thus, multiple 
spliceosomes are needed per transcript (recently reviewed in 71). The 5’ end of the first exon 
is defined as transcription start site (TSS). Downstream of the TSS is the Pol II pause site 
(PS) which marks the center of the promoter-proximal pause window (PS +/- 100 nt). The 
3’ end of the last exon is referred to as poly(A) (pA) site. The RNA is cleaved at the pA 
signal and most RNA 3’ ends get a poly(A) tail 65. Pol II continues transcription downstream 
of the pA site until it reaches a transcription termination site (TTS). The region between pA 
site and TSS is defined as termination window. Slowly elongating polymerases are not only 
observed in the promoter-proximal window but can also be found at intron-exon junctions 
(splice sites) and over the termination window 19. Our multi-omics approach quantifies 
Part IV – Discussion and Outlook 
 
   100 
elongation velocities at different genes (Figure 34 b, unpublished), at genes encoding different 
transcript classes (Figure 34 c, unpublished), or at specific gene segments (Figure 34 d, 
unpublished). Multiple genomic features and factors modulate the Pol II elongation velocity 
v (Figure 16 e). Here, I focus on the interplay of v with co-transcriptional splicing and the 
dynamic histone code (see also Introduction I.1.1). 
 
The complex interplay of elongation velocity and splicing. Slow Pol II elongation velocity can 
promote splicing and inclusion of alternative exons 494-496, but it can also lead to exon skipping 
by extending the window of opportunity to recruit splice repressors 497. It was recently shown 
in plants that light can accelerate Pol II elongation rates along photosynthesis genes, and as 
result of the changed velocity, the corresponding transcripts are subject to alternative 
splicing 498. High resolution (close to single-nucleotide precision) is required to distinguish v 
at exon-intron borders. As discussed, occupancy profiling is ambiguous (Introduction I.3.1.2, 
Supplementary Note 2). But, it can provide clues if Pol II might elongate more (local 
minimum) or less rapidly (accumulation) in specific regions of the gene, assuming that Pol II 
transcription is generally processive and the drop-off rate within the gene body is low. This 
was indeed suggested by published PRO-seq data 347: alignment at 3’ splice sites (3’SS, intron-
exon border) showed a drop in Pol II occupancy at the end of the intron, immediately followed 
by Pol II accumulation at the beginning of the exon. Alignment of PRO-seq density at 5’ SS 
(exon-intron border) showed Pol II accumulation at the end of the exon, and decreasing Pol II 
occupancy within the first 50 bp of the intron after which it returns to baseline levels 347. 
Another study found that the 3’ ends of ~17 nt long splice-site RNAs (spliRNAs) align 
perfectly with the 3’ end of exons and are conserved across species (human, mouse, Drosophila, 
C.elegans and marine sponge) 499. This might indicate a longer residence time of the 
polymerases at the 3’ end of exons since the nascent RNA associated with the elongation 
complex is longer protected (and thus, measurable). These observations agree with our kinetic 
measurements combining TT-seq and mNET-seq data of steady state human K562 cells 
(Figure 34 e, unpublished). Our approach allows to extract kinetic parameters at high 
resolution, and to compare the elongation velocity between segments of different genes which 
might have very diverse initiation frequencies, Ilocal which could not be interpreted by 
occupancy data alone. 
Furthermore, it would be exciting to investigate if spacing between consecutive 
polymerases (spacing defined by the promoter-proximal pause duration) protects against 
polymerase traffic jams that could occur later due to pauses at splice sites. So far, it is 
unknown if promoter-proximal pause durations correlate with pause durations at exons in 
vivo. Thus, the analysis of transcription kinetics has the potential to reveal novel aspects of 
co-transcriptional splicing regulation. 
 
Elongation velocity and a dynamic histone code. Thus far, we and others 130,272,335,336,500 have 
observed links between Pol II elongation velocity and histone modifications but much of this 
data is correlative in nature (Figure 50). To determine whether histone modifications are 
causative for fast or slow elongation velocity one would need to test mutants which cause 
more or less modifications and measure if elongation velocities would be changed. Another 
possibility is that modifiers traveling with Pol II have different time windows to act on the 
underlying chromatin during fast or slow elongation. 
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Figure 34. Elongation velocity at high resolution across human genes. 
(a) Gene architecture. Colors as in (b and d). (b) Metagene analysis of local elongation velocity [kbp min-1] along 
9,329 genes in human K562 cells (steady state), depicted as scaled genomic position, aligned at first TSS and last 
pA site. (c) Boxplot of elongation velocity for different transcript classes annotated in human K562 cells: 886 
eRNAs, 248 conRNAs, 235 uaRNAs, 877 sincRNAs, 1,281 asRNAs, 157 lincRNAs, and 4,582 mRNAs. Black bars 
represent median, boxes mark upper and lower quartiles, whiskers represent 1.5 times the inter-quartile range. 
(d) Boxplot of elongation velocity [kbp min-1] at different transcript segments: first exon (n = 8,674) (dark blue), 
intermediate exons (middle) (n = 7,954) (grey), last exons (n = 7,911) (white), or introns (n = 8,788) (emerald 
green). (e) Metagene analysis of elongation velocity [kbp min-1] aligned at different transcript segments (reference 
point highlighted in green): aligned at TSS (n = 8,821) (dark blue, left), exon start (3’SS) and end (5’SS) 
(n = 69,184) (middle), or pA site (n = 8,072) (right). List of splice sites was generated from RefSeq annotations. 
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V. Supplementary Information 
 
 
 
 
 
 
This chapter contains information in support of the Introduction, Materials and Methods, 
Results and Discussion which could not be integrated within the respective chapter due to 
space limitations. 
 
 
1. Introduction 
 
Supplementary Note 1. The struggle to clarify the mechanistic basis of promoter-proximal 
events. 
 
For simplicity, ‘promoter-proximal pausing’ was introduced as an umbrella term for promoter-
proximal events including Pol II stalling, pausing, abortive elongation, termination and 
attenuation. The observed Pol II peaks close to mammalian promoters could, however, be 
explained by rapidly initiating and then terminating polymerases (promoter-proximal 
attenuation). There has been a lot of effort in the field to measure and eventually understand 
the behavior of Pol II at promoter-proximal windows. But, to date, there is no method 
available to distinguish attenuation from long pause duration. None of the Pol II occupancy 
methods (see Introduction I.3.1.2), not even short capped RNA assays are able to distinguish 
the frequency of these events. Short capped RNA measurements are as well biased by the 
residence time of the polymerases since the nascent RNA associated with the elongation 
complex is longer protected (and thus, measurable) for loci with longer pause durations. In 
summary, it is technically challenging to assess the frequency of these events, and it will be a 
crucial task for future methods development to quantify the extent of each in order to define 
the contribution to transcription regulation in humans (see Discussion IV.3.3). At this point, 
I want to emphasize that the events upstream of the pause site are irrelevant to our model 
and its conclusions. 
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Table 27. Genome-wide approaches used to study Pol II occupancy. 
Abbreviations: native elongating transcript sequencing (NET-seq), precision nuclear run-on sequencing (PRO-seq), 
immunoprecipitation (IP), global run-on sequencing (GRO-seq). ‘All’ Pol II states refers to initiating, elongation-
competent, paused, backtracked, stalled, terminating Pol II states. Note that approaches listed here determine 
Pol II occupancies of potentially heterogenous populations of cells. 
 
Method 
Features 
Refs Treatment Chromatin 
solubilization 
IP Strand-
specific? 
Resolution Mapping of Pol 
II states 
ChIP-seq in vivo 
crosslinking 
‘random’ 
sonication 
Pol II no >200 bp all 382-
384,501 
ChIP-exo, 
ChIP-nexus 
in vivo 
crosslinking 
l-exonuclease 
digest 
Pol II no ~50 bp all 385,386 
GRO-seq in vitro run-on 
using sarkosyl 
- RNA yes ~50 nt only elongation-
competent Pol II 
346 
PRO-seq in vitro run-on 
using sarkosyl 
- RNA yes ~1 nt only elongation-
competent Pol II 
347 
3’NT-seq, 
NET-seq 
cellular 
fractionation 
- - yes ~1 nt all, except 
initiating and 
terminating 
Pol II 
348,349 
mNET-seq cellular 
fractionation 
MNase digest Pol II yes ~1 nt all, except 
initiating Pol II 
350,387 
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Table 28. Comparison of Pol II elongation rate estimates derived from 1976 to 2019. 
‘Wash-out’ refers to the removal of a reversible drug (DRB), and subsequent tracking of the retrieving wave of 
Pol II molecules or its transcripts. Thus, a wash-out experiment resembles the outcome of gene activation by 
natural stimuli (e.g. TNF𝛼, estradiol, heat shock). ‘Shut-down’ refers to disruption of transcription, and subsequent 
tracking of the declining wave of Pol II molecules or its transcripts. For abbreviations used below refer to Table 
38. 
 
Year Gene(s) 
Organism or 
cell line  
Elongation 
rate 
[kbp/min] 
Pol II 
occupancy 
profiling 
(nascent) 
RNA 
Drug / 
stimulus 
Ref 
1976 hnRNA  Human HeLa 
cells  
3–6 - Radioisotope 
labeling 
DRB 
(0-180 sec) 
319 
1984 MMTV (7.8 kbp)  Rat HTC cells  1.5 Nuclease 
protection 
assay 
- - 502 
1990 E74 (60 kbp)  Drosophila  1.1 - Northern 
blotting 
- 503 
1991 Ubx (78 kbp)  Drosophila  1.4 - In situ 
hybridization 
- 504 
1993 Hsp70 (2.4 kbp)  Drosophila S2 
cells 
1.2-1.5 Pol II imaging, 
NRO assay 
- Heat shock 326 
1995 DMD (2,300 kbp)  Human 
myogenic cells  
2.4 - RT-PCR - 323 
1998 ACTB (3 kbp)  Normal rat 
kidney cells  
1.3 - RNA FISH - 329 
2005 Hybrid gene 
(8 kbp)  
Yeast 2 Pol II ChIP-
qPCR 
- Galactose 322 
2007 Hsp70 (2.4 kbp)  Drosophila  1.2-1.5 Pol II imaging 
(FRAP), NRO 
assay 
- - 327 
2007 Engineered HIV 
reporter (3.8 kbp)  
Human U2OS 
cells  
1.9 Pol II imaging RNA FRAP - 330 
2007 Engineered gene 
cassette (3.3 kbp)  
Human U2OS 
cells  
4.3 Pol II imaging - - 328 
2009 10 native genes 
(100–580 kbp)  
Human Tet-21 
cells  
3.8 - RT-qPCR DRB wash-
out 
324 
2009 5 genes 
(>100 kbp) 
Human 
HUVEC cells  
3.1 Pol II ChIP-
qPCR, tiling 
microarrays 
- TNF𝛼 (0-
3 h) 
325 
2009 heat shock genes 
(Hsp70, Hsp83) 
Drosophila S2 
cells 
1.1 Pol II imaging, 
Pol II ChIP-
qPCR 
- Heat shock 
(0-20 min) 
272 
2010 Mouse ACTB (3.6 
kbp) 
Human U2OS 
Tet-On stable 
cells  
3.3 - RNA 
imaging 
Doxycycline-
induced 
331 
2011 4 genes (e.g. β-
globin mini-gene) 
Human U2OS 
Tet-On stable 
cells  
3.6 - RNA FISH, 
FRAP 
Actinomycin 
shut-down 
332 
2011 Yeast gene MDN1 
(15 kbp) 
Saccharomyces 
cerevisiae  
1.2 - RNA 
imaging 
- 333 
2013 140 genes (MCF-
7) / 26 genes 
(AC16) 
Human MCF-7 
/ AC16 cells 
2-3 GRO-seq - E2 / TNF𝛼 
(0-40 min) 
334 
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2014 1,577 genes Human HeLa 
cells 
3.5 - 4sU-seq DRB wash-
out (0-
8 min) 
335 
2014 8,529 genes Human 
HEK293 
3.13 GRO-seq - DRB wash-
out (0-
40 min) 
129 
2014 938 genes mESCs 
 
GRO-seq - TRP / FP 
shut-down 
(0-50 min) 
130 
2014 1,932-2,702 genes Human 
fibroblasts 
(HF1, TM, CS-
B), cancer-
derived cells 
(K562, MCF-7) 
1.5 - BrU-seq DRB wash-
out (0-
10 min) 
336 
2014 4,587 genes Human 
HEK293 Flp-in 
cell 
1.7 GRO-seq - DRB wash-
out (0-
20 min) 
132 
2016 88-2,786 genes Mouse ESCs 1.8–2.4 PRO-seq  Heat shock 
(0-1 h)‚ 
231 
2017 reporter genes Drosophila 
embryos 
2.4-3.0 - RNA 
imaging 
- 505 
2017 2,443 genes Human Raji B 
cells 
2.3 mNET-seq TT-seq 1-NA-PP1 
(0-15 min) 
381 
2018 
 
Human 
HEK293, 
KBM-7 cells 
 
TV-PRO-seq - - 506 
2019 600-1,200 genes Human 
HEK293 cells 
2-3 Pol II ChIP-seq BrU-seq DRB wash-
out (0-20 
min) 
305 
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Figure 35. Commercially available CDK9 kinase inhibitors compared by KInhibition. 
Heatmap shows the inhibition profile of the top 50 CDK9 kinase inhibitors out of 133 compounds compared. Rows 
represent the tested compounds, columns represent the kinases screened. CDK9 is highlighted on the top with an 
arrow. White color highlights missing data. Data for ‘CDK9’ were compared using KInhibition, a kinase inhibitor 
selection portal (https://kinhibition.fredhutch.org) 408. Resources are listed in 408. Note that CDK9 kinase inhibitors 
available to date are unspecific. Full inhibition of the on-target CDK9 comes at the price of severe off-target 
inhibition (other kinases). 
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Figure 36. Heat shock proteins are deregulated in human cancer cells. 
Bar plot shows the most common cancers worldwide (top five: breast, prostate, lung, colorectum, cervix uteri), 
estimated in 2018 of both sexes and all ages (estimated numbers from 507). The age-standardised rate (ASR) per 
100,000 estimates is depicted. Cancers with deregulated gene expression of heat shock proteins (HSPs) are marked 
with red asterisk. Transcriptome data are published for breast 207,508, prostate 509, lung 207, and colon 207 cancer. For 
cervix uteri cancers, overexpression of Hsp27 was shown by immunohistochemistry 510. 
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2. Materials and Methods 
 
 
2.1 Sequencing data pre-processing 
 
Data pre-processing was performed by Dr. Björn Schwalb (MPI-bpc, Dept. of Molecular 
Biology). 
 
 
 
The methods presented in this section 2.1 have been published as: 
 
S. Gressel *, B. Schwalb * et al. CDK9-dependent RNA polymerase II pausing controls 
transcription initiation. Elife 6, doi:10.7554/eLife.29736 (2017). 
(* joint first authorship) 
 
 
2.1.1 TT-seq and RNA-seq 
 
TT-seq and RNA-seq data pre-processing. Paired-end 50 or 75 base reads with additional 6 
base reads of barcodes were obtained for each of the samples. Reads were demultiplexed and 
mapped with STAR 403 to the hg20/hg38 (GRCh38) genome assembly (Human Genome 
Reference Consortium). Samtools 404 was used to quality filter SAM files, whereby alignments 
with MAPQ smaller than 7 (-q 7) were skipped and only proper pairs (-f2) were selected. 
Further data processing was carried out using the R/Bioconductor 406 environment. We used 
a spike-in (RNAs) normalization strategy essentially as described 168 to allow observation of 
global shifts 𝜎o (sequencing depth), cross-contamination rate 𝜖o (proportion of unlabeled reads 
purified in the TT-seq samples) and antisense bias ratio 𝑐o (ratio of spurious reads originating 
from the opposite strand introduced by the reverse transcription reaction). Read counts 𝑘0o 
for spike-ins were calculated using HTSeq 405. Calculations for each parameter are described 
in the following in more detail. 
 
Antisense bias ratio 𝒄𝒋. Antisense bias ratios were calculated for each sample j according to 
𝑐o = median0 c
𝑘0o=W0fe=fe
𝑘0ofe=fe
j 
for all available spike-ins i. 
 
Sequencing depth 𝝈𝒋 and cross-contamination rate 𝝐𝒋. Sequencing depths were calculated 
for each sample j according to 
𝜎o 	= median0 c
𝑘0o
𝑙0
j 
using all available spike-ins i for the RNA-seq samples and the labeled spike-ins i for the TT-
seq samples. The cross-contamination rate 𝜖o was calculated for each sample j as 
𝜖o 	= median0 c
𝑘0o
𝑙0
j 𝜎o  
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using the unlabeled spike-ins i for TT-seq samples. Note that 𝜖o is set to 1 for the RNA-seq 
samples. 
 
Definition of transcription units (TUs). For each annotated gene, transcription units (TUs) 
were defined as the union of all existing inherent transcript isoforms (UCSC RefSeq GRCh38). 
Read counts for all features were calculated using HTSeq 405 and corrected for antisense bias 
using antisense bias ratios cj calculated as described above. The real number of read counts sij 
for transcribed unit i in sample j was calculated as 
𝑠0o =
𝑆0o − 𝑐o𝐴0o
1 − 𝑐o
 
where Sij and Aij are the observed number of read counts on the sense and antisense strand. 
Read counts per kilobase (RPK) were calculated upon bias corrected read counts falling into 
the region of a transcribed unit divided by its length in kilobases. Based on the antisense bias 
corrected RPKs a subgroup of expressed TUs was defined to comprise all TUs with an RPK 
of 100 or higher in two summarized replicates of TT-seq without treatment. An RPK of 100 
corresponds to approximately a coverage of 10 per sample due to an average fragment size of 
200. This subset was used throughout the analysis unless stated otherwise. 
 
Calculation of the number of transcribed bases. Aligned duplicated fragments were 
discarded for each sample. Of the resulting unique fragment isoforms only those were kept 
that exhibited a positive inner mate distance. The number of transcribed bases (tbj) for all 
samples was calculated as the sum of the coverage of evident (sequenced) fragment parts (read 
pairs only) for all fragments smaller than 500 bases in length and with an inner mate interval 
not entirely overlapping a Refseq annotated intron (UCSC RefSeq GRCh38, ~ 96% of all 
fragments) in addition to the sum of the coverage of non-evident fragment parts (entire 
fragment). 
 
2.1.2 mNET-seq data 
 
mNET-seq data pre-processing. Paired-end 50 or 75 base reads with additional 6 base reads 
of barcodes were obtained for each of the samples. Reads were demultiplexed and mapped 
with STAR 403 to the hg20/hg38 (GRCh38) genome assembly (Human Genome Reference 
Consortium). Samtools 404 was used to quality filter SAM files, whereby alignments with 
MAPQ smaller than 7 (-q 7) were skipped and only proper pairs (-f2) were selected. Further 
data processing was carried out using the R/Bioconductor 406 environment. Antisense bias 
(ratio of spurious reads originating from the opposite strand introduced by the RT reactions) 
was determined using positions in regions without antisense annotation with a coverage of at 
least 100 according to Refseq annotated genes (UCSC RefSeq GRCh38). 
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2.2 Additional tables and figures 
 
Table 29. Instruments and laboratory equipment ordered by application. 
Abbreviations for suppliers are listed in Materials II.1. 
 
Instrument Supplier Application 
Eppendorf ThermoMixer® C basic device, add thermoblock (1.5 
mL, 2 mL) 
[L] Basic equipment 
Biometra ProfessionalTRIO Thermocycler Analytik Jena Basic equipment 
Refrigerated bench top centrifuge (rotor and adapters 0.5-2 mL 
tubes) 
[L], 5424 R Basic equipment 
Pipetboy (Thermo Scientific™ S1 Pipettierhilfe) [B], 9501 Basic equipment 
Vortex mixer (Vortex-Genie 2) Scientific Industries Basic equipment 
Wizard Mini-Fuge Scientific Industries Basic equipment 
Reinstwassersystem Milli-Q® Advantage A10 VWR / Merck Basic equipment 
Cell culture water bath LAUDA, Aqualine AL12 Cell culture 
Bottle weights (for 500 mL) [B], A1098801 Cell culture 
VWR® Lead Ring Flask Weights VWR, 13196-076 Cell culture 
Cell culture fume hood, Type A2 Biological Safety Cabinets 
(incl. UV light) 
Herasafe™ KS (NSF) Class 
II 
Cell culture 
Refrigerated bench top centrifuge (rotor and adapters for 50 mL 
and 15 mL tubes) 
[L], 5702 RH Cell culture 
Fluid aspiration system, Biochem VacuuCenter, BVC 
professional 
VWR, 181-0295 Cell culture 
Incubator (37 °C, 5 % CO2) HERAcell 150 i Cell culture 
Nalgene Cryo 1 °C Freezing Container (1-2 mL tubes) [B], 5100-0001 Cell culture 
Light microscope to check confluency and cell morphology Leica Cell culture 
Hemacytometer, counting chamber (Neubauer) VWR, 631-0696 Cell culture 
Scepter™ 2.0 Cell Counter Millipore Merck Cell culture 
Thermometer (water bath)  Cell culture 
DynaMag™ - 15 Magnet (15 mL) [B], 12301D mNET-seq 
DynaMag™ - 2 Magnet (1.5 mL, 2 mL) [B], 12321D mNET-seq 
Typhoon™ FLA 9500 GE Healthcare mNET-seq 
Swing-out rotor (up to 20,000 x g), refrigerated bench top 
centrifuge (adapters for 15 mL tubes) 
Sigma 2-16 KL RNA isolation 
NanoDrop 2000 (dsDNA, RNA quantification >100 ng/µL) [B] RNA/DNA 
quantification 
Qubit Fluorometric Quantification [B] RNA/DNA  
Fragment Analyzer Automated CE System Advanced Analytical, [N] RNA/DNA size  
TapeStation [N] RNA/DNA size  
qTOWER 2.0/2.2 instrument Analytik Jena AG RT-qPCR 
Magnetic stand and separator  [M], 130-042-303 TT-seq 
Magnetic Stand-96 for U-bottom microplates  [B], AM10027 TT-seq 
Covaris S220 Series Focused- ultrasonicators (S220) and chiller Covaris TT-seq 
Rotating wheel, rotator SB3 stuart TT-seq, mNET-
seq 
Xcell II™ Blot Module (Western blot) [B], EI9051 Western blot 
Intas Science imaging, Advanced fluorescence Imager Intas Western blot 
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Figure 37. RNA spike-in pool preparation for TT-seq. 
(a) Purified RNA spike-ins (left to right: 2, 4, 5, 8, 9, 12) were analyzed on a 5 % denaturing PAGE. Bands were 
visualized by SYBRgold staining and quantified using Fiji/Image J. The uncropped image can be found in Figure 
40. (b) Table depicting information regarding 4sU content (in blue), RNA length [nt], and concentration [ng/µL] 
measured by NanoDrop spectrometer. 
 
 
 
Table 30. Normalized Ct values (RT-qPCR, Figure 7). 
Normalized Ct values, ∆Ct, were calculated by multiplication of the primer efficiency (E) with the mean of the 
technical replicates. E was 0.99 for both primers. Two biological replicates were prepared for each condition. 
 
No. RNA 
Cell 
line 
Replicate 
no. 
Treatment ∆𝑪𝒕𝒔𝒑𝒊𝒌𝒆	𝒊𝒏	𝟒 ∆𝑪𝒕𝒔𝒑𝒊𝒌𝒆	𝒊𝒏	𝟏𝟐 ∆∆𝑪𝒕 S.D. 
1 total 
Raji B 
CDK9as 
1 0.05 % v/v DMSO, 15 min. 14.77 14.26 -0.51 0.41 
2 total 
Raji B 
CDK9as 
2 0.05 % v/v DMSO, 15 min. 14.53 14.45 -0.08 0.32 
3 total 
Raji B 
CDK9as 
1 5 µM 1-NA-PP1, 15 min. 14.12 14.17 0.06 0.17 
4 total 
Raji B 
CDK9as 
2 5 µM 1-NA-PP1, 15 min. 14.02 13.92 -0.09 0.08 
5 4sU-
labeled 
Raji B 
CDK9as 
1 0.05 % v/v DMSO, 15 min. 13.65 19.78 6.13 0.50 
6 
4sU-
labeled 
Raji B 
CDK9as 
2 0.05 % v/v DMSO, 15 min. 14.12 20.49 6.36 0.40 
7 4sU-
labeled 
Raji B 
CDK9as 
1 5 µM 1-NA-PP1, 15 min. 12.69 19.12 6.43 0.34 
8 4sU-
labeled 
Raji B 
CDK9as 
2 5 µM 1-NA-PP1, 15 min. 13.35 19.33 5.98 0.67 
9 total K562 1 - 14.29 14.75 0.46 0.01 
10 total K562 2 - 14.44 14.64 0.20 0.02 
11 total K562 1 42 °C, 15 min. 14.40 14.45 0.05 0.02 
12 total K562 2 42 °C, 15 min. 14.28 14.51 0.23 0.01 
13 total K562 1 42 °C, 30 min. 14.36 14.28 -0.09 0.07 
14 total K562 2 42 °C, 30 min. 14.51 14.31 -0.20 0.03 
15 
4sU-
labeled 
K562 1 - 12.87 18.14 5.27 0.09 
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16 
4sU-
labeled 
K562 2 - 12.93 18.53 5.60 0.26 
17 4sU-
labeled 
K562 1 42 °C, 15 min. 12.91 18.50 5.59 0.05 
18 
4sU-
labeled 
K562 2 42 °C, 15 min. 12.81 18.32 5.51 0.15 
19 4sU-
labeled 
K562 1 42 °C, 30 min. 12.94 18.59 5.65 0.37 
20 4sU-
labeled 
K562 2 42 °C, 30 min. 12.86 18.45 5.60 0.22 
21 total 
Raji B 
CDK9as 
1 0.05 % v/v DMSO, 35 min. 13.19 13.37 0.19 0.08 
22 total 
Raji B 
CDK9as 
2 0.05 % v/v DMSO, 35 min. 13.23 13.37 0.14 0.06 
23 total 
Raji B 
CDK9as 
1 5 µM 1-NA-PP1, 35 min. 17.26 16.63 -0.63 0.08 
24 total 
Raji B 
CDK9as 
2 5 µM 1-NA-PP1, 35 min. 17.43 16.83 -0.59 0.25 
25 total 
Raji B 
CDK9as 
1 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
15.31 15.86 0.55 0.47 
26 total 
Raji B 
CDK9as 
2 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
14.31 14.40 0.09 0.24 
27 total 
Raji B 
CDK9as 
1 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
16.72 16.13 -0.59 0.08 
28 total 
Raji B 
CDK9as 
2 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
16.34 16.26 -0.09 0.07 
29 
4sU-
labeled 
Raji B 
CDK9as 
1 0.05 % v/v DMSO, 35 min. 13.59 19.61 6.02 0.20 
30 4sU-
labeled 
Raji B 
CDK9as 
2 0.05 % v/v DMSO, 35 min. 13.54 19.51 5.97 0.09 
31 
4sU-
labeled 
Raji B 
CDK9as 
1 5 µM 1-NA-PP1, 35 min. 15.86 22.77 6.91 0.06 
32 4sU-
labeled 
Raji B 
CDK9as 
2 5 µM 1-NA-PP1, 35 min. 16.13 23.47 7.35 0.38 
33 4sU-
labeled 
Raji B 
CDK9as 
1 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
14.14 19.75 5.61 0.07 
34 
4sU-
labeled 
Raji B 
CDK9as 
2 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
14.82 20.49 5.67 0.27 
35 4sU-
labeled 
Raji B 
CDK9as 
1 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
16.69 24.66 7.97 0.12 
36 
4sU-
labeled 
Raji B 
CDK9as 
2 
0.05 % v/v DMSO, 35 min; 
after 5 min: 42 °C, 30 min. 
16.72 24.56 7.85 0.09 
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3. Results 
 
 
3.1 mNET-seq optimization in suspension cells 
 
This section contains supplementary information (figures) regarding the mNET-seq 
optimization. 
 
 
 
 
Figure 38. Comparison of cell fractionation protocols by marker proteins. 
(a) Schematic depicting the outcome of a high-quality fractionation: GAPDH marks cytoplasm (CP), U1snRNP70 
marks nucleoplasm (NP), histone 3 (H3) marks chromatin (Chr). (b) Western blot analysis of cytoplasm (CP), 
nucleoplasm (NP) and solubilized chromatin (Chr) fractions from K562 cells using indicated antibodies. Different 
fractionation protocols were compared in two biological replicates: Mayer 431, Nojima 388, and Ørom 418. 
Chemiluminescence images were obtained on an INTAS ChemoCam Imager. Uncropped images of the PVDF 
membrane can be found in Figure 40. 
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Figure 39. Optimizing nascent RNA size selection by PAGE (6 % versus 8 %). 
(a) The protocol from the Proudfoot lab used an 8 % PAGE for nascent RNA size selection in combination with 
radioactive monitoring by g-32P-ATP labeling 388. I tested different polyacrylamide concentrations (5-8 %) to define 
the concentration where the two blue tracking dyes frame the RNA target size (25-110 nt). Shown is an overlap 
of a camera picture of the PAGE (left: 6 %, right: 8 %) prior to SYBRgold staining (tracking dyes) and post 
SYBRgold staining (RNA marker), visualized on an INTAS gel imager. Small single stranded RNA (ssRNA) 
marker was used (Abnova). Uncropped images can be found in Figure 40. (b) Nascent RNA of 25-110 nt can be 
selected on a 6 % PAGE by cutting between the two blue dyes. K562 cell were fractionated by the Ørom protocol, 
digested by MNase. For 1 h of immunoprecipitation (IP), Dynabeads coupled to mouse IgG (A), Dynabeads only 
(B), or Dynabeads coupled to MBL antibody (total POLR2A) were used. See Table 11 for antibodies. Left: camera 
picture of 6 % PAGE. Right: corresponding phosphor screen image of the 6 % PAGE after 2 h exposure. The 
screen was scanned on a Typhoon™ FLA 9500 unit. Uncropped images can be found in Figure 40. Experiments 
were performed at least two times, no replication attempt failed. 
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Figure 40. Uncropped gel images and membrane scans for figures. 
Dotted boxes indicate region used for figures. Top rows: protein standard was used as size marker on NuPAGE™ 
4-12 % Bis-Tris Protein Gels (see Methods). If available, Ponceau S staining and longer exposure of the PVDF 
membranes are also shown (INTAS ChemoCam imager). Bottom rows: UV image of 6 or 8 % PAGE after 
SYBRgold staining (INTAS gel imager); camera picture of 6 or 8 % PAGE prior to SYBRgold staining. Phosphor 
screen after 2 h exposure (Typhoon™ FLA 9500); camera picture of 6 % PAGE prior to phosphorimaging. 
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3.2 CDK9-dependent Pol II pausing controls transcription initiation 
 
This section contains supplementary information (figures and tables) regarding the study 
‘CDK9-dependent Pol II pausing controls transcription initiation’. 
 
 
 
 
Figure 41. CDK9 (WT or analog-sensitive) protein levels and cell viability. 
(a) Experimental schematic for Western blot. (b) Raji B wildtype (WT) and CDK9as cells were treated with 10 
µM of 1-NA-PP1 for 0 min, 15 min or 2 h. DMSO was used as solvent control. Stable CDK9 protein levels were 
detected by Western blotting. α-Tubulin was used as loading control. (c) Experimental schematic for metabolic 
activity assay (MTS assay). (d) MTS assay to compare cell viability upon 1-NA-PP1 treatment (0-10 µM) for 72 h 
in wildtype and CDK9as cells. (b, d) Western blot and MTS assay were performed by Dr. Tim M. Decker 
(Helmholtz Center Munich, Dept. of Molecular Epigenetics, group of Prof. Dr. Dirk Eick) (methods are described 
in 381). 
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Figure 42. TT-seq tracks transcription after 10 min of CDK9as inhibition. 
Genome browser views of TT-seq signals of control (grey) and CDK9as inhibited samples at the CYB5R4 gene 
locus (107,781 [bp]) on chromosome 6 (a), at the AGPAT6 gene locus (47,814 [bp]) on chromosome 8 (b), and at 
the PYGB gene locus (49,945 [bp]) on chromosome 20 (c). Grey box depicts transcript body from TSS (black 
arrow) to polyA site (pA). 
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Table 31. Published data sets used in this study (eLife 2017). 
Data sets and references used in the correlation study against genomic features and measures of transcriptional 
context. Abbreviations: chromatin immunoprecipitation (ChIP), dimethyl sulfate (DMS), deoxyribonuclease I 
(DNase I), formaldehyde-assisted isolation of regulatory elements-sequencing (FAIRE), chromosome conformation 
capture (Hi-C), minimum free energy (MFE), micrococcal nuclease (MNase). 
 
Experiment Cell type GEO ID Source Read-out Used in 
AT content in silico This study   Figure 16e 
Bisulfite-seq K562 GSE27584 Myers 144 Sites of DNA 
hypermethylated CpG islands 
Figure 16e 
CG content in silico This study   Figure 16e 
ChIP-seq Brd4 HEK293T GSE51633 Rosenfeld 511 Protein-DNA interactions Figure 21e 
ChIP-seq Brd4 HeLa GSE51633 Rosenfeld 511 Protein-DNA interactions Figure 21e 
ChIP-seq CDK9 HEK293T GSE51633 Rosenfeld 511 Protein-DNA interactions Figure 21e 
ChIP-seq CDK9 HCT116 GSE70408 Shilatifard 440 Protein-DNA interactions Figure 21e 
ChIP-seq NELF-E K562 GSE31477 Struhl 144 Protein-DNA interactions Figure 16e; 
Figure 21e 
ChIP-seq total Pol II 
(N-20) 
HCT116 GSE70408 Shilatifard 440 Protein-DNA interactions Figure 16e 
ChIP-seq TOP1 HCT116 GSE57628  Levens 512 Protein-DNA interactions Figure 16e 
CpG islands  This study   Figure 16e 
DMS-seq (sample 
‘300 µL in vivo’) 
K562 GSE45803 Weißmann 425 RNA secondary structure Figure 21b 
DNA-RNA 
basepairing energy 
in silico This study Wilhelm 513  Figure 16e 
DNA-RNA melting 
temperature 
in silico This study Wilhelm 513  Figure 16e 
DNase-seq K562 GSE32970 Stamatoyannop
oulous 144 
Active regulatory chromatin 
(nucleosome-depleted) 
Figure 16e 
DNaseI-seq K562 GSE29692 Sandstrom 144 Active regulatory chromatin 
(nucleosome-depleted) 
Figure 16e 
FAIRE-seq K562 GSE35239 Lieb 144 Active regulatory chromatin 
(nucleosome-depleted) 
Figure 16e 
Hi-C K562 GSE56869 Crawford 437 3D genome structure Figure 21f 
MFE in silico  Stadler 426 RNA secondary structure Figure 21c 
MNase-seq K562 GSE35586 Snyder 144 Active regulatory chromatin 
(nucleosome-depleted) 
Figure 16e 
MNase-seq Raji B GSE52914 Andrau 514 Active regulatory chromatin 
(nucleosome-depleted) 
Figure 16e 
TOP1-seq HCT116 GSE57628  Levens 512  Figure 16e 
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3.3 The pause-initiation limit restricts transcription activation 
 
This section contains supplementary information (figures, tables, and notes) regarding the 
study ‘The pause-initiation limit restricts transcription activation in human cells’. 
 
 
 
The results presented in section 3.3 are currently under peer review for publication: 
 
S. Gressel *, B. Schwalb * et al. The pause-initiation limit restricts transcription activation 
in human cells. Nature Communications, in revision. 
(* joint first authorship) 
 
 
 
Supplementary Note 2. Occupancy profiling alone does not reveal kinetics. 
 
To test whether Pol II pausing behavior can be inferred from Pol II occupancy changes alone, 
we investigated our mNET-seq data after 15 and 30 min heat shock response (Figure 43). 
After 15 min of heat shock, the average mNET-seq signal for upregulated genes increased in 
the pause window and in the gene body, and this does not allow for conclusions. After 30 min 
of heat shock, the signal had increased further in the gene body but not in the pause window, 
an observation that could have been correctly interpreted as a decrease in d and an increase 
in I (Figure 43, left). For downregulated genes after 15 min of heat shock, the signal in the 
pause window remained unchanged, whereas the signal in the gene body decreased, again not 
allowing for definitive conclusions with respect to the duration of pausing, because the same 
profile change is expected by a decrease in productive initiation frequency. After 30 min of 
heat shock, the signal in the pause window increased, whereas the signal in the gene body 
decreased further, and this could be interpreted as an increase in d and a decrease in I (Figure 
43, right). Assuming unchanged elongation velocity in the gene body upon heat shock 231, 
these Pol II occupancy changes are generally consistent with reduced and increased pause 
durations for up- and down-regulated genes, respectively, although the interpretation of 
mNET-seq data at single time points alone would not always have led to the correct 
conclusions. Taken together, the observed changes in Pol II pausing behavior may in favorable 
cases be inferred from an analysis of occupancy changes alone, but this is not always conclusive 
and cannot provide kinetics. 
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Figure 43. Occupancy profiling by mNET-seq alone does not reveal kinetics. 
Multi-omics, but not occupancy profiling alone, can reveal transcription kinetics. (a-d) For comparison among 
different transcript classes, TT-seq coverage (left y-axis) and mNET-seq coverage (right y-axis) show the same 
range for all metagene profiles. Coverage per cell is shown for two biological replicates of steady-state K562 cells. 
(a-b) mRNAs (6,440, green) and lincRNAs (212, purple) show similar total Pol II peak heights in mNET-seq (with 
Empigen BB). However, the TT-seq signal is significantly lower for lincRNAs indicating less productive initiation 
events compared to mRNAs. (c-d) eRNAs (657, red) and uaRNAs (968, black) show a similar height of the TT-
seq signal. However, Pol II occupancy strongly varies these transcript classes. As a consequence, our multi-omics 
approach shows that pause durations are longer for uaRNAs than for eRNAs. (e) Top: mNET-seq coverage aligned 
at the TSS for 525 significantly upregulated (left), and 1,434 downregulated genes (right) with a minimum length 
of 5 kbp upon 30 min of heat shock (HS). Bottom: close-up showing coverage fold change upon 15 min (light blue) 
and 30 min (dark blue) of heat shock for genes as in top panel. Shaded areas show confidence intervals. The pause 
window is highlighted as grey shaded area 
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Figure 44. TT-seq tracks transcription after 30 min of CDK9as inhibition. 
Based on the assumption that the inhibitor is evenly distributed across cells and within cells, the portion of CDK9as 
molecules that has been fully inhibited by 35 min treatment with 1-NA-PP1 is very high. Note that inhibitory 
effects on pause release by unspecific inhibition of other kinases upon heat shock can be excluded with the use of 
the chemical biology (Shokat) approach, thus, inhibition of CDK9 is highly specific. Genome browser views of TT-
seq signals of control (grey) and CDK9as inhibited samples at the SESTD1 gene locus (163,098 [bp]) on chromosome 
2 (a), at the CYB5R4 gene locus (107,781 [bp]) on chromosome 6 (b), and at the AGPS gene locus (151,192 [bp]) 
on chromosome 2 (c). Grey box depicts transcript body from TSS (black arrow) to polyA site (pA). 
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Figure 45. TSS and TTS are better refined in new annotation of human K562 cells. 
Comparison of published GenoSTAN annotation 168, and new refined annotation (this study) which includes new 
TT-seq data (this study) and published GRO-cap 50 data in K562 cells for the annotation of TSSs. Note that TT-
seq libraries in this study were generated using only random priming while the previous TT-seq library in K562 
was generated using a mixture of random and poly(dT) primers 168. Abbreviations: transcription start site (TSS), 
transcription termination site (TTS). 
 
 
 
 
 
Figure 46. Transcription kinetics of different transcript classes in steady state. 
(a) Plot shows the median productive initiation frequency I [cell-1min-1] depicted against the median pause duration 
d [min] for all transcript classes (circles). The two solid perpendicular lines define the inter-quartile range, the 
dotted whiskers represent 1.5 times the inter-quartile range of the respective estimate for the entire transcript 
class. The grey shaded area depicts impossible combinations of I and d. Striped area shows confidence intervals of 
the pause-initiation limit. The dotted line defines an 8-fold possible fold change until a gene would be restricted 
by the pause-initiation limit. (b) Chromatin features in the pause window (Methods) of different transcript classes. 
Data are ranked by each row across different transcript types to better highlight the contrast of individual features. 
Published data sets are listed in Table 34. 
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Figure 47. Optimal time points for heat shock time-course of human hematopoietic cells. 
(a) Human K562 or Raji B (CDK9as) cells were subjected to a heat shock (42 °C) time-course of 0 to 75 min. Every 
15 min, total RNA was isolated and analyzed by RT-qPCR. Cell viability was tested by trypan blue exclusion 
test. (b) Top: experimental set-up of RT-qPCR of heat shock time-course. Bottom: relative fold change in gene 
expression of b-actin (ACTB, in grey), or hsp70 (HSPA1A, in red) in K562 (left bar plot) or Raji B (CDK9as) 
(right bar plot) cells (spike-ins normalized). Error bars represent the standard deviation.  Differential expression 
observed for HSPA1A in K562 and Raji B (CDK9as) cells agrees very well with other studies 195. Corresponding 
normalized Ct values (∆Ct) and relative fold changes per target gene (2∆∆Ct) can be found in Table 32. (c) Top: 
experimental set-up of trypan blue exclusion assay. Bottom: viable cells [%] for K562 (left bar plot) or Raji B 
(CDK9as) (right bar plot) upon heat shock time-course. Corresponding cell counts can be found in Table 33. 
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Table 32. Normalized Ct values (RT-qPCR, Figure 47 b). 
Normalized Ct values, ∆Ct, were calculated by multiplication of the primer efficiency (E) with the mean of the 
technical replicates. E was 0.99 for spike-in primers (4, 5, 12), 1.04 for ACTB primers, and 1.16 for HSPA1A 
primers. Two biological replicates were prepared for each condition. 
 
No. 
Cell 
line 
Time 
at 
42°C 
(min) 
∆Ct 𝟐∆∆𝑪𝒕 S.D. 
Spike-
in 4 
Spike-
in 5 
Spike-
in 12 
ACTB HSPA1A ACTB HSPA1A ACTB HSPA1A 
1 K562 0 16.08 16.08 15.26 15.87 24.94 1.00 1.00 0.01 0.02 
2 K562 0 15.78 15.79 15.38 15.74 24.84     
3 K562 15 15.37 15.70 15.09 15.50 20.57 0.94 15.92 0.04 0.30 
4 K562 15 15.48 15.47 15.13 15.59 20.52     
5 K562 30 15.40 15.74 14.93 15.84 19.21 0.87 43.66 0.11 4.05 
6 K562 30 15.38 15.63 14.91 15.41 18.90     
7 K562 45 15.52 15.58 14.88 15.60 18.26 0.88 67.86 0.01 7.40 
8 K562 45 15.64 15.73 14.72 15.61 18.61     
9 K562 60 15.50 15.61 15.07 15.83 18.44 0.86 70.02 0.08 1.49 
10 K562 60 15.39 15.75 15.18 15.60 18.46     
11 K562 75 15.67 15.66 16.01 15.97 18.15 0.81 90.70 0.11 19.66 
12 K562 75 15.49 15.58 15.23 16.04 18.44     
13 
Raji B 
CDK9as 
0 14.25 14.35 13.40 13.45 24.62 1.02 1.01 0.20 0.13 
14 Raji B 
CDK9as 
0 14.36 14.22 13.44 13.06 24.36     
15 Raji B 
CDK9as 
15 14.20 14.24 13.69 13.17 22.53 1.19 4.49 0.18 0.62 
16 
Raji B 
CDK9as 
15 14.27 14.28 14.08 13.11 22.39     
17 Raji B 
CDK9as 
30 14.34 14.33 14.03 13.36 21.99 1.06 7.22 0.15 0.89 
18 
Raji B 
CDK9as 
30 14.30 14.39 13.96 13.46 21.74     
19 Raji B 
CDK9as 
45 14.19 14.13 13.71 13.11 21.27 1.15 8.91 0.16 0.92 
20 Raji B 
CDK9as 
45 14.32 14.21 13.34 12.99 21.37     
21 
Raji B 
CDK9as 
60 14.40 14.41 13.99 13.68 20.90 0.87 12.70 0.12 2.09 
22 Raji B 
CDK9as 
60 14.24 14.25 13.60 13.56 21.07     
23 
Raji B 
CDK9as 
75 14.28 14.27 14.06 13.54 20.96 0.93 11.25 0.13 2.27 
24 Raji B 
CDK9as 
75 14.34 14.38 13.74 13.56 21.44     
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Table 33. Cell counts (tryphan blue exclusion assay, Figure 47 c). 
For experimental details see Methods II.2.4.1. Expect for 60 min of heat shock (HS) in K562, two biological 
replicates of all time-points were collected.  
 
No. Cell line 
Replicate 
no. 
Time at 
42 °C 
(min) 
Cell count Mean cell 
number/mL 
Viable 
cells (%) 
S.D. 
1 2 
1 K562 1 0 77 87    
2 K562 2 0 76 76 158 100 3 
3 K562 1 15 83 75    
4 K562 2 15 74 78 155 102 2 
5 K562 1 30 108 76    
6 K562 2 30 73 73 165 96 9 
7 K562 1 45 63 99    
8 K562 2 45 86 70 159 99 9 
9 K562 1 60 NA NA    
10 K562 2 60 75 91 166 95 5 
11 K562 1 75 80 93    
12 K562 2 75 77 84 167 95 4 
13 Raji B 
CDK9as 
1 0 87 81    
14 Raji B 
CDK9as 
2 0 76 88 166 100 3 
15 
Raji B 
CDK9as 
1 15 75 85    
16 Raji B 
CDK9as 
2 15 97 66 162 103 7 
17 
Raji B 
CDK9as 
1 30 89 76    
18 Raji B 
CDK9as 
2 30 74 83 165 101 4 
19 Raji B 
CDK9as 
1 45 91 115    
20 
Raji B 
CDK9as 
2 45 74 78 179 93 9 
21 Raji B 
CDK9as 
1 60 78 85    
22 
Raji B 
CDK9as 
2 60 78 61 151 110 6 
23 Raji B 
CDK9as 
1 75 82 79    
24 Raji B 
CDK9as 
2 75 78 83 161 103 1 
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Figure 48. Constitutive exons analysis agrees with analysis on new annotation. 
(a) Diagram illustrating the main selection steps of constitutive exons in all RefSeq GRCh38 annotated isoforms. 
(b) Differential expression (DE) analysis of upregulated (light red), downregulated (dark blue), and unchanged 
TUs (grey) in human K562 cells upon 15 min (left box plot) or 30 min (right box plot). Heat shock samples (HS15, 
or HS30) were compared to respective control (Ctrl). Spike-in normalized TT-seq data were analyzed for DE of 
constitutive exons in all RefSeq GRCh38 annotated isoforms. A minimum fold change of 1.25 as cutoff and a 
maximum adjusted p-value of 0.001 was set for calling a significant expression change. Black bars represent 
medians, boxes mark upper and lower quartiles, whiskers represent 1.5 times the inter-quartile range. 
(c) Distribution of pause site distance from the TSS for 7,406 investigated genes measured by mNET-seq depicted 
as a histogram with respect to TSS of RefSeq annotated genes (mean 123 [bp], median 104 [bp], mode 81 [bp]). 
Note that this in contrast to GRO-cap refined TSSs of our new K562 annotation for which called pause sites were 
distributed around a maximum located ~50 bp downstream of the TSS (Figure 22 c). (d-e) Representative genome 
browser view of mNET-seq and TT-seq data at the HSPH1 gene locus on chromosome 13 (minus strand) (d), or 
at the EGR1 gene locus on chromosome 5 (plus strand) (e). Visualized with the Integrative Genomics Viewer 
(IGV, version 2.4.10; human hg38) 400. Shown is the strand-specific Pol II occupancy with single nucleotide 
resolution (mNET-seq, top panels), and the number of transcribed bases (TT-seq, bottom panels). Two biological 
replicates are merged. (f-g) Median of pause-initiation trajectories upon heat shock time-course of 247 significantly 
upregulated (red circles, f) or 1,289 downregulated genes (dark blue circles, g) in log scale. The two solid 
perpendicular lines define the inter-quartile range, the dotted whiskers represent 1.5 times the inter-quartile range 
of the respective estimate for the entire transcript class. The grey shaded area depicts impossible combinations of 
I and d. Striped areas show confidence intervals of the pause-initiation limit. 
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Figure 49. GenoSTAN annotation and DE analysis of TUs in Raji B cells. 
(a) Genome browser track of 458 kbp of chromosome 9 (chr9:135,794,708-136,254,365) visualized with the 
Integrative Genomics Viewer (IGV, version 2.4.10) 400. From top to bottom tracks represent: TT-seq coverage in 
Raji B (CDK9as) cells (n=4), new TU annotation (Methods), RefSeq GRCh38 annotation. TUs missing in the 
RefSeq annotation are highlighted in a green. RefSeq transcripts not present in Raji B cells are highlighted in red. 
(b) TUs and transcript classes as annotated in this study: all TUs, mRNAs (green frame), eRNAs (light red frame), 
conRNAs (black frame), lincRNAs (purple frame), asRNAs, uaRNAs, sincRNAs (different shades of grey). 
Boxplots show differential expression (DE) analysis of upregulated (light red), downregulated (dark blue), and 
unchanged TUs (grey) in human Raji B cells upon 30 min of heat shock. Heat shock samples (HS30) were compared 
to respective controls (Ctrl) of spike-in normalized TT-seq data. A minimum fold change of 1.5 in all conditions 
and a maximum adjusted P-value of 0.1 was set for calling a significant expression change. 
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Table 34. Published data sets used in this study. 
For chromatin state annotation of K562 cells (no. 1), Benedikt Zacher et al. used 18 chromatin states leading to 
a definition of promoter and enhancer states. Specifically, the segmentation algorithm GenoSTAN considers K562-
specific DNase-seq and ChIP-seq data of 8 histone modifications (H3K27me3, H3K36me3, H4K20me1, H3K4me1-
3, H3K27ac, H3K9ac) and of the histone acetyltransferase P300 168,177. 
 
No. Data Cell line Used for Reference Available at 
1 Chromatin 
state 
annotation 
K562 
K562 New annotation 
(cTU) of K562 
Gagneur 177 https://i12g-
gagneurweb.in.tum.de/p
ublic/paper/GenoSTAN
/ 
2 GRO-cap K562 New annotation 
(cTU) of K562 
Lis 50 NCBI Gene Expression 
Omnibus (GSE60456) 
3 H3K4me1 Raji B New annotation 
(TU) of Raji B 
Andrau 514 NCBI Gene Expression 
Omnibus (GSE52914) 
4 H3K4me3 Raji B New annotation 
(TU) of Raji B 
Andrau 514 NCBI Gene Expression 
Omnibus (GSE52914) 
5 mNET-seq Raji B 
(CDK9as) 
Pause duration 
d of Raji B 
Cramer 381 NCBI Gene Expression 
Omnibus (GSE96056) 
6 TT-seq Raji B 
(CDK9as) 
Pause duration 
d of Raji B 
Cramer 381 NCBI Gene Expression 
Omnibus (GSE96056) 
7 In situ Hi-C K562 Chromatin 
features of the 
PS (Figure 46) 
Rao et al. 
2014 
NCBI Gene 
Expression Omnibus 
(GSM1551620) 
8 MNase-seq K562 Chromatin 
features of the 
PS (Figure 46) 
Kundaje et al. 
2012 
NCBI Gene 
Expression Omnibus 
(GSE35586) 
9 AT content in silico Chromatin 
features of the 
PS (Figure 46) 
this study NA 
10 TOP1-seq HCT116 Chromatin 
features of the 
PS (Figure 46) 
Baranello et 
al. 2016 
NCBI Gene 
Expression Omnibus 
(GSE57628) 
11 Bisulfite-seq 
(RRBS) 
K562 Chromatin 
features of the 
PS (Figure 46) 
Myers et al. 
2011 
NCBI Gene 
Expression Omnibus 
(GSE27584) 
12 CG content in silico Chromatin 
features of the 
PS (Figure 46) 
this study NA 
13 CpG island in silico Chromatin 
features of the 
PS (Figure 46) 
this study NA 
14 DNA-RNA 
melting 
temperature 
in silico Chromatin 
features of the 
PS (Figure 46) 
this study NA 
15 DNase I 
hypersensitive 
sites (DHSs) 
K562 Chromatin 
features of the 
PS (Figure 46) 
Crawford, 
Ohler et al. 
2012 
NCBI Gene 
Expression Omnibus 
(GSE32970) 
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4. Discussion 
 
 
 
Table 35. Top five players for TPD in combination with multi-omics. 
 
No. Candidates Reasoning for targeted protein degradation (TPD) 
1 NELF complex Establishes pause in vitro and depletion of NELF leads to reduced levels of Pol 
II pausing in Drosophila 241,515. However, so far observed changes in pausing are 
surprisingly small 352. 
2 CTCF Covered in the main text. 
3 PAF1 complex TPD will clarify on-going discussion about PAF1 acting as pausing factor in 
vivo 516 - which is unlikely due to recent structural insights showing that 
NELF and PAF1 binding to Pol II is mutually exclusive in vitro 110. 
4 Cap-binding 
complex (CBC) 
Facilitates P-TEFb recruitment by interaction with P-TEFb and Pol II 517. It 
was further reported that CBC interacts with DSIF and NELF 518,519. 
5 CCNT1 Cyclin subunit of P-TEFb, might be involved in establishing different 
transcription condensates (see LLPS, Introduction I.1.1) 121. 
 
 
 
 
 
Figure 50. Elongation velocity and a dynamic histone code. 
Spearman correlation coefficients rho of elongation velocity v [kbp min-1] against histone marks. Marks were 
normalized by total nucleosome occupancy. Published datasets of ChIP-seq in K562 cells are listed below in Table 
36. Agreement with published data is highlighted in green, while correlations contrary to the literature are 
highlighted with dotted lines (see Table 37 for references). Note, that none of the cited papers is normalizing to 
total nucleosome occupancy. 
 
Part V – Supplementary Information 
 
   130 
Table 36. Published data sets used in Figure 50. 
Data sets and references used in the correlation study of elongation velocity against histone features. All ChIP-seq 
data of histone marks were normalized to total nucleosome occupancy (estimated by MNase-seq). 
 
Experiment Cell type GEO ID Source Read-out 
MNase-seq K562 GSE35586 Snyder 144 Active regulatory 
chromatin (nucleosome-
depleted) 
ChIP-seq H3K4me2 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K4me3 K562 GSE32970 Stamatoyannopoulous 144 Protein-DNA interactions 
ChIP-seq H3K27me3 K562 GSM788088 Farnham Protein-DNA interactions 
ChIP-seq H3K4me1 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K27ac K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K27me3 K562 GSE32970 Stamatoyannopoulous 144 Protein-DNA interactions 
ChIP-seq H3K9ac K562 GSM788082 Farnham Protein-DNA interactions 
ChIP-seq H3K4me1 K562 GSM788085 Farnham Protein-DNA interactions 
ChIP-seq H3K4me3 K562 GSM788087 Farnham Protein-DNA interactions 
ChIP-seq H3K9me1 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H4K20me1 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K36me3 K562 GSE32970 Stamatoyannopoulous 144 Protein-DNA interactions 
ChIP-seq H3K9ac K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K4me3 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H2AZ K562 GSM733786 Bernstein Protein-DNA interactions 
ChIP-seq H3K79me2 K562 GSM733653 Bernstein Protein-DNA interactions 
ChIP-seq H3K27me3 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K9me3 K562 GSE26320 Bernstein 520 Protein-DNA interactions 
ChIP-seq H3K36me3 K562 GSE26320 Bernstein Protein-DNA interactions 
 
 
Table 37. Comparison of correlation in this study with the literature. 
A positive correlation indicates that marks occur at genes transcribed at fast elongation rates. Neutral highlights 
marks with no influence on elongation rates. Abbreviation: not assigned (NA). 
 
Histone mark Reported correlation Refs (if available) Correlation (this study) 
H2AZ   negative 
H2Bub1 positive 500,521 NA 
H3ac, H4ac positive 522 NA (strong negative, see H3K9ac) 
H3K27ac   negative 
H3K27me3   negative 
H3K36me3 neutral 272,335,336 neutral 
H3K4me1 positive 130 strong negative 
H3K4me2   negative 
H3K4me3   negative 
H3K79me2 positive 130,335,336 neutral 
H3K9ac   strong negative 
H3K9me1   neutral 
H3K9me3   neutral 
H4K20me1 positive / negative 336 / 19 neutral 
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Abbreviations 
 
Table 38. Abbreviations. 
 
- minus strand 
r (rho) Spearman correlation rho 
[Å] Ångstrom 
[U] Units 
[v/v] volume per volume 
[w/v] weight per volume 
+ plus strand 
1-NA-PP1 1-Naphthyl-PP1; 
1-(1,1-dimethylethyl)-3-(1-naphthalenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
4-thio-UTP 4-thio-uridine triphosphate 
4sU 4-thiouracil 
A alanine 
ACTB β-actin 
AID auxin-inducible degron system 
APS ammonium persulfate 
asRNA antisense RNA 
ATM Ataxia Telangiectasia Mutated, cell cycle checkpoint kinase 
ATP adenosine triphosphate 
BRD4 acetylated histone binding protein bromodomain containing 4 
BrU 5-bromouridine 5’-triphosphate 
BSA bovine serum albumin 
CBC cap-binding complex 
CDK7 cyclin-dependent kinase 7 
CDK9as analog-sensitive cyclin-dependent kinase 9 
cDNA complementary DNA 
ChIP-seq chromatin immunoprecipitation sequencing 
Chr chromosome 
conRNA convergent RNA 
CRBN Cereblon (E3 protein ligase) 
Ct mean threshold cycle (RT-qPCR) 
CTCF CCCTC-binding factor (zinc finger protein) 
CTD RNA polymerase II C-terminal domain 
Ctrl control 
cTU capped transcription unit 
d [min] pause duration 
DMD Dystrophin 
DMF N,N-Dimethylformamide 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
DNase deoxyribonuclease 
DSIF DRB sensitivity inducing factor 
dTAG degradation tag system 
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DTT DL-Dithiothreitol 
E amplification efficiency (RT-qPCR) 
EC elongation complex 
ECL enhanced luminol-based chemiluminescent 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene-glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid 
enChIP engineered DNA-binding molecule mediated chromatin immunoprecipitation 
eRNA enhancer RNA 
F phenylalanine 
FBS fetal bovine serum 
FCP1 CTD phosphatase 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GenoSTAN genomic state annotation segmentation algorithm 
GRINL1A, 
GDOWN1 
RNA polymerase subunit M 
GRO-seq global nuclear run-on and sequencing 
hnRNA heterogeneous nuclear RNA, intron-containing pre-mRNA 
HS heat shock 
HSPA1A, HSP70 heat shock protein 70 
I [cell-1 min-1] productive initiation frequency 
IgG Immunoglobulin G 
IGV Integrative Genomics Viewer 
IP immunoprecipitation 
IVT in vitro transcription 
K562 ENCODE cell line, human 
KD knockdown 
Length [bp] base pair(s) 
Length [kbp] kilo base pair(s) 
Length [nt] nucleotide(s) 
lincRNA long intergenic noncoding RNA 
MEF [kcal mol-1] minimum free energy 
MMTV murine mammary tumor virus 
MNase micrococcal nuclease 
mNET-seq mammalian native elongating transcript sequencing 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA protein-coding, messenger RNA 
NaCl sodium chloride 
NaOAc sodium acetate 
NCBI National Center for Biotechnology Information 
ncRNA long noncoding RNA 
NELF negative elongation factor 
NET-seq native elongating transcript sequencing 
NFκB nuclear factor κB 
NRO nuclear run-on assay 
NTP nucleotide triphosphoate 
o/n overnight 
p  number of polymerases 
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P-TEFb positive transcription elongation factor b 
pA polyA site 
PAF polymerase associated factor 
PAF1 Pol II associated factor 1 
PAGE polyacrylamide gel electrophoresis 
Pausing promoter-proximal pausing of Pol II 
PB pause button 
PCR polymerase chain reaction 
PE polyethylen 
PE pause element 
PEC paused elongation complex 
PI protease inhibitor cocktail 
PIC pre-initiation complex 
PNK polynucleotide kinase 
Pol II DNA-dependent RNA polymerase II 
PP polypropylene 
PRO-seq precision nuclear run-on and sequencing 
PS pause site 
PVDF polyvinylidene difluoride 
PW pause window 
Raji B Raji Burkitt’s lymphoma 
RNA ribonucleic acid 
RNase ribonuclease 
RPK read counts per kilobase 
RT reverse transcription, reverse transcriptase 
RT-qPCR quantitative reverse transcription PCR 
S slope of standard curve (RT-qPCR) 
sincRNA short intergenic noncoding RNA 
Sirt1 silent information regulator factor 2 related enzyme 1 
SUPT6H, SPT6 transcription elongation factor 6 
tb  transcribed bases 
TEMED tetramethylethylenediamine 
Temperature [°C] degree Celsius 
TF basal transcription factor 
TFIIS transcription elongation factor S 
Time [h] hour(s) 
Time [min] minute(s) 
TIR1 transport Inhibitor Response 1 (E3 protein ligase) 
TPD targeted protein degradation 
TRIM28, KAP-1 tripartite Motif Containing 28 
TSS transcription start site 
TT-seq transient transcriptome sequencing 
TTS transcription termination site 
TU transcription unit 
uaRNA upstream antisense RNA 
v [bp min-1] elongation velocity 
XIST X-inactive specific transcript 
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Sequences and plasmid maps 
 
 
S. pyogenes Cas9 plasmid 
 
 
Plasmid map of pSpCas9(BB)-2A-GFP (PX458). Plasmid map was generated using SnapGene. 
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Spike-ins (TT-seq) 
General note: Spike-ins are derived from ERCC Spike-in Mix but are not polyadenylated (see 
II.2.2.1 and Table 20 for details). At the 5’-end of the transcript ‘GGG’ (included in length) 
is added to facilitate in vitro transcription by T7 polymerase (highlighted by underline). 
 
Sequence (5’ to 3’) of spike-in 2 (length 985 nt) derived from ERCC-00043: 
GGGTGCTTTAACAAGAGGAAATTGTGTTTTTGCCAATTTAAGACCTAATTTAATAGTTAAACCATTA
ACCTTAGTTGTTCCAAGGCATAATATAGAGAGTGAGATACAGGATGAGCTATTTCAGGGAGTTATT
CAGTATGCAGTTGCCAAGGCAGTTGCTGATTTAGATTTAGATGAAGATTTAAAGGTTGTTGTCTCT
GTTAATGTCCCAGAGGTTCCAATAACCAATTTAAATAAAAGAAAACTCTTCCAATACTTCTATGCCT
CAGCAAAGTTAGCTATAAACAGAGCTTTAAATGAATATCCTTCAAAAGAGAAGGTAAAGAAAGAGA
AATATAGAGCTTTGCATCCATTAGTTGGATTTAGGGATGTTAGATTGGAGTATCCTCCATATCTACA
AATTGCTTTGGATGTCCCAACTATGGAGAATTTGGAATTTTTGTTACAAACAATTCCAAATAGCGAC
CACATCATCTTAGAGGCTGGAACACCACTAATTAAAAAGTTTGGTTTAGAGGTTATTGAAATAATG
AGAGAATATTTTGATGGCTTTATTGTTGCTGATTTAAAAACCTTAGACACTGGAAGGGTTGAGGTA
AGATTGGCATTTGAAGCAACAGCTAATGCAGTGGCAATAAGTGGAGTAGCACCAAAATCAACAATA
ATTAAAGCTATCCACGAATGTCAAAAATGTGGTTTAATCAGCTATTTGGATATGATGAACGTCTCTG
AACCTCAAAAATTATATGATTCATTAAAATTAAAGCCAGATGTTGTTATCTTGCATAGAGGGATTGA
TGAGGAGACATTTGGAATTAAAAAGGAATGGAAATTTAAGGAAAACTGCTTATTAGCAATTGCTGG
AGGAGTTGGTGTGGAGAATGTTGAAGAGCTTTTAAAAGAATATCAAATATTAATCGTTGGTAGAGC
AATTACAAAATCAAAAGACCCAGGAAGAGTAATTAGGATTTTATAAACAAGATGG 
 
 
Plasmid map of spike-in 2 pUC19. Plasmid map was generated using SnapGene. 
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Sequence (5’ to 3’) of spike-in 12 (length 949 nt) derived from ERCC-00170: 
GGGGCACAAGTTGCTGAAGTTGCGAGAGGGGCGATAAGTGAGGCAGACAGGCATAATATAAGAGG
GGAGAGAATTAGCGTAGATACTCTTCCAATAGTTGGTGAAGAAAATTTATATGAGGCTGTTAAAGC
TGTAGCAACTCTTCCACGAGTAGGAATTTTAGTTTTAGCTGGCTCTTTAATGGGAGGGAAGATAAC
TGAAGCAGTTAAAGAATTAAAGGAAAAGACTGGCATTCCCGTGATAAGCTTAAAGATGTTTGGCTC
TGTTCCTAAGGTTGCTGATTTGGTTGTTGGAGACCCATTGCAGGCAGGGGTTTTAGCTGTTATGGC
TATTGCTGAAACAGCAAAATTTGATATAAATAAGGTTAAAGGTAGGGTGCTATAAAGATAATTTAA
TAATTTTTGATGAAACCGAAGCGTTAGCTTTGGGTTATGAAACTCCATGATTTTCATTTAATTTTTT
CCTATTAATTTTCTCCTAAAAAGTTTCTTTAACATAAATAAGGTTAAAGGGAGAGCTCTATGATTGT
CTTCAAAAATACAAAGATTATTGATGTATATACTGGAGAGGTTGTTAAAGGAAATGTTGCAGTTGA
GAGGGATAAAATATCCTTTGTGGATTTAAATGATGAAATTGATAAGATAATTGAAAAAATAAAGGA
GGATGTTAAAGTTATTGACTTAAAAGGAAAATATTTATCTCCAACATTTATAGATGGGCATATACAT
ATAGAATCTTCCCATCTCATCCCATCAGAGTTTGAGAAATTTGTATTAAAAAGCGGAGTTAGCAAAG
TAGTTATAGACCCGCATGAAATAGCAAATATTGCTGGAAAAGAAGGAATTTTGTTTATGTTGAATG
ATGCCAAAATTTTAGATGTCTATGTTATGCTTCCTTCCTGTGTTCCAGCTACAAACTTAGAAACAAG
TGGAGCTGAGATTACAGCAGA 
 
 
Plasmid map of 12-pUC19. Plasmid map was generated using SnapGene. 
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Sequence (5’ to 3’) of spike-in 4 (length 1,014 nt) derived from ERCC-00136: 
GGGTTTCGACGTTTTGAAGGAGGGTTTTAAGTAATGATCGAGATTGAAAAACCAAAAATCGAAACG
GTTGAAATCAGCGACGATGCCGAATTTGGTAAGTTTGTCGTAGAGCCACTTGAGCGTGGATATGGT
ACAACTCTGGGTAACTCCTTACGTCGTATCCTCTTATCCTCACTCCCTGGTGCCGCTGTAACATCAA
TCCAGATAGATGGTGTACTGCACGAATTCTCGACAATTGAAGGCGTTGTGGAAGATGTTACAACGA
TTATCTTACACATTAAAAAGCTTGCATTGAAAATCTACTCTGATGAAGAGAAGACGCTAGAAATTGA
TGTACAGGGTGAAGGAACTGTAACGGCAGCTGATATTACACACGATAGTGATGTAGAGATCTTAAA
TCCTGATCTTCATATCGCGACTCTTGGTGAGAATGCGAGTTTCCGAGTTCGCCTTACTGCTCAAAGA
GGACGTGGGTATACGCCTGCTGACGCAAACAAGAGAGGCGATCAGCCAATCGGCGTGATTCCGATC
GATTCTATCTATACGCCAGTTTCCCGTGTATCTTATCAGGTAGAGAACACTCGTGTAGGCCAAGTTG
CAAACTATGATAAACTTACACTTGATGTTTGGACTGATGGAAGCACTGGACCGAAAGAAGCAATTG
CGCTTGGTTCAAAGATTTTAACTGAACACCTTAATATATTCGCTGGTTTAACTGACGAAGCTCAACA
TGCTGAAATCATGGTTGAAGAAGAAGAAGATCAAAAAGAGAAAGTTCTTGAAATGACAATTGAAGA
ATTGGATCTTTCTGTTCGTTCTTACAACTGCTTAAAGCGTGCGGGTATTAACACGGTTCAAGAGCTT
GCGAACAAGACGGAAGAAGATATGATGAAAGTTCGAAATCTAGGACGCAAATCACTTGAAGAAGTG
AAAGCGAGACTAGAAGAACTTGGACTCGGACTTCGCAAAGACGATTGACTAGTTTCCCTTGTGAAC
TAGGATTTTCCCGGGTAC 
 
 
Plasmid map of spike-in 4 pUC19. Plasmid map was generated using SnapGene. 
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Sequence (5’ to 3’) of spike-in 5 (length 1,015 nt) derived from ERCC-00145: 
GGGACTGTCCTTTCATCCATAAGCGGAGAAAGAGGGAATGACATTGTTCTTACACGGCACAAGCAG
ACAAAATCAACATGGTCATTTAGAAATCGGAGGTGTGGATGCTCTCTATTTAGCGGAGAAATATGG
TACACCTCTTTACGTATATGATGTGGCTTTAATACGTGAGCGTGCTAAAAGCTTTAAGCAGGCGTTT
ATTTCTGCAGGGCTGAAAGCACAGGTGGCATATGCGAGCAAAGCATTCTCATCAGTCGCAATGATT
CAGCTCGCTGAGGAAGAGGGACTTTCTTTAGATGTCGTATCCGGAGGAGAGCTATATACGGCTGTT
GCAGCAGGCTTTCCGGCAGAACGCATCCACTTTCATGGAAACAATAAGAGCAGGGAAGAACTGCGG
ATGGCGCTTGAGCACCGCATCGGCTGCATTGTGGTGGATAATTTCTATGAAATCGCGCTTCTTGAA
GACCTATGTAAAGAAACGGGTCACTCCATCGATGTTCTTCTTCGGATCACGCCCGGAGTAGAAGCG
CATACGCATGACTACATTACAACGGGCCAGGAAGATTCAAAGTTTGGTTTCGATCTTCATAACGGA
CAAACTGAACGGGCCATTGAACAAGTATTACAATCGGAACACATTCAGCTGCTGGGTGTCCATTGC
CATATCGGCTCGCAAATCTTTGATACGGCCGGTTTTGTGTTAGCAGCGGAAAAAATCTTCAAAAAA
CTAGACGAATGGAGAGATTCATATTCATTTGTATCCAAGGTGCTGAATCTTGGAGGAGGTTTCGGC
ATTCGTTATACGGAAGATGATGAACCGCTTCATGCCACTGAATACGTTGAAAAAATTATCGAAGCT
GTGAAAGAAAATGCTTCCCGTTACGGTTTTGACATTCCGGAAATTTGGATCGAACCGGGCCGTTCT
CTCGTGGGAGACGCAGGCACAACTCTTTATACGGTTGGCTCTCAAAAAGAAGTGGATAAGCTGTAC
AATCGTTTCATCATTCGGCGTGCG 
 
 
Plasmid map of spike-in 5 pUC19. Plasmid map was generated using SnapGene. 
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Sequence (5’ to 3’) of spike-in 8 (length 1,079 nt) derived from ERCC-00092: 
GGGGATGTCCTTGGACGGGGTGGCGCAGTATTACTGCAAGAGAGCGGACAGATTAGTGTGTTGGAG
CCGACACATCAAAGGTTCGTCCGGGGACCGATCTGCAGCCTACGGGACATTTATCCGTAAAAGCAT
GGCGCTGTTTCGTACTTATCGGAGGCCAGGTATCGTCGCGGCGAGTCTCCCCGACGACGGAGATGG
GCGTTACTATCTGGGCCGTCTCGTACTCTGTTACTTGGCACAGATGCGAGCCCTCGTAATGTGCATC
AGCTAAGGGCGATATTATAATGCGACGTTTGTACGGATTCGTTACTAACGTGTTGGACGCTAGTGG
AATATGTGTCGTTGGTTAGCCTACCCATGGCTTTCGCGGCGACACATGCTTAGACTCTTTCAAAACT
TCGGTGAAGTTCACTCAAGCCGCGGAGCGCCGTCGTAATTCACTAGGGATGGCGGTACCCGTGCCC
GTCCGATTCGTAGCAACCTGCATCACGATTTTGTCTTCGGGCGACTTATCAGATACGGTAATGTAAA
TACCTGGCATTTGGGCACTTCTTGCGTTTAAGCGGGAAAGATCGCGAGGGCCCGCTATTTGCGATA
CTTCCCATGTCGGTGCCGTCGCCTCTATGTACTCGGAGACGTTAATGCAGAGGCTAAGGACAATTT
ACCATGACTCGGTAATCCGTTCGTCAAGCAGGTAGCTCGAGTCTCCCCACGGACACGTAGTGGGTT
TGTAACGATCGATACCGAGTCTTTTTGTCTAGTAGAACCAACCAACCATTAAGGAGTTCACTAGCAC
ATCTTTGCGACCCGATCGTCCGTGTGTCGCGTAATACTTTTGTTATGACGAGACATACGCTCAAGCC
CTGGGTAGCTAGTCGCGGAGGCACGTTACCGCGCACAACCCCTATTCGTTTACATGTACATCGCATC
TGAGGTAGTACACTTCCGGCGTACGTGAGTATTTGCGCGTAATAAGCGCGTGTTTAGCTGATCCCC
TCTCGTATCGAGGTTAAGGCAGATTAGTGCCCAGTAATTGCGTTTTTTTGTCGTTGTCGCAGAACG
CGATTTGCTCCGAAAGC 
 
 
Plasmid map of spike-in 8 pUC19. Plasmid map was generated using SnapGene. 
 Appendix 
 
 175 
Sequence (5’ to 3’) of spike-in 9 (length 1,037 nt) derived from ERCC-00002: 
GGGCCAGATTACTTCCATTTCCGCCCAAGCTGCTCACAGTATACGGGCGTCGGCATCCAGACCGTCG
GCTGATCGTGGTTTTACTAGGCTAGACTAGCGTACGAGCACTATGGTCAGTAATTCCTGGAGGAAT
AGGTACCAAGAAAAAAACGAACCTTTGGGTTCCAGAGCTGTACGGTCGCACTGAACTCGGATAGGT
CTCAGAAAAACGAAATATAGGCTTACGGTAGGTCCGAATGGCACAAAGCTTGTTCCGTTAGCTGGC
ATAAGATTCCATGCCTAGATGTGATACACGTTTCTGGAAACTGCCTCGTCATGCGACTGTTCCCCGG
GGTCAGGGCCGCTGGTATTTGCTGTAAAGAGGGGCGTTGAGTCCGTCCGACTTCACTGCCCCCTTT
CAGCCTTTTGGGTCCTGTATCCCAATTCTCAGAGGTCCCGCCGTACGCTGAGGACCACCTGAAACGG
GCATCGTCGCTCTTCGTTGTTCGTCGACTTCTAGTGTGGAGACGAATTGCCAGAATTATTAACTGCG
CAGTTAGGGCAGCGTCTGAGGAAGTTTGCTGCGGTTTCGCCTTGACCGCGGGAAGGAGACATAACG
ATAGCGACTCTGTCTCAGGGGATCTGCATATGTTTGCAGCATACTTTAGGTGGGCCTTGGCTTCCTT
CCGCAGTCAAAACCGCGCAATTATCCCCGTCCTGATTTACTGGACTCGCAACGTGGGTCCATCAGTT
GTCCGTATACCAAGACGTCTAAGGGCGGTGTACACCCTTTTGAGCAATGATTGCACAACCTGCGAT
CACCTTATACAGAATTATCAATCAAGCTCCCCGAGGAGCGGACTTGTAAGGACCGCCGCTTTCGCTC
GGGTCTGCGGGTTATAGCTTTTCAGTCTCGACGGGCTAGCACACATCTGGTTGACTAGGCGCATAG
TCGCCATTCACAGATTTGCTCGGCAATCAGTACTGGTAGGCGTTAGACCCCGTGACTCGTGGCTGA
ACGGCCGTACAACTCGACAGCCGGTGCTTGCGTTTTACCC 
 
 
Plasmid map of spike-in 9 pUC19. Plasmid map was generated using SnapGene.  
 
